Thymosin Alpha-1: Approvals, Trial Record, Dosing and What It Does Not Treat
Thymosin alpha-1 is a chain of 28 amino acids that the thymus gland releases into the blood, where it tells immature T cells to finish growing up. The synthetic copy is called thymalfasin, it is sold as Zadaxin, and it is a licensed
Thymosin alpha-1 is a chain of 28 amino acids that the thymus gland releases into the blood, where it tells immature T cells to finish growing up. The synthetic copy is called thymalfasin, it is sold as Zadaxin, and it is a licensed prescription medicine in roughly 35 countries — which makes it the only compound in this library that a drug regulator anywhere has ever approved.
That single fact reorders everything else, so take the evidence state before anything is argued from it. Most peptides in this library have animal data and a handful of uncontrolled human reports. Thymosin alpha-1 has 63 studies registered on ClinicalTrials.gov, four completed phase 3 programmes, a licensed package insert with a real dosing schedule, and more than 3,000 patients dosed across over 70 studies since 1979. Two of the randomised trials are large and both missed their main endpoint: TESTS, 1,106 adults with sepsis, where 28-day death was 23.4% against 24.1% on placebo; and TRACE, 508 people with severe pancreatitis, where infected dead tissue came out at 15.7% against 18.1%. Two results went the other way: in chronic hepatitis B on its own the odds of clearing the virus and holding it cleared came out 2.87 times placebo, and in a 120-person randomised trial in dialysis patients the drug carried a flu vaccine over the European licensing threshold that the vaccine alone did not reach. One observational study in COVID-19 recorded worse outcomes. The animal record is mice, and its cleanest single result is that the whole effect vanishes in mice bred without the TLR9 receptor. Then the absence that governs this page: across all 63 registered trials there is no tendon, no ligament, no disc, no muscle and no joint. Nothing has been measured in a person for any musculoskeletal problem, and no animal model of one has been run either.
One disclosure, because it should change how you read the rest. The operator of this site has a commercial interest in compounds described here. That is a reason to weigh what is on this page against the sources it cites rather than against its tone, and every claim below carries the source that supports it for exactly that reason.
Thymalfasin holds marketing approvals for chronic hepatitis B, chronic hepatitis C, use as a vaccine adjuvant in immunocompromised patients, and certain cancers, with the exact indication set varying by country. The United States is not among them. Neither is the European Union.
Jurisdiction
Status
Indications where approved
China
Approved; marketed as Zadaxin and by domestic manufacturers
Hepatitis B, hepatitis C, vaccine adjuvant, certain cancers, per each national label
United States
Not approved. No Drugs@FDA entry, no FDA-approved label, no openFDA label record
None
European Union
Not approved
None
The manufacturer's own monograph puts the count at "over 30 countries" and states the exclusion in one sentence: "ZADAXIN has not been approved for sale in the United States or Europe." The peer-reviewed literature puts it at "more than 35 countries."
The US absence is not a rejection on the merits. No sponsor has completed a US registration filing. Thymalfasin has held FDA orphan drug designations — for malignant melanoma, chronic active hepatitis B, DiGeorge anomaly with immune defects, and hepatocellular carcinoma. A designation is a development incentive: fee waivers, tax credits, and seven years of market exclusivity if the drug is later approved. It is not an approval, it permits no marketing, and it carries no finding about whether the drug works. Sources that describe those designations as approvals are wrong, and the distinction is the whole of the US position.
Withdrawn from the danger list is not the same as cleared for use
The entire United States position turns on one table on one FDA page, and the row is easy to misread.
FDA maintains a page titled Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. It carries two tables. The first is Category 2 proper — substances FDA has flagged as posing significant safety risks, which bars compounding under the interim policies. The second is headed Bulk drug substances nominated but withdrawn, described as substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators."
Thymosin-alpha 1 sits in the second table, alongside BPC-157, KPV, TB-500, epitalon, semax, selank and DSIP. FDA's recorded concern reads:
Compounded drugs containing thymosin-alpha-1 (Ta1) may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. The safety-related information is inadequate for the agency to sufficiently understand the extent of any safety issues raised by the proposed compounded drug.
Three consequences follow, and they are not the same as each other.
Withdrawal is a procedural act by the party who filed the nomination. It removes the substance from the active Category 2 listing. It is not FDA finding the substance safe, and no agency review concluded in the substance's favour.
Absence from Category 2 creates no permission. To be lawfully compounded from a bulk substance under section 503A, a substance must be the subject of an applicable USP or National Formulary monograph, be a component of an FDA-approved drug, or appear on the 503A bulks list. Thymosin alpha-1 is none of the three in the United States. The 503B outsourcing-facility channel is separate, narrower, and does not list it either.
The practical position in the United States is therefore an unapproved drug obtainable only through the grey market or a compounder operating outside the bulks framework. Any source still describing it as "FDA Category 2" is quoting a status the current page no longer assigns to it. That page was last updated 22 April 2026.
It gives back a signal the thymus stops sending
The thymus is largest in childhood and shrinks from puberty onward. By the sixth decade most of its functional tissue has been replaced by fat, and the output of new naive T cells falls with it. Thymosin alpha-1 is one of the peptides that tissue secretes; circulating levels in healthy adults run between 0.1 and 1 ng/mL and are lower in disease.
The mechanism reads as a chain. The links are not equally well established, and the difference matters.
Step one — it binds Toll-like receptors on dendritic cells. This is the anchoring finding and it is demonstrated directly. In mice, thymosin alpha-1 activated plasmacytoid dendritic cells through TLR9 and MyD88, switching on interferon regulatory factor 7 and driving an interferon-alpha and interferon-gamma effector response. Mice lacking TLR9 lost the protection. That is a knockout-confirmed dependency, not a correlation.
Step two — the dendritic cell decides what kind of immunity follows. Dendritic cells read an infection and instruct the rest of the immune system. Priming them through TLR/MyD88 produced Th1-type antifungal resistance in living animals. The same work found thymosin alpha-1 inducing indoleamine 2,3-dioxygenase in dendritic cells — the enzyme that pushes toward tolerance rather than attack.
Step three — T cells mature and differentiate. The 1972 characterisation was of a thymic fraction that restored immune function to thymectomised mice. The measurable human version is a rise in CD4+ percentage and a normalising CD4+/CD8+ ratio. A meta-analysis of five randomised trials in severe acute pancreatitis quantified it: CD4+ percentage rose by 4.53 points (95% CI 3.02 to 6.04) and the CD4+/CD8+ ratio by 0.42 (95% CI 0.26 to 0.58). CD8+ counts did not fall significantly, which is the point — the ratio normalised by lifting the deficient arm.
Step four — natural killer cells and cytotoxic T lymphocytes. Thymosin alpha-1 modulates NK cell maturation and cytotoxic T lymphocyte responses, and raises MHC class I surface expression on tumour cell lines. The target cell becomes easier to see, not only the effector cell more aggressive.
Step five — reversal of T-cell exhaustion. In severe COVID-19 patients, treatment was associated with reduced PD-1 and Tim-3 expression on CD8+ T cells and a rise in T-cell receptor excision circles, the standard marker of fresh thymic output. This is observational human data from a retrospective cohort of 76 patients, not a controlled experiment, and it belongs in a different evidentiary tier from step one.
What separates this compound from a stimulant is that the same molecule pushes in opposite directions depending on the state it finds. It induces tolerance-promoting IDO in one context and interferon-driven antiviral attack in another. That bidirectionality is why the literature calls it restoration rather than stimulation. It is also why the dose-response is not a straight line, and why the sepsis subgroups below point in opposite directions in different patients.
Sixty-three registered trials, and the two largest disagree
Sixty-three studies are registered on ClinicalTrials.gov with thymosin alpha-1 as an intervention. The named human record is set out below with the result stated as each trial reported it, including the failures.
Trial
NCT
n
Population
Dose
Duration
Primary endpoint
Result
TESTS — phase 3, quadruple-blind, 22 centres
NCT02867267
1,106
Sepsis-3 adults, 18–85
1.6 mg SC every 12 h
≤7 days
28-day all-cause mortality
Missed. 23.4% vs 24.1% placebo; HR 0.99 (0.77–1.27); P=0.93
The approvals were granted on chronic hepatitis B. An independent meta-analysis of 435 patients across randomised controlled trials of thymalfasin monotherapy found a sustained virological response advantage over placebo with an odds ratio of 2.87 (95% CI 1.58–5.22, P=0.0005), and a non-significant trend favouring it over interferon alpha (OR 2.62, 95% CI 0.80–8.56). Across the individual monotherapy studies, disease remission ran 26% to 41%.
Two caveats belong in the same breath. The comparator was interferon or placebo, in an era before tenofovir and entecavir; a 2020 review states plainly that hepatitis B and C treatment with thymosin alpha-1 "has been discontinued in favor of direct antiviral agents." And the two large phase 3 hepatitis C programmes in non-responders — 552 and 500 patients, both completed more than fifteen years ago — have never reported. A completed 552-patient phase 3 with no published outcome is not neutral evidence about a drug; it is a hole where the answer should be.
Sepsis is where it was tested hardest and came up short
ETASS in 2013 was the encouraging trial. 361 patients, 28-day mortality 26.0% on thymosin alpha-1 against 35.0% on control, plus a measurable rise in monocyte HLA-DR — the clearest available marker of reversed immunoparalysis — at day 3 (mean difference 3.9%, 95% CI 0.2–7.6) and day 7 (5.8%, 95% CI 1.0–10.5). The mortality difference did not clear significance on the primary unstratified analysis at P=0.062.
TESTS was built to settle it. 1,106 patients, 22 centres, quadruple-blinded, placebo-controlled, phase 3. It found nothing: 28-day mortality 23.4% against 24.1%, hazard ratio 0.99, P=0.93. No secondary endpoint separated, and no safety endpoint separated either.
The subgroup analysis is where it stops being simply negative. Patients under 60 did worse on the drug (HR 1.67, 1.04–2.67). Patients 60 and over trended better (HR 0.81, 0.61–1.09). Interaction P=0.01. Diabetic patients did better (HR 0.58, 0.35–0.99), non-diabetic patients did not (HR 1.16, 0.87–1.53), interaction P=0.04. These are prespecified subgroups inside a negative trial. They are hypotheses, and a younger patient doing worse on an immune-restoring drug is a hypothesis worth taking seriously in both directions.
A 2025 meta-analysis pooled 11 randomised trials and 1,927 patients. Overall it found a 28-day mortality benefit (OR 0.73, 95% CI 0.59–0.90, P=0.003). That benefit disappeared when restricted to high-quality trials (OR 0.82, P=0.09) and to multicentre trials (OR 0.86, P=0.20). Trial sequential analysis concluded the accumulated sample is still inadequate to answer the question.
Pancreatitis: the trial missed, and one subgroup did not
TRACE randomised 508 patients with predicted severe acute necrotising pancreatitis, 94.3% of whom required intensive care. Infected pancreatic necrosis occurred in 15.7% of treated patients and 18.1% of placebo patients, P=0.48. New-onset organ failure, bleeding and gastrointestinal fistula were all similar between arms.
The post-hoc analysis found what the whole trial did not. Among the 290 patients whose baseline absolute lymphocyte count was at or above 0.8×10⁹/L, thymosin alpha-1 reduced infected necrosis with an adjusted risk difference of −0.12 (95% CI −0.21 to −0.02, P=0.015). Patients between 0.79 and 2.00×10⁹/L benefited most.
Read carefully, that is the single most informative result in the file. An immune-restoring drug worked in the patients who still had lymphocytes to restore and did nothing in the patients too depleted to respond. It is post-hoc, it needs prospective confirmation, and it explains why an unselected population produces a null. It also implies that any honest use of this compound starts with a lymphocyte count.
COVID-19 produced three answers, and one of them was harm
The Wuhan retrospective covered 76 severe cases and reported mortality of 11.11% with treatment against 30.00% without (P=0.044), alongside restored CD8+ and CD4+ counts and reduced exhaustion markers.
A five-hospital multicentre cohort of 2,282 patients found the reverse. After adjustment for confounders, thymosin alpha-1 use was associated with a higher non-recovery rate (OR 1.5, 95% CI 1.1–2.1, P=0.028), with risk concentrated in patients with SOFA scores of 2 or more, ICU admission, and lower PaO₂/FiO₂. Later initiation was worse than earlier.
A propensity-matched cohort of 1,388 non-severe patients found no difference in progression to severe disease (2.17% vs 2.71%) or in mortality, but shorter viral shedding (13 vs 16 days, P=0.025) and shorter hospital stay (14 vs 18 days, P<0.001).
All three are observational and all three are subject to confounding by indication — sicker patients get more drugs. The only randomised study that targeted the lymphocytopenic patients the mechanism predicts should respond was terminated at 56 patients and never reported.
Vaccine response is the cleanest positive signal in the file
Haemodialysis patients mount poor antibody responses to influenza vaccine. In the pilot trial, patients given the adjuvanted H1N1 vaccine alone did not meet the CHMP licensing criteria for seroconversion, seroprotection and geometric mean ratio. Patients given the vaccine plus 3.2 mg or 6.4 mg of thymosin alpha-1 on day −7 and day 0 met all three. No adverse event was attributed to the peptide, and no change appeared in haematology or blood chemistry.
This is 94 patients in an intention-to-treat analysis, in a population defined by immune failure, in a pilot study. It is also the one result where the drug did the specific thing its mechanism predicts, in humans, judged against a prespecified regulatory standard rather than an author's own endpoint.
The cancer file is adjuvant work with one real trial still running
The melanoma dose-ranging study is the largest completed oncology dataset: 488 patients across five arms, responses in 6 to 12 patients per thymosin arm against 4 of 97 in the dacarbazine-plus-interferon control, and median overall survival of 8.6 to 10.3 months against 6.6. It was a phase 2 designed to select a dose, not to prove survival, and no phase 3 followed it in the nineteen years since it started.
The trial that would settle the oncology question is enrolling now: 2,500 patients with resected high-risk stage II and III colorectal cancer, randomised to 1.6 mg twice weekly for six months or to no thymosin, with three-year disease-free survival as the primary endpoint and primary completion in March 2027.
Every trial population is an infection, an organ failure or a cancer, and not one of them is a back
Every trial population above is a hepatitis patient, a septic ICU patient, a pancreatitis patient, a cancer patient, or a dialysis patient. Not one is a back-pain patient. There is no musculoskeletal indication, no tendon, ligament, disc or muscle model, and no mechanism connecting T-cell maturation to tissue repair.
What brings a person to look this up
What the human record actually covers
Strength of the connection
Recurrent infection, slow recovery from every cold
Vaccine-response pilot in dialysis patients; hepatitis approvals; 3,000-patient safety file
Moderate, and only by extrapolation from immunocompromised populations
Documented immunosuppression with a measured low-normal lymphocyte count
TRACE subgroup: the effect appeared where lymphocytes were preserved but suppressed
Moderate. Post-hoc, and it requires the blood test to identify
Post-viral fatigue after a confirmed infection
No completed randomised trial. The COVID file is acute hospitalised disease and it contradicts itself
Absent
Chronic inflammatory load in a chronic-pain patient
CRP fell 30.12 mg/L in the lower-dose arms of the pancreatitis meta-analysis — in patients with necrotising pancreatitis in intensive care
Absent for this population
Immune-related fatigue with no diagnosis and no abnormal labs
Hashimoto's, MCAS, ankylosing spondylitis, other autoimmunity
No trial. The mechanism cuts both ways — tolerance in one context, interferon-driven attack in another
Absent, and the self-reports below include people who got measurably worse
The one row the record can defend is the immune row, in a person with documented immune compromise, and even that defence is an off-label extrapolation from populations that do not look like that person. Selling thymosin alpha-1 for musculoskeletal repair is a claim that nothing in 63 trials supports.
Dosing, and the arithmetic behind the syringe
The licensed product is a 1.6 mg lyophilised vial supplied with 1.0 mL of Sterile Water for Injection. Reconstituted, that is 1.6 mg/mL, and the whole vial is one dose. The approved hepatitis B regimen is 1.6 mg (900 µg/m²) subcutaneously twice a week for 6 to 12 months. Patients under 40 kg receive 40 µg/kg.
The critical-illness regimens run at 3.2 mg per day — twice the hepatitis dose, for one to two weeks. The vaccine regimen runs up to 6.4 mg in a single dose. The cumulative safety record spans 1 mg to 16 mg per dose, and 0.6 to 9.6 mg/m². There is no dose ceiling hiding in that range. There is also nothing showing that a larger dose does more for a stable outpatient.
Reconstitution, shown as arithmetic
Grey-market vials come as 5 mg or 10 mg of lyophilised powder, not 1.6 mg, so the arithmetic has to be done rather than read off a label.
Concentration in mcg per mL = total micrograms in the vial ÷ millilitres of bacteriostatic water added. A U-100 insulin syringe holds 1.0 mL across 100 units, so one unit is 0.01 mL, and micrograms per unit = concentration ÷ 100.
Worked: a 10 mg vial holds 10,000 mcg. Add 4.0 mL of bacteriostatic water. 10,000 ÷ 4.0 = 2,500 mcg/mL. 2,500 ÷ 100 = 25 mcg per unit. A 1.6 mg dose is 1,600 ÷ 25 = 64 units on the barrel.
Vial
Bacteriostatic water added
Concentration
Mcg per unit
Units for 1.6 mg
Full 1.6 mg doses per vial
5 mg (5,000 mcg)
2.0 mL
2,500 mcg/mL
25
64
3, with 200 mcg left over
5 mg (5,000 mcg)
2.5 mL
2,000 mcg/mL
20
80
3
5 mg (5,000 mcg)
5.0 mL
1,000 mcg/mL
10
160 — two injections
3
10 mg (10,000 mcg)
2.0 mL
5,000 mcg/mL
50
32
6, with 400 mcg left over
10 mg (10,000 mcg)
4.0 mL
2,500 mcg/mL
25
64
6
10 mg (10,000 mcg)
5.0 mL
2,000 mcg/mL
20
80
6
At 5,000 mcg/mL — a 10 mg vial in 2.0 mL, the concentration that keeps every trial dose inside one syringe — the conversion is:
Dose
Micrograms
Units on a U-100 barrel
0.25 mg
250
5
0.5 mg
500
10
0.8 mg
800
16
1.0 mg
1,000
20
1.6 mg
1,600
32
3.2 mg
3,200
64
6.4 mg
6,400
128 — two injections
Below about five units, graduation error on a U-100 barrel starts to dominate the dose, which is the argument for more diluent at the sub-milligram tiers and less at 1.6 mg and above.
Route is subcutaneous in every trial and on every label. Sites are the abdomen at least two inches from the navel, the outer thigh, or the back of the upper arm, rotated between doses. Nothing in the record supports taking this peptide into a muscle, into a vein or by mouth outside a study protocol.
Bring the vial to room temperature before adding water. Run the water down the inside wall rather than jetting it onto the powder. Swirl until dissolved and never shake — shear at the air-liquid interface unfolds peptides and makes them clump, and that clumping is the exact mechanism FDA named when it warned about the immune system reacting to the drug.
Storage, and the difference the diluent makes
State
Temperature
Practical shelf life
Sealed lyophilised vial
2–8 °C, protected from light
To the manufacturer's date
Reconstituted with Sterile Water for Injection — the licensed diluent
—
Use immediately. No preservative present
Reconstituted with bacteriostatic water, 0.9% benzyl alcohol
2–8 °C
About four weeks, set by the preservative rather than by the peptide
Reconstituted, held at room temperature
20–25 °C
Hours to days. Treat as compromised
Reconstituted, frozen
−20 °C
Avoid. Freeze-thaw aggregates peptides
The licensed insert says use immediately because the supplied diluent is preservative-free. A multi-dose vial reconstituted with bacteriostatic water is a different object running a different clock.
Timelines
Peak serum concentration is reached about 2 hours after a subcutaneous dose, the elimination half-life is about 2 hours, and 31% to 60% of the dose is recovered in urine. The drug leaves the blood the same day. Everything that persists is downstream of what it did to cells, which is why the schedules are twice weekly rather than daily.
What was measured
When it read out in the trials
Monocyte HLA-DR improvement — ETASS
Days 3 and 7
CD4+ percentage and CD4+/CD8+ ratio change
Within the 7–14 day critical-illness courses
Vaccine seroconversion — H1N1 pilot
Day 21 after vaccination, dosed day −7 and day 0
Hepatitis B sustained virological response
6–12 months of dosing, assessed 6 months after treatment
Hepatitis C sustained virological response
Week 72, after 48 weeks of dosing
Colorectal disease-free survival
3 years, after 6 months of dosing
The safety record is the longest in this library, which is not the same as no risk
Most compounds in this library have no human safety file at all. This one has a specific, quantified record.
Since 1979, thymalfasin has been given to more than 3,000 patients in over 70 clinical studies, at doses from 1 mg to 16 mg, for periods from a single day to 18 months. The monograph's summary sentence is that "no serious adverse experiences have been observed." Patients as old as 101 and children as young as 13 months have been dosed. Patients with decompensated liver disease and patients on haemodialysis tolerated it.
The label puts drug-related adverse events at under 1% across all indications and describes them as "infrequent and mild, consisting primarily of local discomfort at the injection site, and rare instances of erythema, transient muscle atrophy, polyarthralgia combined with hand edema, and rash." It is contraindicated in hypersensitivity to the drug or its components.
The controlled trials support that. TESTS randomised 1,106 patients and reported no safety outcome differing significantly between drug and placebo. TRACE randomised 508 and found no difference in bleeding, fistula or new organ failure. The H1N1 pilot attributed no adverse event to the peptide. In the dialysis prevention trial, serious adverse events were 28 of 91 on treatment against 26 of 98 on control, and deaths were 3 of 91 against 7 of 98.
Preclinical toxicity never reached a maximum tolerated dose. Single subcutaneous doses up to 20 mg/kg in mice, rats and marmosets — more than 800 times the human 1.6 mg dose by weight — produced no drug-related toxicity, as did repeat dosing at 6 mg/kg/day for 13 weeks.
Three qualifications matter more than the reassurance.
Immune activation can itself be the adverse event. A 29-year-old man with nasopharyngeal carcinoma received a single 1.6 mg subcutaneous dose eleven days after the checkpoint inhibitor sintilimab. Within 48 hours he had fever of 39–40.5 °C, facial rash and oedema, progressive hypoxaemia with interstitial pulmonary oedema, AST of 742 U/L, and a prothrombin time of 23.2 seconds. He required 160 mg of intravenous methylprednisolone daily and was discharged on day 33. He later tolerated a sintilimab rechallenge without recurrence, which points the causal finger at the peptide rather than the checkpoint inhibitor.
The COVID cohort recorded worse outcomes, not merely absent benefit. An adjusted odds ratio of 1.5 for non-recovery in the sicker patients is a harm signal, and the mechanism is plausible: adding immune activation to a hyperinflammatory state is not obviously safe.
FDA's stated concern is manufacturing, not what the drug does in the body. The risk of the immune system reacting to the drug, raised by clumping and by peptide-related impurities, is a supply-chain problem. The 3,000-patient safety record belongs to a pharmaceutical product made to a licensed specification. A grey-market vial carrying a vendor's own certificate of analysis is not that product, and a cloudy reconstitution is a visible sign of the exact aggregation the agency named.
What people using it outside the trials report
These are self-reports with dates and permalinks, gathered from public discussion. They are not evidence of whether it works, they are not filtered for anything, and they are here because they show what the experience looks like and how often it goes badly.
Approved as thymalfasin in roughly 35 countries for hepatitis B, hepatitis C and vaccine adjuvant use
Proven
Not approved in the United States or the European Union; no Drugs@FDA entry and no FDA label
Proven
Listed in FDA's "nominated but withdrawn" bulk-substances table, not in Category 2, and on neither the 503A nor the 503B bulks list
Proven
Acts through TLR9/MyD88/IRF7 on plasmacytoid dendritic cells; the effect is abolished in TLR9-deficient mice
Proven
Raises CD4+ percentage by 4.53 points and the CD4+/CD8+ ratio by 0.42 in critically ill humans
Proven
Peak serum at about 2 hours, elimination half-life about 2 hours, 31–60% urinary recovery
Proven
Sustained virological response advantage in chronic hepatitis B monotherapy, OR 2.87 (1.58–5.22)
Proven
Met the European regulator's antibody-response criteria as an influenza vaccine adjuvant in haemodialysis patients where vaccine alone did not
Proven
No mortality benefit in sepsis in a 1,106-patient placebo-controlled phase 3
Proven
No reduction in infected pancreatic necrosis in a 508-patient placebo-controlled trial
Proven
Drug-related adverse events under 1% across indications in the licensed record, predominantly injection-site discomfort
Unproven
Any benefit in post-viral fatigue, chronic fatigue, MCAS, or any autoimmune condition — no completed randomised trial exists
Unproven
Benefit in COVID-19. Three observational studies, three different answers, one of them harm
Unproven
Whether the pancreatitis lymphocyte-count subgroup effect survives prospective testing
Unproven
Whether it improves disease-free survival in colorectal cancer; that trial reads out in 2027
Unknown
The outcome of two completed phase 3 hepatitis C trials totalling 1,052 patients, never reported
Unknown
Any effect on tendon, ligament, disc, muscle or joint tissue. No model, no trial, no mechanism
Unknown
The correct dose for an outpatient with no diagnosed immune deficiency
Unknown
Whether grey-market material matches the pharmaceutical product that generated the safety record
Thymosin alpha-1 is not an approved drug in the United States and is not lawfully available there through the bulk-compounding pathways. Nothing here is a dosing or treatment recommendation.
The sibling objects for this page, each one inspectable on its own terms:
Immune Modulation with Thymosin Alpha 1 Treatment“Thymosin alpha 1 (Ta1) is a peptide originally isolated from thymic tissue as the compound responsible for restoring immune function to thymectomized mice.”
Thymosin Alpha-1 Peptide: Benefits and Safety [2026]“In contrast to those findings, a placebo-controlled trial from early 2025 with over 1,000 subjects found “no clear evidence” that TA-1 decreased 28-day all-cause mortality in adults with sepsis.”
be careful about thymosin alpha-1 : r/cfs“I am having the same problems with TA-1 I just connected the dots after 2 weeks of being on TA-1 my lymph nodes are swollen in my neck ...”
Anyone get side effects/an immune reaction to Thymosin- ...“Im 2 weeks into TA-1 , its working as expected. Immune activation/rebalancing - clearing out virus/viral debris my body was unable to deal with before (Feels like a bad cold/minor flu).”
A Complete Guide for Thymosin Alpha 1“I have been experimenting with ta1 and vip for a few weeks for some really bad eczema and doing a similar protocol. my eczema seems to respond really well to ta1...”
Megadose experience with Thymosin Alpha 1“I took a megadose of Thymosin Alpha 1 peptide for 3 days in a row. By day 3, I was so sick I could not go outside. Today, I woke up and I feel significantly *stronger* than before.”
Thymosin Alpha-1 (Zadaxin): A Thymic Peptide and Toll-Like Receptor Signaling Modulator“Thymosin alpha-1 is a 28-amino-acid thymic peptide approved as Zadaxin in more than 35 countries for chronic hepatitis B but not FDA-approved in the US. ... As of April 2026, thymosin alpha-1 is not FDA-approved in the United States. It is approved internationally under the brand name Zadaxin for chronic hepatitis B in more than 35 countries, including China and Italy. In the US, it holds FDA 503A”
Thymosin alpha 1 peptide?“The peptide thymosin alpha 1 has been shown to be able retrain the immune system. Ankylosing is an autoimmune disorder. It helps heal the gut but also helps ... Ok I have tried this peptide.”
Has anyone tried Thymosin Alpha 1 for Long COVID?“Hi all, Our team is curious if anyone out there has tried the peptide Thymosin Alpha 1 for Long COVID. We’re asking for research purposes (not endorsing ...”
Aging and Thymosin Alpha-1“Thymosin alpha-1 (Tα1), a peptide hormone produced by the thymus, exhibits potent immunomodulatory, anti-inflammatory, and antioxidant properties.”
Thymosin-alpha 1 ??“I actually tried it back in October and it sent me into the worst flare I’ve had in 4 years. Felt awful and took me almost 2 full months to recover.”
Peptides“I tried TA-1 for 8 weeks and it increased my TPO antibodies.”
Thymosin-alpha 1 ??“Each herx reaction was slightly different but the first one, I felt “classicly sick”, like how normal people feel when they get the flu... Then after that they started to feel a bit more similar, usually severe fatigue plus normal viral symptoms. ... once I stabilize at each dose increase, I feel like I get about 2-3% of my life back.”
X post by @CaneGrrl“Anyone else experience sleep benefits with Thymosin Alpha-1? Could be a coincidence but my REM and deep sleep have gone up every night I’ve take it (which is only 3 so far, but still…)”
X post by @quardoqu“My top Long Covid treatments so far after six years in order of effectiveness out of a 100+: 1. LDN ... 2. Subq TA-1 (Thymosin Alpha 1) ...”
X post by @quardoqu“Any idea why Thymosin Alpha 1 takes my Long Covid symptoms away for 48 hours?”
Thymalin and Thymosin Alpha-1 Both Target the Thymus“Thymosin Alpha-1 is a single defined 28-amino acid peptide sequence. It has an approved pharmaceutical form - Zadaxin - used clinically in over 35 countries”
Long-term Prognosis of Patients With Sepsis After ...“Current clinical studies of thymosin α1 for sepsis have focused on short-term outcomes (28-day or 90-day mortality), and lack of clinical data on long-term ...”
Thymosin Alpha 1 - experiences and anecdotes. A treatment for severe allergies?“I love TA1 and cycle it twice a year. In spring and fall. I'll mix it in other times if I'm feeling off. I personally use it to help my immune responses to both spring and fall allergies. It's worked well to have a lower response to the allergens.”
Peptides? Anyone taking these?“I will be testing my TPO at the 6 week mark in 2 weeks for TA-1. I was at 97 at the start, and I had actually done a single vial of 1 mg a day for 10 days and my Tpo had dropped about 10 points so I am hoping that was the cause and I can bring it down with a longer protocol.”
What resolved my chronic fatigue - 5 years later“Peptides: I have started taking Thymosin Alpha 1, Thymosin Beta 4, Semax and Selank. ... Thymosin Alpha 1 is an immune modulator so it helps improve the immune system. It also has anti inflammatory effects.”
Thymosin Alpha 1“Within an hour felt significantly better, I mean total package of energy and good mood. ... Inflammation has been decreasing and histamine reaction is definitely getting better. ... within an hour I could do full range squats. Walking down stairs with full flexing and no pain. I’ve lost 3.5lbs of inflammation in 3 days.”
Thymosin Alpha 1“TA1 is one of my favorite peptides! I’m allergic to animals but I love them. Was wrestling around w my brothers dog last night ... and left without washing my hands and did not wheeze, cough, choke or blow my nose. ... my first time, within 2 hours I can only compare my reaction to Covid like symptoms. ... lasted about eight hours.”
Those who tried peptides - permanent shift in baseline?“Thymosin-Alpha-1 _destroyed me_ - one 0.5mg injection and within 12 hours I had a severe flu-like immune reaction (fever, diarrhea, pins and needles, the works). The immune reaction continued the next day as well, and even after subsiding, I'm still crashed from it five days later - in the 70s whereas previously I was in the high 80s.”
Thymosin Alpha 1 and Peptides for LC Discussed on Huberman Lab“ME/CFS here - I’ve used TA1 and Thymulin with great success. I’ve had to increase the dose and I can still overdo it and cause PEM and I have to take it daily or the benefit is lost but….it absolutely provides a lift in energy and brain fog and functionality.”
X post by @thecoercednurse“It helped to stop the progression of my immune/cardiovascular/respiratory failure. Decreased the debilitating muscle spasms. Improved my ADL function. Kept my autonomic swings more level. Essentially stopped me from needing to choose hospice/palliative care as my only option.”
X post by @squarian24“I’m being very serious. There’s minimal side effects, no long term effects have been shown after a near decade of studies, and it works.”
Thymosin Alpha 1“I did find some pre clinical evidence that Thymosin Alpha 1 was protective against opportunistic infection due to suppression from 5-flurouracil.”
Thymosin Alpha-1 testing“My kids caught cold again 3 days ago My mother also caught cold from them It didn't spread to me yet and I didn't take my Thymosin Alpha -1 Testing if the previous doses are working or not”
Thymosin Alpha-1 for sinusitis“For someone who suffers from sinusitis, one of the best remedies I’ve used is Thymosin Alpha-1. I use it as needed. But it almost immediately opens the sinuses up and cleans out the gunk. Same with the throat.”
RNA seq data with TA1“Day 0 meds: baseline, Thymosin Alpha 1 for a few days. ... Good news is a substantial amount of my out of range genes went back into range on day 42.”
Thymosin Alpha 1“It's a risky gamble imo. There is a small subset of SFN patients who I would expect to get modestly better from Ta1, with the rest either getting no benefit or even feeling _worse_. You don't want to jack up T cell activity if T cell activity is already problematic.”
Thymosin Alpha 1“I just started! Haven’t seen any results or had any relief yet but I will keep you posted!”
Thymosin alpha 1 daily vs twice weekly administration“I basically get more ill for a few days every time I take the TA1. So it’s a bit of a hinderance to general work and life stuff. I might try lower doses to see if that is easier to handle.”
Ta1 Cloudy at Reconstitution“I have tried two different vials of Thymosin Alpha 1 from the same source and both are cloudy with suspended ...”
LL37 & Thymosin Alpha Review“I have begun a LL37 and Thymosin Alpha cycle, this time for the exact purpose of healing the body in all the ways these peptides are said to do.”
SciClone Pharmaceuticals ZADAXIN (thymalfasin) Product Monograph“Since 1979, Zadaxin has been evaluated in more than 3,000 patients in over 70 clinical studies. Administration has been in daily doses ranging from 0.6 to 9.6 mg/m2 and 1 mg to 16 mg, primarily administered subcutaneously on a biweekly schedule, for treatment periods ranging from 1 day to 18 months. No serious adverse experiences have been observed.”
A Case Report of a Multisystemic Immune-Related Adverse Event Induced by Thymosin Alpha-1“A 29-year-old man with nasopharyngeal carcinoma developed high fever 39-40.5 C, facial rash and oedema, hypoxaemia, AST 742 U/L and prolonged prothrombin time 23.2 s within 48 hours of a single 1.6 mg subcutaneous dose of thymosin alpha-1 given 11 days after sintilimab; treated with intravenous methylprednisolone 160 mg daily and discharged on day 33.”
the whole object this page is drawn from, as JSON
{
"schema":"https://miscsubjects.com/schemas/jarticle.json",
"status":"published",
"slug":"thymosin-alpha-1",
"title":"Thymosin Alpha-1: Approvals, Trial Record, Dosing and What It Does Not Treat",
"kind":"essay",
"summary":"Thymosin alpha-1 is a chain of 28 amino acids that the thymus gland releases into the blood, where it tells immature T cells to finish growing up. The synthetic copy is called thymalfasin, it is sold as Zadaxin, and it is a licensed",
"created":"2026-06-29 08:23:19",
"body": [
"Thymosin alpha-1 is a chain of 28 amino acids that the thymus gland releases into the blood, where it tells immature T cells to finish growing up. The synthetic copy is called thymalfasin, it is sold as Zadaxin, and it is a licensed prescription medicine in roughly 35 countries — which makes it the only compound in this library that a drug regulator anywhere has ever approved.\n\nThat single fact reorders everything else, so take the evidence state before anything is argued from it. Most peptides in this library have animal data and a handful of uncontrolled human reports. Thymosin alpha-1 has 63 studies registered on ClinicalTrials.gov, four completed phase 3 programmes, a licensed package insert with a real dosing schedule, and more than 3,000 patients dosed across over 70 studies since 1979. Two of the randomised trials are large and both missed their main endpoint: TESTS, 1,106 adults with sepsis, where 28-day death was 23.4% against 24.1% on placebo; and TRACE, 508 people with severe pancreatitis, where infected dead tissue came out at 15.7% against 18.1%. Two results went the other way: in chronic hepatitis B on its own the odds of clearing the virus and holding it cleared came out 2.87 times placebo, and in a 120-person randomised trial in dialysis patients the drug carried a flu vaccine over the European licensing threshold that the vaccine alone did not reach. One observational study in COVID-19 recorded worse outcomes. The animal record is mice, and its cleanest single result is that the whole effect vanishes in mice bred without the TLR9 receptor. Then the absence that governs this page: across all 63 registered trials there is no tendon, no ligament, no disc, no muscle and no joint. Nothing has been measured in a person for any musculoskeletal problem, and no animal model of one has been run either.\n\nOne disclosure, because it should change how you read the rest. The operator of this site has a commercial interest in compounds described here. That is a reason to weigh what is on this page against the sources it cites rather than against its tone, and every claim below carries the source that supports it for exactly that reason.",
{
"type":"source",
"id":"w_18bl3rtc"
},
"## Approved in Beijing, unapproved in Bethesda\n\nThymalfasin holds marketing approvals for chronic hepatitis B, chronic hepatitis C, use as a vaccine adjuvant in immunocompromised patients, and certain cancers, with the exact indication set varying by country. The United States is not among them. Neither is the European Union.\n\n| Jurisdiction | Status | Indications where approved |\n|---|---|---|\n| China | Approved; marketed as Zadaxin and by domestic manufacturers | Hepatitis B, immune enhancement, vaccine response, critical-illness adjunct |\n| Italy | Approved | Hepatitis B, hepatitis C |\n| Roughly 35 countries in total | Approved | Hepatitis B, hepatitis C, vaccine adjuvant, certain cancers, per each national label |\n| United States | **Not approved.** No Drugs@FDA entry, no FDA-approved label, no openFDA label record | None |\n| European Union | **Not approved** | None |\n\nThe manufacturer's own monograph puts the count at \"over 30 countries\" and states the exclusion in one sentence: \"ZADAXIN has not been approved for sale in the United States or Europe.\" The peer-reviewed literature puts it at \"more than 35 countries.\"",
{
"type":"source",
"id":"w_d85m6gah"
},
{
"type":"source",
"id":"s1"
},
"The US absence is not a rejection on the merits. No sponsor has completed a US registration filing. Thymalfasin has held FDA orphan drug designations — for malignant melanoma, chronic active hepatitis B, DiGeorge anomaly with immune defects, and hepatocellular carcinoma. A designation is a development incentive: fee waivers, tax credits, and seven years of market exclusivity if the drug is later approved. It is not an approval, it permits no marketing, and it carries no finding about whether the drug works. Sources that describe those designations as approvals are wrong, and the distinction is the whole of the US position.\n\n## Withdrawn from the danger list is not the same as cleared for use\n\nThe entire United States position turns on one table on one FDA page, and the row is easy to misread.\n\nFDA maintains a page titled *Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks*. It carries two tables. The first is Category 2 proper — substances FDA has flagged as posing significant safety risks, which bars compounding under the interim policies. The second is headed *Bulk drug substances nominated but withdrawn*, described as substances \"previously in category 2 of the interim policies\" that \"were withdrawn by the nominators.\"\n\nThymosin-alpha 1 sits in the second table, alongside BPC-157, KPV, TB-500, epitalon, semax, selank and DSIP. FDA's recorded concern reads:\n\n> Compounded drugs containing thymosin-alpha-1 (Ta1) may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. The safety-related information is inadequate for the agency to sufficiently understand the extent of any safety issues raised by the proposed compounded drug.",
{
"type":"source",
"id":"w_uzdfttix"
},
"Three consequences follow, and they are not the same as each other.\n\nWithdrawal is a procedural act by the party who filed the nomination. It removes the substance from the active Category 2 listing. It is not FDA finding the substance safe, and no agency review concluded in the substance's favour.\n\nAbsence from Category 2 creates no permission. To be lawfully compounded from a bulk substance under section 503A, a substance must be the subject of an applicable USP or National Formulary monograph, be a component of an FDA-approved drug, or appear on the 503A bulks list. Thymosin alpha-1 is none of the three in the United States. The 503B outsourcing-facility channel is separate, narrower, and does not list it either.\n\nThe practical position in the United States is therefore an unapproved drug obtainable only through the grey market or a compounder operating outside the bulks framework. Any source still describing it as \"FDA Category 2\" is quoting a status the current page no longer assigns to it. That page was last updated 22 April 2026.\n\n## It gives back a signal the thymus stops sending\n\nThe thymus is largest in childhood and shrinks from puberty onward. By the sixth decade most of its functional tissue has been replaced by fat, and the output of new naive T cells falls with it. Thymosin alpha-1 is one of the peptides that tissue secretes; circulating levels in healthy adults run between 0.1 and 1 ng/mL and are lower in disease.\n\nThe mechanism reads as a chain. The links are not equally well established, and the difference matters.\n\n**Step one — it binds Toll-like receptors on dendritic cells.** This is the anchoring finding and it is demonstrated directly. In mice, thymosin alpha-1 activated plasmacytoid dendritic cells through TLR9 and MyD88, switching on interferon regulatory factor 7 and driving an interferon-alpha and interferon-gamma effector response. Mice lacking TLR9 lost the protection. That is a knockout-confirmed dependency, not a correlation.",
{
"type":"source",
"id":"w_e7vuijxz"
},
"**Step two — the dendritic cell decides what kind of immunity follows.** Dendritic cells read an infection and instruct the rest of the immune system. Priming them through TLR/MyD88 produced Th1-type antifungal resistance in living animals. The same work found thymosin alpha-1 inducing indoleamine 2,3-dioxygenase in dendritic cells — the enzyme that pushes toward tolerance rather than attack.",
{
"type":"source",
"id":"w_pptae9m4"
},
"**Step three — T cells mature and differentiate.** The 1972 characterisation was of a thymic fraction that restored immune function to thymectomised mice. The measurable human version is a rise in CD4+ percentage and a normalising CD4+/CD8+ ratio. A meta-analysis of five randomised trials in severe acute pancreatitis quantified it: CD4+ percentage rose by 4.53 points (95% CI 3.02 to 6.04) and the CD4+/CD8+ ratio by 0.42 (95% CI 0.26 to 0.58). CD8+ counts did not fall significantly, which is the point — the ratio normalised by lifting the deficient arm.",
{
"type":"source",
"id":"s7"
},
"**Step four — natural killer cells and cytotoxic T lymphocytes.** Thymosin alpha-1 modulates NK cell maturation and cytotoxic T lymphocyte responses, and raises MHC class I surface expression on tumour cell lines. The target cell becomes easier to see, not only the effector cell more aggressive.",
{
"type":"source",
"id":"w_ekm6tk8i"
},
"**Step five — reversal of T-cell exhaustion.** In severe COVID-19 patients, treatment was associated with reduced PD-1 and Tim-3 expression on CD8+ T cells and a rise in T-cell receptor excision circles, the standard marker of fresh thymic output. This is observational human data from a retrospective cohort of 76 patients, not a controlled experiment, and it belongs in a different evidentiary tier from step one.",
{
"type":"source",
"id":"w_or6weneu"
},
"What separates this compound from a stimulant is that the same molecule pushes in opposite directions depending on the state it finds. It induces tolerance-promoting IDO in one context and interferon-driven antiviral attack in another. That bidirectionality is why the literature calls it restoration rather than stimulation. It is also why the dose-response is not a straight line, and why the sepsis subgroups below point in opposite directions in different patients.",
{
"type":"source",
"id":"s2"
},
"## Sixty-three registered trials, and the two largest disagree\n\nSixty-three studies are registered on ClinicalTrials.gov with thymosin alpha-1 as an intervention. The named human record is set out below with the result stated as each trial reported it, including the failures.\n\n| Trial | NCT | n | Population | Dose | Duration | Primary endpoint | Result |\n|---|---|---|---|---|---|---|---|\n| TESTS — phase 3, quadruple-blind, 22 centres | NCT02867267 | 1,106 | Sepsis-3 adults, 18–85 | 1.6 mg SC every 12 h | ≤7 days | 28-day all-cause mortality | **Missed.** 23.4% vs 24.1% placebo; HR 0.99 (0.77–1.27); P=0.93 |\n| ETASS — RCT, single-blind, 6 centres | NCT00711620 | 361 analysed | Severe sepsis | 1.6 mg SC twice daily ×5 d, then daily ×2 d | 7 days | 28-day all-cause mortality | Borderline. 26.0% vs 35.0%; RR 0.74 (0.54–1.02); P=0.062 unstratified, 0.049 log-rank |\n| TRACE — phase 4, double-blind, 16 centres | NCT02473406 | 508 | Predicted severe acute necrotising pancreatitis | 1.6 mg SC q12h ×7 d, then daily ×7 d | 14 days | Infected pancreatic necrosis | **Missed.** 15.7% vs 18.1%; difference −2.4% (−7.4 to 5.1); P=0.48 |\n| TRACE post-hoc, lymphocyte-stratified | NCT02473406 | 290 of 502 | Same trial, baseline ALC ≥0.8×10⁹/L | as above | 14 days | Infected pancreatic necrosis at 90 d | Positive in subgroup. Adjusted risk difference −0.12 (−0.21 to −0.02); P=0.015 |\n| Hepatitis C non-responders — phase 3, 52 European sites | NCT01178996 | 552 | Chronic HCV, prior peg-IFN + ribavirin failure | 1.6 mg SC twice weekly + peg-IFN α-2a + ribavirin | 48 weeks | Sustained virological response at week 72 | Completed July 2009. **No results posted or published** |\n| Hepatitis C non-responders, non-cirrhotic — phase 3 | NCT00040027 | 500 | Chronic HCV interferon non-responders | 1.6 mg twice weekly + peg-IFN α-2a | — | Virological response | Completed. **No results posted** |\n| Metastatic melanoma — phase 2, dose-ranging, 5 arms | NCT00911443 | 488 | Stage IV melanoma | 1.6, 3.2 or 6.4 mg SC on days 8–11 and 15–18 of each 28-day cycle | ≤6 cycles | Overall tumour response | Responders 7/97, 10/97, 6/98, 12/99 in the four Tα1 arms vs 4/97 control. Median OS 8.6–10.3 months vs 6.6 |\n| COVID-19 prevention in dialysis — phase 2 | NCT04428008 | 189 | ESRD on haemodialysis | 1.6 mg SC | 6 months | Number infected with COVID-19 | 5/91 treated vs 7/98 control. Deaths 3/91 vs 7/98. Underpowered for both |\n| COVID-19 with lymphocytopenia — phase 2 | NCT04487444 | 56 | Hospitalised, lymphocytopenic | 1.6 mg SC daily ×7 d | 1 week | Time to freedom from respiratory failure | **Terminated** February 2023. No results posted |\n| H1N1 vaccine adjuvant pilot | NCT01031966 | 120 enrolled, 94 ITT | ESRD on chronic dialysis | 3.2 mg or 6.4 mg on day −7 and day 0 | 2 doses | Antibody response measured by haemagglutination-inhibition | Positive. CHMP licensing criteria fully met in both Tα1 arms, not in vaccine-only |\n| Colorectal cancer adjuvant — phase 3 | NCT05086614 | 2,500 planned | Resected high-risk stage II/III colorectal cancer | 1.6 mg SC twice weekly | 6 months | 3-year disease-free survival | **Recruiting.** Primary completion March 2027 |\n| Acute aortic dissection, immune dysregulation | NCT05339529 | 330 | Post-operative acute aortic syndrome | Per protocol | — | Organ dysfunction | Recruiting |\n| Vaccine response in older adults — phase 1 | NCT06821100 | 75 | Adults over 65 receiving COVID-19 vaccine | Per protocol | — | Immune response | Recruiting |",
{
"type":"source",
"id":"w_vzvtwnky"
},
{
"type":"source",
"id":"w_zlvvtukb"
},
"## Hepatitis is the indication the licences rest on\n\nThe approvals were granted on chronic hepatitis B. An independent meta-analysis of 435 patients across randomised controlled trials of thymalfasin monotherapy found a sustained virological response advantage over placebo with an odds ratio of 2.87 (95% CI 1.58–5.22, P=0.0005), and a non-significant trend favouring it over interferon alpha (OR 2.62, 95% CI 0.80–8.56). Across the individual monotherapy studies, disease remission ran 26% to 41%.",
{
"type":"source",
"id":"w_d85m6gah"
},
"Two caveats belong in the same breath. The comparator was interferon or placebo, in an era before tenofovir and entecavir; a 2020 review states plainly that hepatitis B and C treatment with thymosin alpha-1 \"has been discontinued in favor of direct antiviral agents.\" And the two large phase 3 hepatitis C programmes in non-responders — 552 and 500 patients, both completed more than fifteen years ago — have never reported. A completed 552-patient phase 3 with no published outcome is not neutral evidence about a drug; it is a hole where the answer should be.",
{
"type":"source",
"id":"w_xmbjsj3u"
},
"## Sepsis is where it was tested hardest and came up short\n\nETASS in 2013 was the encouraging trial. 361 patients, 28-day mortality 26.0% on thymosin alpha-1 against 35.0% on control, plus a measurable rise in monocyte HLA-DR — the clearest available marker of reversed immunoparalysis — at day 3 (mean difference 3.9%, 95% CI 0.2–7.6) and day 7 (5.8%, 95% CI 1.0–10.5). The mortality difference did not clear significance on the primary unstratified analysis at P=0.062.\n\nTESTS was built to settle it. 1,106 patients, 22 centres, quadruple-blinded, placebo-controlled, phase 3. It found nothing: 28-day mortality 23.4% against 24.1%, hazard ratio 0.99, P=0.93. No secondary endpoint separated, and no safety endpoint separated either.\n\nThe subgroup analysis is where it stops being simply negative. Patients under 60 did worse on the drug (HR 1.67, 1.04–2.67). Patients 60 and over trended better (HR 0.81, 0.61–1.09). Interaction P=0.01. Diabetic patients did better (HR 0.58, 0.35–0.99), non-diabetic patients did not (HR 1.16, 0.87–1.53), interaction P=0.04. These are prespecified subgroups inside a negative trial. They are hypotheses, and a younger patient doing worse on an immune-restoring drug is a hypothesis worth taking seriously in both directions.\n\nA 2025 meta-analysis pooled 11 randomised trials and 1,927 patients. Overall it found a 28-day mortality benefit (OR 0.73, 95% CI 0.59–0.90, P=0.003). That benefit disappeared when restricted to high-quality trials (OR 0.82, P=0.09) and to multicentre trials (OR 0.86, P=0.20). Trial sequential analysis concluded the accumulated sample is still inadequate to answer the question.",
{
"type":"source",
"id":"s27"
},
"## Pancreatitis: the trial missed, and one subgroup did not\n\nTRACE randomised 508 patients with predicted severe acute necrotising pancreatitis, 94.3% of whom required intensive care. Infected pancreatic necrosis occurred in 15.7% of treated patients and 18.1% of placebo patients, P=0.48. New-onset organ failure, bleeding and gastrointestinal fistula were all similar between arms.",
{
"type":"source",
"id":"w_0c2625io"
},
"The post-hoc analysis found what the whole trial did not. Among the 290 patients whose baseline absolute lymphocyte count was at or above 0.8×10⁹/L, thymosin alpha-1 reduced infected necrosis with an adjusted risk difference of −0.12 (95% CI −0.21 to −0.02, P=0.015). Patients between 0.79 and 2.00×10⁹/L benefited most.",
{
"type":"source",
"id":"w_cbj4dxj3"
},
"Read carefully, that is the single most informative result in the file. An immune-restoring drug worked in the patients who still had lymphocytes to restore and did nothing in the patients too depleted to respond. It is post-hoc, it needs prospective confirmation, and it explains why an unselected population produces a null. It also implies that any honest use of this compound starts with a lymphocyte count.\n\n## COVID-19 produced three answers, and one of them was harm\n\nThe Wuhan retrospective covered 76 severe cases and reported mortality of 11.11% with treatment against 30.00% without (P=0.044), alongside restored CD8+ and CD4+ counts and reduced exhaustion markers.",
{
"type":"source",
"id":"w_or6weneu"
},
"A five-hospital multicentre cohort of 2,282 patients found the reverse. After adjustment for confounders, thymosin alpha-1 use was associated with a *higher* non-recovery rate (OR 1.5, 95% CI 1.1–2.1, P=0.028), with risk concentrated in patients with SOFA scores of 2 or more, ICU admission, and lower PaO₂/FiO₂. Later initiation was worse than earlier.",
{
"type":"source",
"id":"w_q4kpjhai"
},
"A propensity-matched cohort of 1,388 non-severe patients found no difference in progression to severe disease (2.17% vs 2.71%) or in mortality, but shorter viral shedding (13 vs 16 days, P=0.025) and shorter hospital stay (14 vs 18 days, P<0.001).",
{
"type":"source",
"id":"w_vxfrwa56"
},
"All three are observational and all three are subject to confounding by indication — sicker patients get more drugs. The only randomised study that targeted the lymphocytopenic patients the mechanism predicts should respond was terminated at 56 patients and never reported.\n\n## Vaccine response is the cleanest positive signal in the file\n\nHaemodialysis patients mount poor antibody responses to influenza vaccine. In the pilot trial, patients given the adjuvanted H1N1 vaccine alone did not meet the CHMP licensing criteria for seroconversion, seroprotection and geometric mean ratio. Patients given the vaccine plus 3.2 mg or 6.4 mg of thymosin alpha-1 on day −7 and day 0 met all three. No adverse event was attributed to the peptide, and no change appeared in haematology or blood chemistry.",
{
"type":"source",
"id":"w_23spjiq3"
},
"This is 94 patients in an intention-to-treat analysis, in a population defined by immune failure, in a pilot study. It is also the one result where the drug did the specific thing its mechanism predicts, in humans, judged against a prespecified regulatory standard rather than an author's own endpoint.\n\n## The cancer file is adjuvant work with one real trial still running\n\nThe melanoma dose-ranging study is the largest completed oncology dataset: 488 patients across five arms, responses in 6 to 12 patients per thymosin arm against 4 of 97 in the dacarbazine-plus-interferon control, and median overall survival of 8.6 to 10.3 months against 6.6. It was a phase 2 designed to select a dose, not to prove survival, and no phase 3 followed it in the nineteen years since it started.",
{
"type":"source",
"id":"w_omh8z65r"
},
"The trial that would settle the oncology question is enrolling now: 2,500 patients with resected high-risk stage II and III colorectal cancer, randomised to 1.6 mg twice weekly for six months or to no thymosin, with three-year disease-free survival as the primary endpoint and primary completion in March 2027.",
{
"type":"source",
"id":"w_dkfbbahz"
},
"## Every trial population is an infection, an organ failure or a cancer, and not one of them is a back\n\nEvery trial population above is a hepatitis patient, a septic ICU patient, a pancreatitis patient, a cancer patient, or a dialysis patient. Not one is a back-pain patient. There is no musculoskeletal indication, no tendon, ligament, disc or muscle model, and no mechanism connecting T-cell maturation to tissue repair.\n\n| What brings a person to look this up | What the human record actually covers | Strength of the connection |\n|---|---|---|\n| Recurrent infection, slow recovery from every cold | Vaccine-response pilot in dialysis patients; hepatitis approvals; 3,000-patient safety file | Moderate, and only by extrapolation from immunocompromised populations |\n| Documented immunosuppression with a measured low-normal lymphocyte count | TRACE subgroup: the effect appeared where lymphocytes were preserved but suppressed | Moderate. Post-hoc, and it requires the blood test to identify |\n| Post-viral fatigue after a confirmed infection | No completed randomised trial. The COVID file is acute hospitalised disease and it contradicts itself | Absent |\n| Chronic inflammatory load in a chronic-pain patient | CRP fell 30.12 mg/L in the lower-dose arms of the pancreatitis meta-analysis — in patients with necrotising pancreatitis in intensive care | Absent for this population |\n| Immune-related fatigue with no diagnosis and no abnormal labs | No trial, no endpoint, no measurement | Absent |\n| Tendinopathy, disc pain, muscle strain, joint repair | No model, no trial, no proposed mechanism | Absent. The extrapolation is unsupported |\n| Post-adjustment soreness | Nothing | Absent |\n| Hashimoto's, MCAS, ankylosing spondylitis, other autoimmunity | No trial. The mechanism cuts both ways — tolerance in one context, interferon-driven attack in another | Absent, and the self-reports below include people who got measurably worse |\n\nThe one row the record can defend is the immune row, in a person with documented immune compromise, and even that defence is an off-label extrapolation from populations that do not look like that person. Selling thymosin alpha-1 for musculoskeletal repair is a claim that nothing in 63 trials supports.\n\n## Dosing, and the arithmetic behind the syringe\n\nThe licensed product is a 1.6 mg lyophilised vial supplied with 1.0 mL of Sterile Water for Injection. Reconstituted, that is 1.6 mg/mL, and the whole vial is one dose. The approved hepatitis B regimen is 1.6 mg (900 µg/m²) subcutaneously twice a week for 6 to 12 months. Patients under 40 kg receive 40 µg/kg.",
{
"type":"source",
"id":"w_dt6aln8r"
},
"| Setting | Dose | Frequency | Duration |\n|---|---|---|---|\n| Hepatitis B — approved label | 1.6 mg SC | Twice weekly | 6–12 months |\n| Hepatitis C — phase 3 protocol | 1.6 mg SC | Twice weekly | 48 weeks |\n| Sepsis — TESTS | 1.6 mg SC | Every 12 hours | ≤7 days |\n| Sepsis — ETASS | 1.6 mg SC | Twice daily ×5 d, then daily ×2 d | 7 days |\n| Necrotising pancreatitis — TRACE | 1.6 mg SC | Every 12 h ×7 d, then daily ×7 d | 14 days |\n| Colorectal adjuvant — phase 3 | 1.6 mg SC | Twice weekly | 6 months |\n| Metastatic melanoma — phase 2 | 1.6, 3.2 or 6.4 mg SC | Days 8–11 and 15–18 of a 28-day cycle | ≤6 cycles |\n| Influenza vaccine adjuvant | 3.2 or 6.4 mg SC | Day −7 and day 0 | 2 doses |\n\nThe critical-illness regimens run at 3.2 mg per day — twice the hepatitis dose, for one to two weeks. The vaccine regimen runs up to 6.4 mg in a single dose. The cumulative safety record spans 1 mg to 16 mg per dose, and 0.6 to 9.6 mg/m². There is no dose ceiling hiding in that range. There is also nothing showing that a larger dose does more for a stable outpatient.\n\n### Reconstitution, shown as arithmetic\n\nGrey-market vials come as 5 mg or 10 mg of lyophilised powder, not 1.6 mg, so the arithmetic has to be done rather than read off a label.\n\nConcentration in mcg per mL = total micrograms in the vial ÷ millilitres of bacteriostatic water added.\nA U-100 insulin syringe holds 1.0 mL across 100 units, so one unit is 0.01 mL, and micrograms per unit = concentration ÷ 100.\n\nWorked: a 10 mg vial holds 10,000 mcg. Add 4.0 mL of bacteriostatic water. 10,000 ÷ 4.0 = 2,500 mcg/mL. 2,500 ÷ 100 = 25 mcg per unit. A 1.6 mg dose is 1,600 ÷ 25 = 64 units on the barrel.\n\n| Vial | Bacteriostatic water added | Concentration | Mcg per unit | Units for 1.6 mg | Full 1.6 mg doses per vial |\n|---|---|---|---|---|---|\n| 5 mg (5,000 mcg) | 2.0 mL | 2,500 mcg/mL | 25 | 64 | 3, with 200 mcg left over |\n| 5 mg (5,000 mcg) | 2.5 mL | 2,000 mcg/mL | 20 | 80 | 3 |\n| 5 mg (5,000 mcg) | 5.0 mL | 1,000 mcg/mL | 10 | 160 — two injections | 3 |\n| 10 mg (10,000 mcg) | 2.0 mL | 5,000 mcg/mL | 50 | 32 | 6, with 400 mcg left over |\n| 10 mg (10,000 mcg) | 4.0 mL | 2,500 mcg/mL | 25 | 64 | 6 |\n| 10 mg (10,000 mcg) | 5.0 mL | 2,000 mcg/mL | 20 | 80 | 6 |\n\nAt 5,000 mcg/mL — a 10 mg vial in 2.0 mL, the concentration that keeps every trial dose inside one syringe — the conversion is:\n\n| Dose | Micrograms | Units on a U-100 barrel |\n|---|---|---|\n| 0.25 mg | 250 | 5 |\n| 0.5 mg | 500 | 10 |\n| 0.8 mg | 800 | 16 |\n| 1.0 mg | 1,000 | 20 |\n| 1.6 mg | 1,600 | 32 |\n| 3.2 mg | 3,200 | 64 |\n| 6.4 mg | 6,400 | 128 — two injections |\n\nBelow about five units, graduation error on a U-100 barrel starts to dominate the dose, which is the argument for more diluent at the sub-milligram tiers and less at 1.6 mg and above.\n\nRoute is subcutaneous in every trial and on every label. Sites are the abdomen at least two inches from the navel, the outer thigh, or the back of the upper arm, rotated between doses. Nothing in the record supports taking this peptide into a muscle, into a vein or by mouth outside a study protocol.\n\nBring the vial to room temperature before adding water. Run the water down the inside wall rather than jetting it onto the powder. Swirl until dissolved and never shake — shear at the air-liquid interface unfolds peptides and makes them clump, and that clumping is the exact mechanism FDA named when it warned about the immune system reacting to the drug.\n\n### Storage, and the difference the diluent makes\n\n| State | Temperature | Practical shelf life |\n|---|---|---|\n| Sealed lyophilised vial | 2–8 °C, protected from light | To the manufacturer's date |\n| Reconstituted with Sterile Water for Injection — the licensed diluent | — | Use immediately. No preservative present |\n| Reconstituted with bacteriostatic water, 0.9% benzyl alcohol | 2–8 °C | About four weeks, set by the preservative rather than by the peptide |\n| Reconstituted, held at room temperature | 20–25 °C | Hours to days. Treat as compromised |\n| Reconstituted, frozen | −20 °C | Avoid. Freeze-thaw aggregates peptides |\n\nThe licensed insert says use immediately because the supplied diluent is preservative-free. A multi-dose vial reconstituted with bacteriostatic water is a different object running a different clock.\n\n### Timelines\n\nPeak serum concentration is reached about 2 hours after a subcutaneous dose, the elimination half-life is about 2 hours, and 31% to 60% of the dose is recovered in urine. The drug leaves the blood the same day. Everything that persists is downstream of what it did to cells, which is why the schedules are twice weekly rather than daily.\n\n| What was measured | When it read out in the trials |\n|---|---|\n| Monocyte HLA-DR improvement — ETASS | Days 3 and 7 |\n| CD4+ percentage and CD4+/CD8+ ratio change | Within the 7–14 day critical-illness courses |\n| Vaccine seroconversion — H1N1 pilot | Day 21 after vaccination, dosed day −7 and day 0 |\n| Hepatitis B sustained virological response | 6–12 months of dosing, assessed 6 months after treatment |\n| Hepatitis C sustained virological response | Week 72, after 48 weeks of dosing |\n| Colorectal disease-free survival | 3 years, after 6 months of dosing |\n\n## The safety record is the longest in this library, which is not the same as no risk\n\nMost compounds in this library have no human safety file at all. This one has a specific, quantified record.\n\nSince 1979, thymalfasin has been given to more than 3,000 patients in over 70 clinical studies, at doses from 1 mg to 16 mg, for periods from a single day to 18 months. The monograph's summary sentence is that \"no serious adverse experiences have been observed.\" Patients as old as 101 and children as young as 13 months have been dosed. Patients with decompensated liver disease and patients on haemodialysis tolerated it.",
{
"type":"source",
"id":"w_d85m6gah"
},
"The label puts drug-related adverse events at under 1% across all indications and describes them as \"infrequent and mild, consisting primarily of local discomfort at the injection site, and rare instances of erythema, transient muscle atrophy, polyarthralgia combined with hand edema, and rash.\" It is contraindicated in hypersensitivity to the drug or its components.",
{
"type":"source",
"id":"w_dt6aln8r"
},
"The controlled trials support that. TESTS randomised 1,106 patients and reported no safety outcome differing significantly between drug and placebo. TRACE randomised 508 and found no difference in bleeding, fistula or new organ failure. The H1N1 pilot attributed no adverse event to the peptide. In the dialysis prevention trial, serious adverse events were 28 of 91 on treatment against 26 of 98 on control, and deaths were 3 of 91 against 7 of 98.",
{
"type":"source",
"id":"w_jzf25pn3"
},
"Preclinical toxicity never reached a maximum tolerated dose. Single subcutaneous doses up to 20 mg/kg in mice, rats and marmosets — more than 800 times the human 1.6 mg dose by weight — produced no drug-related toxicity, as did repeat dosing at 6 mg/kg/day for 13 weeks.\n\nThree qualifications matter more than the reassurance.\n\n**Immune activation can itself be the adverse event.** A 29-year-old man with nasopharyngeal carcinoma received a single 1.6 mg subcutaneous dose eleven days after the checkpoint inhibitor sintilimab. Within 48 hours he had fever of 39–40.5 °C, facial rash and oedema, progressive hypoxaemia with interstitial pulmonary oedema, AST of 742 U/L, and a prothrombin time of 23.2 seconds. He required 160 mg of intravenous methylprednisolone daily and was discharged on day 33. He later tolerated a sintilimab rechallenge without recurrence, which points the causal finger at the peptide rather than the checkpoint inhibitor.",
{
"type":"source",
"id":"w_c958vpgi"
},
"**The COVID cohort recorded worse outcomes, not merely absent benefit.** An adjusted odds ratio of 1.5 for non-recovery in the sicker patients is a harm signal, and the mechanism is plausible: adding immune activation to a hyperinflammatory state is not obviously safe.\n\n**FDA's stated concern is manufacturing, not what the drug does in the body.** The risk of the immune system reacting to the drug, raised by clumping and by peptide-related impurities, is a supply-chain problem. The 3,000-patient safety record belongs to a pharmaceutical product made to a licensed specification. A grey-market vial carrying a vendor's own certificate of analysis is not that product, and a cloudy reconstitution is a visible sign of the exact aggregation the agency named.\n\n## What people using it outside the trials report\n\nThese are self-reports with dates and permalinks, gathered from public discussion. They are not evidence of whether it works, they are not filtered for anything, and they are here because they show what the experience looks like and how often it goes badly.",
{
"type":"source",
"id":"s8"
},
{
"type":"source",
"id":"s61"
},
{
"type":"source",
"id":"s75"
},
{
"type":"source",
"id":"s41"
},
"The most consistent thread across the positive reports is a flu-like reaction in the first days, which users describe as the immune system waking up.",
{
"type":"source",
"id":"s14"
},
"The negative reports describe the same reaction without the recovery on the other side of it.",
{
"type":"source",
"id":"s63"
},
{
"type":"source",
"id":"s37"
},
{
"type":"source",
"id":"s13"
},
"Two reports concern measured markers rather than symptoms, in the same condition, and they disagree.",
{
"type":"source",
"id":"s38"
},
{
"type":"source",
"id":"s59"
},
"One comment states the risk in exactly the terms the mechanism implies.",
{
"type":"source",
"id":"s77"
},
"And one describes the physical failure mode that FDA's warning is about.",
{
"type":"source",
"id":"s84"
},
"## Proven, unproven, unknown\n\n| Status | Claim |\n|---|---|\n| Proven | Approved as thymalfasin in roughly 35 countries for hepatitis B, hepatitis C and vaccine adjuvant use |\n| Proven | Not approved in the United States or the European Union; no Drugs@FDA entry and no FDA label |\n| Proven | Listed in FDA's \"nominated but withdrawn\" bulk-substances table, not in Category 2, and on neither the 503A nor the 503B bulks list |\n| Proven | Acts through TLR9/MyD88/IRF7 on plasmacytoid dendritic cells; the effect is abolished in TLR9-deficient mice |\n| Proven | Raises CD4+ percentage by 4.53 points and the CD4+/CD8+ ratio by 0.42 in critically ill humans |\n| Proven | Peak serum at about 2 hours, elimination half-life about 2 hours, 31–60% urinary recovery |\n| Proven | Sustained virological response advantage in chronic hepatitis B monotherapy, OR 2.87 (1.58–5.22) |\n| Proven | Met the European regulator's antibody-response criteria as an influenza vaccine adjuvant in haemodialysis patients where vaccine alone did not |\n| Proven | No mortality benefit in sepsis in a 1,106-patient placebo-controlled phase 3 |\n| Proven | No reduction in infected pancreatic necrosis in a 508-patient placebo-controlled trial |\n| Proven | Drug-related adverse events under 1% across indications in the licensed record, predominantly injection-site discomfort |\n| Unproven | Any benefit in post-viral fatigue, chronic fatigue, MCAS, or any autoimmune condition — no completed randomised trial exists |\n| Unproven | Benefit in COVID-19. Three observational studies, three different answers, one of them harm |\n| Unproven | Whether the pancreatitis lymphocyte-count subgroup effect survives prospective testing |\n| Unproven | Whether it improves disease-free survival in colorectal cancer; that trial reads out in 2027 |\n| Unknown | The outcome of two completed phase 3 hepatitis C trials totalling 1,052 patients, never reported |\n| Unknown | Any effect on tendon, ligament, disc, muscle or joint tissue. No model, no trial, no mechanism |\n| Unknown | The correct dose for an outpatient with no diagnosed immune deficiency |\n| Unknown | Whether grey-market material matches the pharmaceutical product that generated the safety record |\n\n*Thymosin alpha-1 is not an approved drug in the United States and is not lawfully available there through the bulk-compounding pathways. Nothing here is a dosing or treatment recommendation.*\n\nThe sibling objects for this page, each one inspectable on its own terms:\n\n![[kpv]]\n\n![[ghk-cu]]\n\n![[bpc-157]]\n\n![[dsip]]\n\n![[tb-500]]"
],
"facts": {
"converted_from":"markdown",
"original_updated":"2026-08-04T20:47:55.530Z",
"register":"essay",
"category":null
},
"hero":"https://miscsubjects.com/img/gen/arcads-gpt-image-859c9a53-b102-44a2-aa98-37b9e7a65088.png",
"model":"grok/grok-4.3",
"tags": [
"peptide",
"thymosin-alpha-1"
],
"sources": [
{
"id":"s1",
"type":"review",
"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7747025/",
"title":"Thymosin alpha 1: A comprehensive review of the literature",
"quote":"Thymosin alpha 1 is a peptide naturally occurring in the thymus that has long been recognized for modifying, enhancing, and restoring immune function.",
"summary":"2020 review covering background, mechanisms, and clinical uses in immune contexts.",
"claim_ids": [
"c1",
"c2",
"c3",
"c4",
"c61"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T08:34:27.728Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"genesis",
"hash":"c8865aacafa144a2f67170c723701cb4a77bda313934858527b1017c76a7e6d7",
"source_role":"mechanism_support",
"quote_sha256":"69ae2ec6dce0f41b26d3dbc42a502d3e5e40aab08f2ae00cd1d9ada060e5dee2"
},
{
"id":"s2",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/27450734/",
"title":"Immune Modulation with Thymosin Alpha 1 Treatment",
"quote":"Thymosin alpha 1 (Ta1) is a peptide originally isolated from thymic tissue as the compound responsible for restoring immune function to thymectomized mice.",
"summary":"2016 review on preclinical and clinical immune modulation.",
"claim_ids": [
"c2"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T08:34:27.728Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"c8865aacafa144a2f67170c723701cb4a77bda313934858527b1017c76a7e6d7",
"hash":"3a2c49cdbadc8c73b2aa5932c1671e7661c89fa1910ab017c66d56af98bdbbdb",
"source_role":"mechanism_support",
"quote_sha256":"8ecd71b1d34b2eb5de6deb05120fad983d4a9ca5de2d1d90557e1b8d1e83ba46"
},
{
"id":"s3",
"type":"review",
"url":"https://pubmed.ncbi.nlm.nih.gov/38308608/",
"title":"Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials",
"quote":"This study aims to assess the safety and efficacy of Thymosin Alpha 1 (Tα1) through a comprehensive narrative review of clinical studies involving over 11 000 human subjects in more than 30 trials.",
"summary":"2024 review of human trials and safety.",
"claim_ids": [
"c3"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T08:34:27.728Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"3a2c49cdbadc8c73b2aa5932c1671e7661c89fa1910ab017c66d56af98bdbbdb",
"hash":"62e0108ba1db6835b71fca9afb198b2f63ea2cd29c89f43b79b986aa5b20e9b3",
"source_role":"mechanism_support",
"quote_sha256":"2bb7d5ee0a9a69f6ba820fa207ae43a3571819ed9985205446dc558142c5ca6c"
},
{
"id":"s4",
"type":"clinical_trial",
"url":"https://www.bmj.com/content/388/bmj-2024-082583",
"title":"The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial",
"quote":"This trial found no clear evidence to suggest that thymosin α1 decreases 28 day all cause mortality in adults with sepsis.",
"summary":"Large 2025 phase 3 RCT (n=1106) showing no significant mortality benefit of thymosin α1 in sepsis patients.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c10"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:00:12.760Z",
"link_status":"http_403",
"quote_status":"unverified",
"prev":"62e0108ba1db6835b71fca9afb198b2f63ea2cd29c89f43b79b986aa5b20e9b3",
"hash":"1370e624ff7f434258d00b61dd61709182caf5dea0547dffa7862c403de14a20",
"source_role":"adjacent_context",
"quote_sha256":"1d2c8b4989808eefc57e21960a9896f81220f37f0f13efc71a2c7483b0b121f4"
},
{
"id":"s5",
"type":"review",
"url":"https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1388959/full",
"title":"Phenotypic drug discovery: a case for thymosin alpha-1",
"quote":"This article explores the experiences of researchers testing the effect of a thymic peptide hormone, thymosin alpha-1, in preclinical and clinical settings.",
"summary":"2024 review framing thymosin alpha-1 as example of phenotypic drug discovery with broad immunomodulatory applications.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c11"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:00:12.760Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"1370e624ff7f434258d00b61dd61709182caf5dea0547dffa7862c403de14a20",
"hash":"938ad57612eecfe66f1cdeefc1e303c64743e3153bc5f0a1a289e84fc6219e3b",
"source_role":"mechanism_support",
"quote_sha256":"19707f07a6ae134442d36824352e99bf8ebc866cbbab58538c9410dd52017134"
},
{
"id":"s6",
"type":"clinical_trial",
"url":"https://clinicaltrials.gov/study/NCT06821100",
"title":"Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine",
"quote":"This research study will test the safety and possible harms of Ta1 when it is given to people at different dose levels before COVID-19 vaccination.",
"summary":"Ongoing/2025+ trial investigating thymalfasin for enhancing COVID vaccine response in older adults.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c12"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:00:12.760Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"938ad57612eecfe66f1cdeefc1e303c64743e3153bc5f0a1a289e84fc6219e3b",
"hash":"fc889eeca93b27d2caf383f88531bb14611bc7f94c2fa2f1f9fd73ed6da8e032",
"source_role":"adjacent_context",
"quote_sha256":"d0dba429367c75bb8e4f7f2b93429c329bb295f173e9bb93302c3f27078c9984"
},
{
"id":"s7",
"type":"review",
"url":"https://pubmed.ncbi.nlm.nih.gov/40599771/",
"title":"Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis",
"quote":"Thymosin alpha 1 (Tα1) is an important immunomodulatory agent in clinical practice, but there is a lack evidence to prove its effectiveness in improving the condition of SAP patients.",
"summary":"2025 systematic review/meta-analysis on Tα1 for severe acute pancreatitis.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c13"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:00:12.760Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"fc889eeca93b27d2caf383f88531bb14611bc7f94c2fa2f1f9fd73ed6da8e032",
"hash":"d5b3bd78fd9f4c74891acae0d44d845668807bb82e1949925f008992c0a048cd",
"source_role":"mechanism_support",
"quote_sha256":"e6e7b77fb1fdafda1aa454ef2b4fd3ccab180b8875fb47715317179433767bee"
},
{
"id":"s8",
"type":"reddit",
"url":"https://www.reddit.com/r/covidlonghaulers/comments/1r5ekd8/5_years_long_covid_thymosin_alpha_1_peptide_wow/",
"title":"5 Years Long Covid - Thymosin Alpha 1 Peptide - WOW!",
"quote":"I am now testing Thymosin Alpha 1 Peptide and I have to say WOW! This peptide brings me back to life.",
"summary":"User anecdote reporting significant improvement in long COVID symptoms after starting TA-1 peptide.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c14",
"c62"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:00:12.760Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"d5b3bd78fd9f4c74891acae0d44d845668807bb82e1949925f008992c0a048cd",
"hash":"3e5ab07568cb6fa3568b27587a971d9eec905f68a22fccbeae05606449554955",
"source_role":"anecdotal_report",
"quote_sha256":"6b1862cdfa35eea659eae5405f681767523f85b5a0c7a6d8dfe053b0b5d3263f"
},
{
"id":"s9",
"type":"review",
"url":"https://www.mdpi.com/1422-0067/26/23/11470",
"title":"Aging and Thymosin Alpha-1",
"quote":"Preclinical and clinical studies show that Tα1 can improve vaccine response in the elderly and mitigate immunosenescence.",
"summary":"2025 review on thymosin alpha-1 for aging-related immune decline and vaccine enhancement.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c15"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:00:12.760Z",
"link_status":"http_403",
"quote_status":"unverified",
"prev":"3e5ab07568cb6fa3568b27587a971d9eec905f68a22fccbeae05606449554955",
"hash":"90d4f5cda865c21ed4a30938ec962a87c01d2d97de52f25dae23c371d8fd1de7",
"source_role":"mechanism_support",
"quote_sha256":"d5f11fb073f9b94faff2c56e7af138e8e561dcfb90bcd06fcf06977d4e81112e"
},
{
"id":"s10",
"type":"clinical_trial",
"url":"https://clinicaltrials.gov/study/NCT07644897",
"title":"Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma",
"quote":"Primary Objective: To evaluate the effectiveness of Thymosin Alpha-1 combined with PD-1 monoclonal antibody in elderly patients with advanced melanoma .",
"summary":"New 2026 clinical trial testing thymosin alpha 1 combined with anti-PD-1 for advanced melanoma in elderly patients.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c5"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:00:41.437Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"90d4f5cda865c21ed4a30938ec962a87c01d2d97de52f25dae23c371d8fd1de7",
"hash":"e5e1e222ffd54fd30995422fd6ba404746b3a9427f5b286bf9685bbc949579c4",
"source_role":"adjacent_context",
"quote_sha256":"a2b24476bb1a398a0ea0d8a9c44634007706627f156b91ae6728fcacbdd63758"
},
{
"id":"s11",
"type":"review",
"url":"https://www.innerbody.com/thymosin-alpha-1-peptide",
"title":"Thymosin Alpha-1 Peptide: Benefits and Safety [2026]",
"quote":"In contrast to those findings, a placebo-controlled trial from early 2025 with over 1,000 subjects found “no clear evidence” that TA-1 decreased 28-day all-cause mortality in adults with sepsis.",
"summary":"2026 comprehensive article reviewing uses, safety, and recent 2025 sepsis trial results for thymosin alpha-1.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c17"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:00:41.437Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"e5e1e222ffd54fd30995422fd6ba404746b3a9427f5b286bf9685bbc949579c4",
"hash":"e8f5edcd020b445158365d0497fd41735fa13ad8af2fea625cf8c727d36158d4",
"source_role":"mechanism_support",
"quote_sha256":"ac4a4cf0074337d41428a04b4df2cd2dce7c1b9bf75ca639b28c1160406ef67c"
},
{
"id":"s12",
"type":"youtube",
"url":"https://www.youtube.com/shorts/_3M2gu4kG68",
"title":"Autoimmune Peptides: Just Hype? (Thymosin Alpha-1 ...",
"quote":"Thymosin Alpha-1 helps recalibrate immune function so your body stops attacking itself while still defending against infections.",
"summary":"2026 YouTube short discussing thymosin alpha-1 for autoimmune conditions.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c18"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:00:41.437Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"e8f5edcd020b445158365d0497fd41735fa13ad8af2fea625cf8c727d36158d4",
"hash":"782d884dc34110bda4abf8ff61402db53c5298779c92c3a7451370e7e289620c",
"source_role":"anecdotal_report",
"quote_sha256":"1903f40318a67c5236aa659f60090f1ff12821e390e96c8fe76a947b34f981ed"
},
{
"id":"s13",
"type":"reddit",
"url":"https://www.reddit.com/r/cfs/comments/1nl65vu/be_careful_about_thymosin_alpha1/",
"title":"be careful about thymosin alpha-1 : r/cfs",
"quote":"I am having the same problems with TA-1 I just connected the dots after 2 weeks of being on TA-1 my lymph nodes are swollen in my neck ...",
"summary":"User reports swollen lymph nodes as a negative side effect after 2 weeks on TA-1.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c19"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:00:59.705Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"782d884dc34110bda4abf8ff61402db53c5298779c92c3a7451370e7e289620c",
"hash":"196082d97ac04d7df970d50558f1720b5406e76a70d51c656becb81e5d913bfe",
"source_role":"anecdotal_report",
"quote_sha256":"44e7102ef2f9ca59616bda594ba09a120c991c16077db20fa6aa3c5b9e975a13"
},
{
"id":"s14",
"type":"reddit",
"url":"https://www.reddit.com/r/covidlonghaulers/comments/1pbotcz/anyone_get_side_effectsan_immune_reaction_to/",
"title":"Anyone get side effects/an immune reaction to Thymosin- ...",
"quote":"Im 2 weeks into TA-1 , its working as expected. Immune activation/rebalancing - clearing out virus/viral debris my body was unable to deal with before (Feels like a bad cold/minor flu).",
"summary":"User describes initial flu-like symptoms as part of positive immune activation, followed by overall improvement after waves.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c20"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:00:59.705Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"196082d97ac04d7df970d50558f1720b5406e76a70d51c656becb81e5d913bfe",
"hash":"cb1cd196b18a80c106845108e087b7a3b8c9b32bd54cf1a12a0dead79a08e81e",
"source_role":"anecdotal_report",
"quote_sha256":"0e6bac5d6abb4117709df237342cc79290b8a2405d97fa9f21f176abe360edb3"
},
{
"id":"s15",
"type":"reddit",
"url":"https://www.reddit.com/r/Ameano_Peptides/comments/1ojbasq/a_complete_guide_for_thymosin_alpha_1/",
"title":"A Complete Guide for Thymosin Alpha 1",
"quote":"I have been experimenting with ta1 and vip for a few weeks for some really bad eczema and doing a similar protocol. my eczema seems to respond really well to ta1...",
"summary":"User reports good outcome with reduced eczema using TA-1.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c21"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:00:59.705Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"cb1cd196b18a80c106845108e087b7a3b8c9b32bd54cf1a12a0dead79a08e81e",
"hash":"53ce60a83e3337a6b83726e1cc8b5a94aed82392960276d7bfb50e84d1263756",
"source_role":"anecdotal_report",
"quote_sha256":"a85c455569386b3e148ac1b4170dd29873f1fa81d03e1583bc99cf3201830a0a"
},
{
"id":"s16",
"type":"reddit",
"url":"https://www.reddit.com/r/covidlonghaulers/comments/1l2k4tj/thymosin_alpha1_t%CE%B11_has_anyone_seen_any_studies/",
"title":"Thymosin Alpha 1 (Tα1) has anyone seen any studies or ...",
"quote":"I just stated my ta-1 about two weeks ago and I can confirm I have felt the benefits majorly. Clearer head, heightened energy, just the ...",
"summary":"Positive user experience: clearer head and increased energy after 2 weeks on TA-1.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c22"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:00:59.705Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"53ce60a83e3337a6b83726e1cc8b5a94aed82392960276d7bfb50e84d1263756",
"hash":"42fd462166db0170a0940b5b5bbce4c0b676331ab16aa38f30b4e4d4b1ab8cea",
"source_role":"anecdotal_report",
"quote_sha256":"6fa2764789c9fd3b37c31b740ba8af0cc8f2eeb0d014f3ef006462112fa772db"
},
{
"id":"s17",
"type":"reddit",
"url":"https://www.reddit.com/r/MCAS/comments/1mcx0o3/peptide_called_thymosin_alpha_1_is_resolving_my/",
"title":"Peptide called Thymosin Alpha 1 is resolving my MCAS",
"quote":"TA-1 works when I use it! But it doesn't have a noticeable benefit when I'm not using it.",
"summary":"User reports TA-1 helps resolve MCAS symptoms while using it, with relapse when stopping; another user noted a flare.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c23"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:00:59.705Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"42fd462166db0170a0940b5b5bbce4c0b676331ab16aa38f30b4e4d4b1ab8cea",
"hash":"2f6bfc90da8731e622e1e3c82498870e0f3adc1d18b6b51166c2e7d7ed88d373",
"source_role":"anecdotal_report",
"quote_sha256":"83ad14bfeb231aaa8a695487fa7d4f45f49eaa852dfea8d88294c2e013ce1d65"
},
{
"id":"s18",
"type":"x",
"url":"https://x.com/BowTiedUM/status/1760474750730568092",
"title":"The Superhuman Immune System Peptide Big Pharma Wants BANNED",
"quote":"I knew I struck gold when I caught a cold, took a 2mg shot, and woke up the next day feeling GREAT. My cough, runny nose, and body aches: GONE",
"summary":"Personal anecdote of rapid recovery from cold symptoms after TA-1 injection.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c24"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:00:59.705Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"2f6bfc90da8731e622e1e3c82498870e0f3adc1d18b6b51166c2e7d7ed88d373",
"hash":"988bbc26e9a8bee45daba8c10c694667f635b6fd9b2f970018a4b4a2a55d07d3",
"source_role":"anecdotal_report",
"quote_sha256":"1bdf644e60830f61a09614f124e7f11effceddb7d2aeceafca725cb7651ea2bd"
},
{
"id":"s19",
"type":"x",
"url":"https://x.com/jessicaalanas/status/1755232184317649040",
"title":"Megadose experience with Thymosin Alpha 1",
"quote":"I took a megadose of Thymosin Alpha 1 peptide for 3 days in a row. By day 3, I was so sick I could not go outside. Today, I woke up and I feel significantly *stronger* than before.",
"summary":"User felt temporarily worse (sick) then stronger afterward, attributing to immune activation against stealth infections.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c25"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:00:59.705Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"988bbc26e9a8bee45daba8c10c694667f635b6fd9b2f970018a4b4a2a55d07d3",
"hash":"30ac172e3e3cb07ab02c345f054738f5baaa5db793384d81e84f747a2f89b543",
"source_role":"anecdotal_report",
"quote_sha256":"1c0fda619995fa46e17ee6a3c2bea8fba3992d2266cfe673add134db3d3955f6"
},
{
"id":"s20",
"type":"clinical_trial",
"url":"https://clinicaltrials.gov/study/NCT04487444",
"title":"Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection",
"quote":"A course of Ta1 administered to hospitalized individuals with COVID-19 infection and lymphocytopenia will improve the time to recovery (primary objective) and ...",
"summary":"Ongoing or completed trial on Ta1 for COVID-19 recovery in lymphocytopenic patients.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c26"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:01:20.752Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"30ac172e3e3cb07ab02c345f054738f5baaa5db793384d81e84f747a2f89b543",
"hash":"2d618dcafbb985e456b6c835438178dbf008c5db740bc76dc8b5c2dabac1074d",
"source_role":"adjacent_context",
"quote_sha256":"0ae1a8a59f39489d278e004786efb2bf86c783865a1b0024e59829d3730dc0e7"
},
{
"id":"s21",
"type":"review",
"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12208829/",
"title":"Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis",
"quote":"Five randomized controlled trials comprising 706 patients with SAP were included.",
"summary":"2025 meta-analysis showing Ta1 reduces inflammation and infection in severe acute pancreatitis via immune regulation.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c27"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:01:20.752Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"2d618dcafbb985e456b6c835438178dbf008c5db740bc76dc8b5c2dabac1074d",
"hash":"3d3fc4e7fefbf325257788fd95bf85f5764d3c0a43d8b43d3ff799b5582139fa",
"source_role":"mechanism_support",
"quote_sha256":"6bdb40c8d59f5e22e39709e58230b6d26a1b56b7509a04ac2666b087bca203ef"
},
{
"id":"s22",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/40955371/",
"title":"The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets",
"quote":"The Immunomodulatory Activity of Thymosin Alpha 1 on Tumor Cell Lines and Distinct Immune Cell Subsets. Onco Targets Ther. 2025 Sep 10:18:995-1012.",
"summary":"2025 study on Ta1's immunomodulatory effects on cancer cells and immune subsets.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c28"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:01:20.752Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"3d3fc4e7fefbf325257788fd95bf85f5764d3c0a43d8b43d3ff799b5582139fa",
"hash":"5d6f1e6fb3f1a0d095118761419d3384973f1fb9ba1625bb7c176ac5dbf2a11c",
"source_role":"mechanism_support",
"quote_sha256":"f4fa116527f4faccbde2f9e828907b90ada6c509e429774b7bfce6616b6d0f6b"
},
{
"id":"s23",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/39867848/",
"title":"Indications for an antidepressive effect of thymosin alpha-1 in a small open-label proof of concept study in common variable immune deficiency",
"quote":"Indications for an antidepressive effect of thymosin alpha-1 in a small open-label proof of concept study in common variable immune deficiency.",
"summary":"2025 proof-of-concept on potential antidepressant effects of Ta1 in CVID patients.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c29"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:01:20.752Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"5d6f1e6fb3f1a0d095118761419d3384973f1fb9ba1625bb7c176ac5dbf2a11c",
"hash":"276d491d3db1e0a68a56f2ce64e07f1b000dc36419c6007c3da47a4241b65aa5",
"source_role":"mechanism_support",
"quote_sha256":"e7f185d979391c1b2cf70514875e3b0fa731171b653931e1f8b4feeca047ea25"
},
{
"id":"s24",
"type":"reddit",
"url":"https://www.reddit.com/r/HairlossResearch/comments/1rgcn3a/peptide_for_alopecia_thymosin_alpha_1_as_an/",
"title":"Peptide for alopecia: Thymosin Alpha 1 as an Alternative to ...",
"quote":"TA1 is taken to suppress inflammation caused by the immune system. There is no clinical data that shows TA1 can heal your alopecia but it sounds promising.",
"summary":"Reddit discussion on using TA1 for alopecia via immune modulation.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c30"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:01:20.752Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"276d491d3db1e0a68a56f2ce64e07f1b000dc36419c6007c3da47a4241b65aa5",
"hash":"9f6c54b2e2aecd0e76d3b3092918f94d75fe9e98cdba572aaae575fb0ad1a96f",
"source_role":"anecdotal_report",
"quote_sha256":"09ae5b852419fea76f162c7881b1109b65f3ba2bb9774a5532bd14c2369bfd23"
},
{
"id":"s25",
"type":"reddit",
"url":"https://www.reddit.com/r/Biohack_Blueprint/comments/1thd0od/thymosin_alpha1_complete_guide_the_immune_peptide/",
"title":"Thymosin Alpha-1 Complete Guide: The Immune Peptide ...",
"quote":"Thymosin Alpha-1 modulates immune function in multiple ways: T-cell maturation and function.",
"summary":"User guide and discussion on TA1 mechanisms and use.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c31"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:01:20.752Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"9f6c54b2e2aecd0e76d3b3092918f94d75fe9e98cdba572aaae575fb0ad1a96f",
"hash":"b54f56b49f3228ec6669eac333a7d711dbc45637ef7dfde842bf4a5c3e1293c6",
"source_role":"anecdotal_report",
"quote_sha256":"24cca77138a90494a83cacc560659067202c2eea3c6f10971e66905e372dbbeb"
},
{
"id":"s26",
"type":"x",
"url":"https://x.com/RickWingfield5/status/2071331718015918545",
"title":"X post on Thymosin Alpha 1",
"quote":"One \"immune peptides\" out there is Thymosin ALPHA 1. It is approved in over 40 countries.",
"summary":"Recent X post noting international approval of TA1 as immune peptide.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c32"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:01:20.752Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"b54f56b49f3228ec6669eac333a7d711dbc45637ef7dfde842bf4a5c3e1293c6",
"hash":"6196a28f924807abca91901453613efd7306b096875d484b8d96410ae70f8147",
"source_role":"anecdotal_report",
"quote_sha256":"8b678f94d4b567156d6e2ee6341d56f7eac1d07beeee1472281c06f9ae5ad489"
},
{
"id":"s27",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/40969554/",
"title":"Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials",
"quote":"Tα1 has the potential to decrease 28-day mortality rates in patients with sepsis; however, it is crucial to recognize that its efficacy differs among various subgroups. These observations underscore the significance of personalized immunotherapy strategies in forthcoming clinical trials.",
"summary":"2025 meta-analysis of 11 RCTs finds Tα1 associated with reduced 28-day sepsis mortality overall but no benefit in high-quality or multicenter subgroups; notes heterogeneity and need for more data.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c33"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:02:22.999Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"6196a28f924807abca91901453613efd7306b096875d484b8d96410ae70f8147",
"hash":"172517fd35a7a45e69faa54e7d29137526465340f0ec81146261870ca6efd966",
"source_role":"mechanism_support",
"quote_sha256":"cf80c537ff2af4186edff2d027b042cd63f6082d149af8569cafbdc99a980437"
},
{
"id":"s28",
"type":"medical",
"url":"https://superpower.com/guides/thymosin-alpha-1",
"title":"Thymosin Alpha-1 (Zadaxin): A Thymic Peptide and Toll-Like Receptor Signaling Modulator",
"quote":"Thymosin alpha-1 is a 28-amino-acid thymic peptide approved as Zadaxin in more than 35 countries for chronic hepatitis B but not FDA-approved in the US. ... As of April 2026, thymosin alpha-1 is not FDA-approved in the United States. It is approved internationally under the brand name Zadaxin for chronic hepatitis B in more than 35 countries, including China and Italy. In the US, it holds FDA 503A Category 2 status following the February 2026 reclassification.",
"summary":"April 2026 reviewed guide on TA-1 mechanisms, hepatitis B evidence, regulatory status (not FDA-approved, compounding available), and clinical data.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c5"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:02:22.999Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"172517fd35a7a45e69faa54e7d29137526465340f0ec81146261870ca6efd966",
"hash":"44cd95302dedadb9c88af6acbf98e693d33d877b541606d0c7f69b570932b377",
"source_role":"adjacent_context",
"quote_sha256":"174ed1807ca030721930048c6722b784c67c1370a0e6d8c27bd598a19a79b191"
},
{
"id":"s29",
"type":"reddit",
"url":"https://www.reddit.com/r/ankylosingspondylitis/comments/1rzhnmd/thymosin_alpha_1_peptide/",
"title":"Thymosin alpha 1 peptide?",
"quote":"The peptide thymosin alpha 1 has been shown to be able retrain the immune system. Ankylosing is an autoimmune disorder. It helps heal the gut but also helps ... Ok I have tried this peptide.",
"summary":"2026 Reddit thread in r/ankylosingspondylitis discussing TA-1 for autoimmune conditions like ankylosing spondylitis; user reports trying it.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c35"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:02:22.999Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"44cd95302dedadb9c88af6acbf98e693d33d877b541606d0c7f69b570932b377",
"hash":"59e34a8cd6e92fc0d1c69c79091f610ffeb6fd483d1cde7e9435f7aec685c746",
"source_role":"anecdotal_report",
"quote_sha256":"f7107042dd7969b8c3554740e2c9f4d226a32b0a87b09c7a691cd513e76fc139"
},
{
"id":"s30",
"type":"reddit",
"url":"https://www.reddit.com/r/NTNPerformance/comments/1sx69j7/thymosin_alpha1_guide_immune_support_dosing_and/",
"title":"Thymosin Alpha-1 guide immune support, dosing, and ...",
"quote":"Thymosin Alpha-1 guide immune support, dosing , It helps regulate immune response. Its been studied in hepatitis B and C",
"summary":"Reddit post providing guide on TA-1 for immune support, dosing, and mentions studies in hepatitis B and C.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c36"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:02:22.999Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"59e34a8cd6e92fc0d1c69c79091f610ffeb6fd483d1cde7e9435f7aec685c746",
"hash":"b2208a8b3d3a2011a9f2cdc4956daf3f4f698122a51bc2a63d6dd6f27099e850",
"source_role":"anecdotal_report",
"quote_sha256":"97357da829d793f273f7f855c8a40c6655d622fc4371a855c94ce36bf1ee39b7"
},
{
"id":"s31",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/41883056",
"title":"IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8+ T Cells and Enhances Antitumor Immunity in Hepatocellular Carcinoma",
"quote":"Combined IL-15 and Tα1 therapy reverses CD8 + T cell senescence and enhances antitumor immunity in HCC through suppression of the phosphatidylinositol ...",
"summary":"2026 study on IL-15 combined with thymosin α1 reducing senescent CD8+ T cells and boosting antitumor effects in HCC.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c37"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:02:47.432Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"b2208a8b3d3a2011a9f2cdc4956daf3f4f698122a51bc2a63d6dd6f27099e850",
"hash":"331691eeaf0167b3fdcec6ddfb392cbf376610a499dd72eb78afd33aa7919d5a",
"source_role":"mechanism_support",
"quote_sha256":"38866b08841112bfa1a2c2bec06283bec1ed0ed0fc9ff708db1c36608ee12d16"
},
{
"id":"s32",
"type":"review",
"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12904209/",
"title":"Age-related thymic involution: Mechanistic insights and rejuvenating approaches to restore immune function",
"quote":"Thymosin α1 is used to treat some chronic viral infections , such as hepatitis B and C, as an immunomodulator (125). In a recent retrospective analysis of patients with COVID-19 treated with thymosin α, this hormone enhanced T cell production...",
"summary":"2026 review discusses thymosin α1 as immunomodulator for viral infections and its role in improving thymic function and T cell production in COVID-19 contexts.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c38"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:02:47.432Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"331691eeaf0167b3fdcec6ddfb392cbf376610a499dd72eb78afd33aa7919d5a",
"hash":"9baa65ceb457b591d6cf5132ed8e5bbe9a74800cb54f654544c7ddf21bc18297",
"source_role":"mechanism_support",
"quote_sha256":"b233bde3a7a3127ed4b7f5b92e64ad0a1420779edd98e0e6a590cef625208056"
},
{
"id":"s33",
"type":"review",
"url":"https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1571456/full",
"title":"Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis",
"quote":"Five randomized controlled trials comprising 706 patients with SAP were included. The results indicated that Tα1 could increase the percentages of CD4 + cells (MD=4.53, 95%CI [3.02, 6.04], P<0.00001) and improve the CD4 + /CD8 + ratio...",
"summary":"2025 meta-analysis of 5 RCTs (706 SAP patients) showing Tα1 improves CD4+ cells, CD4/CD8 ratio, reduces CRP (low dose), and prevents extrapancreatic infections.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c39"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:02:47.432Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"9baa65ceb457b591d6cf5132ed8e5bbe9a74800cb54f654544c7ddf21bc18297",
"hash":"4ef6beeaffd9d1fbfb343a3bf51250753b6dc84c8171114674dc9f38db7005a9",
"source_role":"mechanism_support",
"quote_sha256":"2cabaf8167cf971ac4fc2fb531f1795084bb25535715c445893429fb8b1b4a6e"
},
{
"id":"s34",
"type":"youtube",
"url":"https://www.youtube.com/watch?v=d_ZW05Wrm_s",
"title":"What Is Thymosin Alpha 1? How It Works and What the Clinical Data Shows",
"quote":"We cover: 🛡️ What Thymosin Alpha-1 is and how it regulates your immune system Why it's ideal for inflammation, immune burnout, and chronic ...",
"summary":"2026 YouTube video reviewing thymosin alpha 1 mechanism, clinical data, benefits for immune regulation and inflammation.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c5"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:02:47.432Z",
"link_status":"http_429",
"quote_status":"unverified",
"prev":"4ef6beeaffd9d1fbfb343a3bf51250753b6dc84c8171114674dc9f38db7005a9",
"hash":"c11839fe5d2ccfb168bbfa7008fb3e31831bfc13ab5e9cbca75ef4c89a7e151f",
"source_role":"anecdotal_report",
"quote_sha256":"01da3f04aabb4fe3c7a7a29b75759eaf17c58126ab2f9a98e9d331059379e1fa"
},
{
"id":"s35",
"type":"reddit",
"url":"https://www.reddit.com/r/LongCovidTrials/comments/1opyifn/has_anyone_tried_thymosin_alpha_1_for_long_covid/",
"title":"Has anyone tried Thymosin Alpha 1 for Long COVID?",
"quote":"Hi all, Our team is curious if anyone out there has tried the peptide Thymosin Alpha 1 for Long COVID. We’re asking for research purposes (not endorsing ...",
"summary":"2025 Reddit post in LongCovidTrials seeking anecdotal experiences with thymosin alpha 1 for long COVID.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c41"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:02:47.432Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"c11839fe5d2ccfb168bbfa7008fb3e31831bfc13ab5e9cbca75ef4c89a7e151f",
"hash":"d0ac7e52f1109ca84229b3913906c62dbb4d581fb266e4a8d206b809a7c62260",
"source_role":"anecdotal_report",
"quote_sha256":"0a73fb7398923f2cbf36ee2dc3a75d4e57ee51651b55ce78f8a61b5a608ef80d"
},
{
"id":"s36",
"type":"review",
"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12692621/",
"title":"Aging and Thymosin Alpha-1",
"quote":"Thymosin alpha-1 (Tα1), a peptide hormone produced by the thymus, exhibits potent immunomodulatory, anti-inflammatory, and antioxidant properties.",
"summary":"2025 review on thymosin alpha-1's role in aging, immunomodulation, anti-inflammatory and antioxidant effects.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c42"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:02:47.432Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"d0ac7e52f1109ca84229b3913906c62dbb4d581fb266e4a8d206b809a7c62260",
"hash":"1b88ee0d44eb9b7294067d00ab67e744645d5129315c027931b77088146d0569",
"source_role":"mechanism_support",
"quote_sha256":"f39633c2df6930569a6e366c7f934386926667248eea8eb5c8e6a4155768d069"
},
{
"id":"s37",
"type":"reddit",
"url":"https://www.reddit.com/r/CIRS/comments/1ncxx31/thymosinalpha_1/",
"title":"Thymosin-alpha 1 ??",
"quote":"I actually tried it back in October and it sent me into the worst flare I’ve had in 4 years. Felt awful and took me almost 2 full months to recover.",
"summary":"User reported severe negative reaction/flare after trying TA-1 while possibly exposed to mold; others report herxing initially but gradual improvement with slow titration, better energy, or immune balancing.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c43"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:03:23.964Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"1b88ee0d44eb9b7294067d00ab67e744645d5129315c027931b77088146d0569",
"hash":"ca4a4ad545c23e812dac6fcc689a152ffa0a724e2297e6f996fdd18bda103712",
"source_role":"anecdotal_report",
"quote_sha256":"128ce7b93ce840920ce33c90b276b4326a73f068705f320aba68115649e04f7e"
},
{
"id":"s38",
"type":"reddit",
"url":"https://www.reddit.com/r/Hashimotos/comments/1lped2z/peptides/",
"title":"Peptides",
"quote":"I tried TA-1 for 8 weeks and it increased my TPO antibodies.",
"summary":"Negative outcome: TA-1 increased thyroid antibodies in Hashimoto's patient after 8 weeks.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c44"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:03:23.964Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"ca4a4ad545c23e812dac6fcc689a152ffa0a724e2297e6f996fdd18bda103712",
"hash":"e801e492487a055718a78ecdb6abfcf2114abcddd0f94f48464e27d5acbc78a6",
"source_role":"anecdotal_report",
"quote_sha256":"efa9843fc62d464ecbe8123ef4ba8c704b2a82aa394083cd995f4e135f01cca8"
},
{
"id":"s39",
"type":"reddit",
"url":"https://www.reddit.com/r/CIRS/comments/1ncxx31/thymosinalpha_1/",
"title":"Thymosin-alpha 1 ??",
"quote":"Each herx reaction was slightly different but the first one, I felt “classicly sick”, like how normal people feel when they get the flu... Then after that they started to feel a bit more similar, usually severe fatigue plus normal viral symptoms. ... once I stabilize at each dose increase, I feel like I get about 2-3% of my life back.",
"summary":"Mixed: initial herx reactions (flu-like, fatigue, cytokine storm) but eventual positive slow improvements in symptoms and quality of life with titration.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c45"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:03:23.964Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"e801e492487a055718a78ecdb6abfcf2114abcddd0f94f48464e27d5acbc78a6",
"hash":"042c814e39174e473562ae7fe839a563e096bb93b6b7a31e320ce0463e8ff8f9",
"source_role":"anecdotal_report",
"quote_sha256":"e238ee2636bdac0e5c4a70161c6f3991415482cdae1c6bbcf7bd23ab6ffbf9c0"
},
{
"id":"s40",
"type":"x",
"url":"https://x.com/CaneGrrl/status/2068318610662072812",
"title":"X post by @CaneGrrl",
"quote":"Anyone else experience sleep benefits with Thymosin Alpha-1? Could be a coincidence but my REM and deep sleep have gone up every night I’ve take it (which is only 3 so far, but still…)",
"summary":"Positive user-reported sleep improvement (increased REM and deep sleep) with TA-1 use.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c46"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:03:23.964Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"042c814e39174e473562ae7fe839a563e096bb93b6b7a31e320ce0463e8ff8f9",
"hash":"84db43541b45ba97e0fe949760d2cbae9e08f5f98b6d8202af6a1403324ede5f",
"source_role":"anecdotal_report",
"quote_sha256":"32383818bb5c25ab5a7cf61b42bcb9487b24ee513c3b729325d7a567d71f4d66"
},
{
"id":"s41",
"type":"x",
"url":"https://x.com/quardoqu/status/2060338402189353350",
"title":"X post by @quardoqu",
"quote":"My top Long Covid treatments so far after six years in order of effectiveness out of a 100+: 1. LDN ... 2. Subq TA-1 (Thymosin Alpha 1) ...",
"summary":"Positive: TA-1 ranked as second most effective treatment for long COVID symptoms after 6 years.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c47"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:03:23.964Z",
"link_status":"http_404",
"quote_status":"unverified",
"prev":"84db43541b45ba97e0fe949760d2cbae9e08f5f98b6d8202af6a1403324ede5f",
"hash":"fb23f602acb86a4de629ea91fe86041b3eb990e686c77ca9096bda4ea88062ae",
"source_role":"anecdotal_report",
"quote_sha256":"3d6c0c1c19df711d3118dbfa97e2acf6846bbe5eb143f6d723f7b1169914ecd2"
},
{
"id":"s42",
"type":"x",
"url":"https://x.com/quardoqu/status/2042676733057405170",
"title":"X post by @quardoqu",
"quote":"Any idea why Thymosin Alpha 1 takes my Long Covid symptoms away for 48 hours?",
"summary":"Positive: TA-1 eliminates long COVID symptoms for ~48 hours per dose.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c48"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:03:23.964Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"fb23f602acb86a4de629ea91fe86041b3eb990e686c77ca9096bda4ea88062ae",
"hash":"a1dabd0f4e86198de39c7ab87b8147889bb04e4f175dce5e26bfb3f51b2b846c",
"source_role":"anecdotal_report",
"quote_sha256":"e733c7922abe1142dba3a421d6b1f9cf3e23e562516143fd6dd8d7047c8dc2ad"
},
{
"id":"s43",
"type":"review",
"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12440967/",
"title":"Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis",
"quote":"In this updated meta-analysis, we found that thymosin alpha 1 (Tα1) may reduce 28-day mortality in patients with sepsis compared to the control group",
"summary":"2025 updated meta-analysis concluding Tα1 may reduce 28-day mortality in sepsis.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c49"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:04:12.543Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"a1dabd0f4e86198de39c7ab87b8147889bb04e4f175dce5e26bfb3f51b2b846c",
"hash":"07901af711c0441411b3de5321be0ec858054cfbdb234bfe329298f32aa9ca04",
"source_role":"mechanism_support",
"quote_sha256":"27f522fa32ac129c164c6699415e2346e7ffe7883d404c13fc0f7be492e51498"
},
{
"id":"s44",
"type":"medical",
"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12883329/",
"title":"A Case Report of a Multisystemic Immune‐Related Adverse Event Induced by Thymosin Alpha‐1",
"quote":"Thymosin alpha‐1 (Tα1 ) is an immunomodulatory peptide known to play critical roles in T cell maturity and differentiation",
"summary":"2026 case report discussing immune-related adverse event from Tα1 use.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c50"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:04:12.543Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"07901af711c0441411b3de5321be0ec858054cfbdb234bfe329298f32aa9ca04",
"hash":"cb45fd08318651ce5a70a4db5d31d87de9e631d1e8b6cc758200e56bacd667ad",
"source_role":"adjacent_context",
"quote_sha256":"6534a308ae17cc9ccde911721388ca815a59d60a0ce97d0aba9993e1b4707e94"
},
{
"id":"s45",
"type":"medical",
"url":"https://journals.lww.com/imd/fulltext/2025/06000/expert_consensus_on_the_clinical_application_of.2.aspx",
"title":"Expert Consensus on the Clinical Application of Thymosin Alpha 1 in Infectious Diseases and Critical Care Medicine",
"quote":"10 recommendations on the application of Tα1 in treatment of liver diseases, viral infections, bacterial infections and critical illnesses.",
"summary":"2025 expert consensus with 10 recommendations for Tα1 in infectious diseases and critical care.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c51"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:04:12.543Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"cb45fd08318651ce5a70a4db5d31d87de9e631d1e8b6cc758200e56bacd667ad",
"hash":"2cf6d20a13578a0e0828328b37cccfb94cfcb4fd1f12cfc69c0d9fc9080edd32",
"source_role":"adjacent_context",
"quote_sha256":"9810e2352c5496d0eb755c9c8a8c20264ab5d9292586e480ef3767b870714c6e"
},
{
"id":"s46",
"type":"other",
"url":"https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.e14606",
"title":"Thymosin alpha-1–enhanced PRaG regimen: A novel approach to boosting immune dynamics and therapeutic efficacy in advanced solid tumors",
"quote":"Thymosin Alpha 1 (Tα-1), a well-established immunomodulator, is known to protect lymphocytes, reduce lymphocytopenia during radiotherapy, and enhance T lymphocytes.",
"summary":"2025 ASCO abstract on Tα1 combined with PRaG regimen in solid tumors, reporting ORR and immune changes.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c5"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:04:12.543Z",
"link_status":"http_403",
"quote_status":"unverified",
"prev":"2cf6d20a13578a0e0828328b37cccfb94cfcb4fd1f12cfc69c0d9fc9080edd32",
"hash":"e9a695a8a7d71a2731a18a4332bc5a5e4f13b46558ad3c7ad38959c10b5405e8",
"source_role":"adjacent_context",
"quote_sha256":"9a09c535cf580f2df087d3acf9f5008b17cc9a0bb6f7d9f6670d45963dc59d86"
},
{
"id":"s47",
"type":"reddit",
"url":"https://www.reddit.com/r/IonPeptideGuide/comments/1tp86o7/thymalin_and_thymosin_alpha1_both_target_the/",
"title":"Thymalin and Thymosin Alpha-1 Both Target the Thymus",
"quote":"Thymosin Alpha-1 is a single defined 28-amino acid peptide sequence. It has an approved pharmaceutical form - Zadaxin - used clinically in over 35 countries",
"summary":"2025 Reddit discussion comparing Thymalin and TA1 mechanisms and uses.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c53"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:04:12.543Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"e9a695a8a7d71a2731a18a4332bc5a5e4f13b46558ad3c7ad38959c10b5405e8",
"hash":"a5d870101ff12beb28636f4adfcd53511068c39c45d22531f8f3a4dcad025bf5",
"source_role":"anecdotal_report",
"quote_sha256":"27de5c908c012a5e23521a9ffc7f97d32165b5f6545c96928700ecb9896527d9"
},
{
"id":"s48",
"type":"x",
"url":"https://x.com/dogalyasalar/status/2067307286138143114",
"title":"GELİŞEN PEPTİD NOMENKLATÜRÜ",
"quote":"○ Bağışıklık Modülasyonu — Thymosin Alpha-1 (TA1) — Thymosin Beta-4 (TB-500) — LL-37 — KPV",
"summary":"2026 X post categorizing peptides including TA1 under immune modulation.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c54"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:04:12.543Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"a5d870101ff12beb28636f4adfcd53511068c39c45d22531f8f3a4dcad025bf5",
"hash":"ae9956e8194cda282cefe6ba1943be09a08860776864abaf22b4ea478b0a493e",
"source_role":"anecdotal_report",
"quote_sha256":"b265622dbb9e1e7c5ebd1a01f75b74c7c730b0eac74e5adc860f9673b74fbf57"
},
{
"id":"s49",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/41883056/",
"title":"IL-15 Plus Thymosin α1 Reduces Senescent Hepatic CD8+ ...",
"quote":"Conclusions: Combined IL-15 and Tα1 therapy reverses CD8 + T cell senescence and enhances antitumor immunity in HCC through suppression of the ...",
"summary":"2026 study on combined IL-15 and thymosin α1 therapy for hepatocellular carcinoma, reversing T cell senescence.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c55"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:04:35.297Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"ae9956e8194cda282cefe6ba1943be09a08860776864abaf22b4ea478b0a493e",
"hash":"5b181d12f90a9df6d03377ad87c8f0b6443331aaa03570ac8f6a1144df35eb48",
"source_role":"mechanism_support",
"quote_sha256":"bdf69bc47282f48f947516165f9a9b7f658a10fcbc30a65b69ae8d706b9ca38f"
},
{
"id":"s50",
"type":"clinical_trial",
"url":"https://clinicaltrials.gov/study/NCT04901104",
"title":"Long-term Prognosis of Patients With Sepsis After ...",
"quote":"Current clinical studies of thymosin α1 for sepsis have focused on short-term outcomes (28-day or 90-day mortality), and lack of clinical data on long-term ...",
"summary":"Ongoing trial on long-term prognosis after thymosin α1 in sepsis patients.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c56"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:04:35.297Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"5b181d12f90a9df6d03377ad87c8f0b6443331aaa03570ac8f6a1144df35eb48",
"hash":"d3c40e66037ed42564e4b9c81e53135770440643e78fdafe7b5c15d00a92328f",
"source_role":"adjacent_context",
"quote_sha256":"d5a5a1166dee5e77e9b0aeccdd0bd148b3793d24884c28bf037112aae8dd2d62"
},
{
"id":"s51",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/41293232/",
"title":"Thymosin α1 Elevates Lymphocyte Counts and Improves ...",
"quote":"Tα1 treatment for 7 days significantly increased the median counts of peripheral blood total T cells (422.5/μL to 614.0 /μL, P<0.001), CD4 + T ...",
"summary":"2025 study showing thymosin α1 increases T cell counts in patients.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c57"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:04:35.297Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"d3c40e66037ed42564e4b9c81e53135770440643e78fdafe7b5c15d00a92328f",
"hash":"2800e5883b9bd0af0b835ac18c0d3c8a0f2312ffe9ef5ff4bd1c952702a9cd2b",
"source_role":"mechanism_support",
"quote_sha256":"5b68a26b86102e45583810550ededea485d6cef549f43820ac06135da5f1db70"
},
{
"id":"s52",
"type":"clinical_trial",
"url":"https://clinicaltrials.gov/study/NCT06966687",
"title":"Protective Effect of Ulinastatin and Thymosin α1 Against ...",
"quote":"This study was designed to test the hypothesis that the administration of Ulinastatin and Thymosin α1 during the acute phase of AAS will result in a reduced ...",
"summary":"Trial on ulinastatin + thymosin α1 for acute aortic syndrome.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c58"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:04:35.297Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"2800e5883b9bd0af0b835ac18c0d3c8a0f2312ffe9ef5ff4bd1c952702a9cd2b",
"hash":"f626ce42cb08923c196f1d50c26441ab37192ab5e8a9c8d78f753d4801bc93c2",
"source_role":"adjacent_context",
"quote_sha256":"22b7e0f31ce0879aa0167b12db77d316a5ccf95fdfd38f68a6f6accc69283331"
},
{
"id":"s53",
"type":"pubmed",
"url":"https://pubmed.ncbi.nlm.nih.gov/40263352/",
"title":"The efficacy and safety of thymosin alpha-1 combined with ...",
"quote":"Thymosin α-1 combined with lenvatinib plus sintilimab is an effective and safe therapeutic regimen in unresectable hepatocellular carcinoma.",
"summary":"2025 study on thymosin α1 combo therapy for HCC.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c59"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:04:35.297Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"f626ce42cb08923c196f1d50c26441ab37192ab5e8a9c8d78f753d4801bc93c2",
"hash":"6031bd41fb73230d31357441cf767b5911f37d54a8636d2c43a9f96eabec086e",
"source_role":"mechanism_support",
"quote_sha256":"968cc73fc251e8c8517d9cec2ea551a696f481131e4ca40c4af5a7fda1d71846"
},
{
"id":"s54",
"type":"youtube",
"url":"https://www.youtube.com/watch?v=HgcNS3pkeyE",
"title":"Thymosin Alpha-1: Transforming Immunotherapy for ...",
"quote":"patient considerations associated with thymosin alpha 1 additionally we will review three clinical case studies to",
"summary":"Video discussing thymosin alpha 1 in immunotherapy with case studies.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c60"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T10:04:35.297Z",
"link_status":"http_429",
"quote_status":"unverified",
"prev":"6031bd41fb73230d31357441cf767b5911f37d54a8636d2c43a9f96eabec086e",
"hash":"5c7da8985a388c08ec8593db0b28cd3d169666e50967809936554542d0c56163",
"source_role":"anecdotal_report",
"quote_sha256":"c35580b649fff1c881e5e1c9193d1f4a5d8231a15c8c52c798265239a747577b"
},
{
"id":"s55",
"type":"anecdotal",
"url":"https://www.evolutionary.org/forums/threads/thymosin-alpha-1-experiences-and-anecdotes-a-treatment-for-severe-allergies.109790/",
"title":"Thymosin Alpha 1 - experiences and anecdotes. A treatment for severe allergies?",
"quote":"I love TA1 and cycle it twice a year. In spring and fall. I'll mix it in other times if I'm feeling off. I personally use it to help my immune responses to both spring and fall allergies. It's worked well to have a lower response to the allergens.",
"summary":"Forum user reports positive cycling of TA1 for seasonal allergies, reduced response to allergens.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c64"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T15:39:25.531Z",
"link_status":"http_403",
"quote_status":"unverified",
"prev":"5c7da8985a388c08ec8593db0b28cd3d169666e50967809936554542d0c56163",
"hash":"aadf7379b2a313f49c08c89665a10a4d37468d89708ff2216efd6d8d61844ad1",
"source_role":"anecdotal_report",
"quote_sha256":"448c5715dafb1d5af9c6e914189b8bc81c8deb439d762303b85832cbb6fac17a"
},
{
"id":"s56",
"type":"anecdotal",
"url":"https://www.evolutionary.org/forums/threads/thymosin-alpha-1-experiences-and-anecdotes-a-treatment-for-severe-allergies.109790/",
"title":"Thymosin Alpha 1 - experiences and anecdotes. A treatment for severe allergies?",
"quote":"I put a mate onto Regenex as his eldest kid had Harishmotos disease and jumped on TA1 and apparently working well.",
"summary":"User reports positive results for Hashimoto's in a family member using TA1.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c65"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T15:39:25.531Z",
"link_status":"http_403",
"quote_status":"unverified",
"prev":"aadf7379b2a313f49c08c89665a10a4d37468d89708ff2216efd6d8d61844ad1",
"hash":"a42b19695736bc338e61fbd2033b215e13d4981f451a72eb52a4ff133b0001db",
"source_role":"anecdotal_report",
"quote_sha256":"e6daadb7ab56b7b12acb8f6b09c922e5d15e2f05ded3a32814bacb17477c999b"
},
{
"id":"s57",
"type":"anecdotal",
"url":"https://www.ozarkholisticcenter.com/post/thymosin-alpha-1-the-immune-boosting-peptide-you-should-know-about",
"title":"Thymosin Alpha-1: The Immune-Boosting Peptide You Should Know About",
"quote":"One patient who had struggled with recurrent respiratory infections told us, “It feels like my body finally has its army back.”",
"summary":"Clinic reports patient testimonial of improved resilience against infections with TA1.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c5"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T15:39:25.531Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"a42b19695736bc338e61fbd2033b215e13d4981f451a72eb52a4ff133b0001db",
"hash":"0f2f9bd7ae874147dd3eeb51f6477940ad5b084a81be4eab16e073f24c1d44cd",
"source_role":"anecdotal_report",
"quote_sha256":"80d818ff7e395993bc6c89e2d6a15d63d68bcaba1e062c66c12de3d6db1f224c"
},
{
"id":"s58",
"type":"reddit",
"url":"https://www.reddit.com/r/MCAS/comments/1lki5p2/best_peptides_and_brands_for_mcas_bpc157_kpv_and/",
"title":"Best peptides and brands for MCAS ? BPC-157, KPV and Thymosin / Thymogen ?",
"quote":"Don't use BCP for treating Mast Cell, honestly, for me thymosin-1 microdosing worked the best. Hard to get your hands on it, but a lab called Next Gen Peps was where I ended up at, pretty reliable & its a USA based.",
"summary":"User reports positive experience with Thymosin Alpha 1 microdosing for MCAS symptoms, better than BPC-157.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c67"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T15:39:49.214Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"0f2f9bd7ae874147dd3eeb51f6477940ad5b084a81be4eab16e073f24c1d44cd",
"hash":"fb6ad3beaab050431b9dcc23b2b4ec87a6989856151e20aa972c63594623b302",
"source_role":"anecdotal_report",
"quote_sha256":"925e9d36f2176e4c061a9edd6dce582b15bf25ec2adbc2e2a1971e1cf04b4b3b"
},
{
"id":"s59",
"type":"reddit",
"url":"https://www.reddit.com/r/Hashimotos/comments/1sylqox/peptides_anyone_taking_these/",
"title":"Peptides? Anyone taking these?",
"quote":"I will be testing my TPO at the 6 week mark in 2 weeks for TA-1. I was at 97 at the start, and I had actually done a single vial of 1 mg a day for 10 days and my Tpo had dropped about 10 points so I am hoping that was the cause and I can bring it down with a longer protocol.",
"summary":"User reports initial drop in TPO antibodies after short TA-1 course and plans longer protocol for Hashimoto's.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c68"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T15:39:49.214Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"fb6ad3beaab050431b9dcc23b2b4ec87a6989856151e20aa972c63594623b302",
"hash":"419e18f0ba8abb8347a0e8b112a32f1e636a55ced5de5a0ab2fc0eabfb5bb436",
"source_role":"anecdotal_report",
"quote_sha256":"016c5baa1877a8a42f8cdea47d0f08a01c2ed7e2ccdd160a3a5a10d90914662f"
},
{
"id":"s60",
"type":"reddit",
"url":"https://www.reddit.com/r/chronicfatigue/comments/1j2z1az/what_resolved_my_chronic_fatigue_5_years_later/",
"title":"What resolved my chronic fatigue - 5 years later",
"quote":"Peptides: I have started taking Thymosin Alpha 1, Thymosin Beta 4, Semax and Selank. ... Thymosin Alpha 1 is an immune modulator so it helps improve the immune system. It also has anti inflammatory effects.",
"summary":"User starting TA1 as part of mold illness/CFS protocol, describes its expected immune modulating and anti-inflammatory benefits.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c69"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T15:39:49.214Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"419e18f0ba8abb8347a0e8b112a32f1e636a55ced5de5a0ab2fc0eabfb5bb436",
"hash":"291b8326f8de108f42b028baf5edc1d8be18052591b442fe810ef3e59897218c",
"source_role":"anecdotal_report",
"quote_sha256":"a7706b33d0edcf05068c432cadbe1bbdd18aa1e4ca09dcfb761379418ec51a69"
},
{
"id":"s61",
"type":"reddit",
"url":"https://www.reddit.com/r/Peptides_for_Women/comments/1gy3d3a/thymosin_alpha_1/",
"title":"Thymosin Alpha 1",
"quote":"Within an hour felt significantly better, I mean total package of energy and good mood. ... Inflammation has been decreasing and histamine reaction is definitely getting better. ... within an hour I could do full range squats. Walking down stairs with full flexing and no pain. I’ve lost 3.5lbs of inflammation in 3 days.",
"summary":"User reports rapid improvement in energy, mood, allergies, inflammation, and chronic pain (e.g., plantar fasciitis-like symptoms) after starting TA-1 1mg every 3 days, with continued benefits and reduced allergy meds after weeks/months; some initial itchy/detox sensations but overall highly positive.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c70"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T15:40:14.484Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"291b8326f8de108f42b028baf5edc1d8be18052591b442fe810ef3e59897218c",
"hash":"99834a4d101e7a9dd7ad7e836dd6a02064d892180a30fdd3657bccf6d1bd9273",
"source_role":"anecdotal_report",
"quote_sha256":"796d59435c94ebd331c4a9b4f6349dbcc1a6854ce11d12d29c1062ec8868719d"
},
{
"id":"s62",
"type":"reddit",
"url":"https://www.reddit.com/r/Peptides_for_Women/comments/1gy3d3a/thymosin_alpha_1/",
"title":"Thymosin Alpha 1",
"quote":"TA1 is one of my favorite peptides! I’m allergic to animals but I love them. Was wrestling around w my brothers dog last night ... and left without washing my hands and did not wheeze, cough, choke or blow my nose. ... my first time, within 2 hours I can only compare my reaction to Covid like symptoms. ... lasted about eight hours.",
"summary":"Positive for reducing animal allergies and symptoms; initial flu-like reaction that resolved, leading to ongoing use.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c71"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T15:40:14.484Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"99834a4d101e7a9dd7ad7e836dd6a02064d892180a30fdd3657bccf6d1bd9273",
"hash":"ed520a26e52bdc0e21a7008757cf3caa064298ea2f8ee608ff2811cd33aeacbb",
"source_role":"anecdotal_report",
"quote_sha256":"8cbff1b441c6a0b370acc0da6f51e61633ec9cefdc8a065f5ec658e1b189fe92"
},
{
"id":"s63",
"type":"reddit",
"url":"https://www.reddit.com/r/covidlonghaulers/comments/1peun65/those_who_tried_peptides_permanent_shift_in/",
"title":"Those who tried peptides - permanent shift in baseline?",
"quote":"Thymosin-Alpha-1 _destroyed me_ - one 0.5mg injection and within 12 hours I had a severe flu-like immune reaction (fever, diarrhea, pins and needles, the works). The immune reaction continued the next day as well, and even after subsiding, I'm still crashed from it five days later - in the 70s whereas previously I was in the high 80s.",
"summary":"Severe negative experience with TA-1 causing prolonged flu-like immune reaction and crash in energy/function for Long COVID user.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c72"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T15:40:14.484Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"ed520a26e52bdc0e21a7008757cf3caa064298ea2f8ee608ff2811cd33aeacbb",
"hash":"50f00c70c61b0bf69e958be3d6741613c2a99c41dac5b74b8d1a7573e5392157",
"source_role":"anecdotal_report",
"quote_sha256":"b44d4171b121804e87c1c691416df4bbb0ac3d5834fea078d339d61c79e0f1e3"
},
{
"id":"s64",
"type":"reddit",
"url":"https://www.reddit.com/r/covidlonghaulers/comments/1peun65/those_who_tried_peptides_permanent_shift_in/",
"title":"Those who tried peptides - permanent shift in baseline?",
"quote":"Thymosin alpha makes me feel acutely ill for a day or two.",
"summary":"User notes acute illness feeling from Thymosin alpha (TA-1), part of broader peptide experiences without permanent baseline shift.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c73"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T15:40:14.484Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"50f00c70c61b0bf69e958be3d6741613c2a99c41dac5b74b8d1a7573e5392157",
"hash":"27f8e324571eea36b5833dbbc376a6c3cb5a8e87110a659ecb46a1ff43498b8d",
"source_role":"anecdotal_report",
"quote_sha256":"44cc02128d08283987d406bec748c4b8938b65c826903b3416776a8205db5cb9"
},
{
"id":"s65",
"type":"reddit",
"url":"https://www.reddit.com/r/tressless/comments/1rgcm86/peptide_for_alopecia_thymosin_alpha_1_as_an/",
"title":"Peptide for alopecia: Thymosin Alpha 1 as an Alternative to JAK Inhibitors",
"quote":"Hair loss due to Long Covid here, with TA-1 the hairs grew back.",
"summary":"Anecdotal positive report of hair regrowth from TA-1 in Long COVID-related hair loss.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c74"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T15:40:14.484Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"27f8e324571eea36b5833dbbc376a6c3cb5a8e87110a659ecb46a1ff43498b8d",
"hash":"8657800bf5e8f21b2a96839681d98d5221ebbcfe9e5ae098b51b883cb7d91eef",
"source_role":"anecdotal_report",
"quote_sha256":"b75fcfb77e1c2700c4f597e35c5ea6946e1dade05bb4a4d24d61491c1d9c8d37"
},
{
"id":"s66",
"type":"reddit",
"url":"https://www.reddit.com/r/covidlonghaulers/comments/1g2y1yx/thymosin_alpha_1_and_peptides_for_lc_discussed_on/",
"title":"Thymosin Alpha 1 and Peptides for LC Discussed on Huberman Lab",
"quote":"ME/CFS here - I’ve used TA1 and Thymulin with great success. I’ve had to increase the dose and I can still overdo it and cause PEM and I have to take it daily or the benefit is lost but….it absolutely provides a lift in energy and brain fog and functionality.",
"summary":"User reports great success with TA1 (and Thymulin) for ME/CFS/LC symptoms including energy, brain fog, and functionality; notes need to increase dose over time and daily use for benefit, risk of PEM if overdone.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c75"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T15:40:50.201Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"8657800bf5e8f21b2a96839681d98d5221ebbcfe9e5ae098b51b883cb7d91eef",
"hash":"b5d2c77cd372142a469d311e7b7e9ca962382b5d305137eeb46b848af6180a38",
"source_role":"anecdotal_report",
"quote_sha256":"1e4b64320dde8aea9b6ac0d2dc71b9aed548676a4a6082c3ec533c6354351c21"
},
{
"id":"s67",
"type":"reddit",
"url":"https://www.reddit.com/r/covidlonghaulers/comments/1g2y1yx/thymosin_alpha_1_and_peptides_for_lc_discussed_on/",
"title":"Thymosin Alpha 1 and Peptides for LC Discussed on Huberman Lab",
"quote":"Nice! I just did a cycle which caused a lot of side effects. I thought I'd made a huge mistake, but once I stopped taking it, I found my baseline came back higher.",
"summary":"User experienced significant side effects during cycle (fatigue without activity, muscle twitching, chills) but reported improved baseline after stopping; restarting at lower dose.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c76"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T15:40:50.201Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"b5d2c77cd372142a469d311e7b7e9ca962382b5d305137eeb46b848af6180a38",
"hash":"b6f99db4858ad8bb97815ee7a8fd9abb57a32e25bcbedbfa180443f9d9879b35",
"source_role":"anecdotal_report",
"quote_sha256":"fbf9bc8ee7a757021cef4ba95f97437c8c638f06e5d9e7dc499624e3a880520a"
},
{
"id":"s68",
"type":"x",
"url":"https://x.com/thecoercednurse/status/2070187778584047692",
"title":"X post by @thecoercednurse",
"quote":"It helped to stop the progression of my immune/cardiovascular/respiratory failure. Decreased the debilitating muscle spasms. Improved my ADL function. Kept my autonomic swings more level. Essentially stopped me from needing to choose hospice/palliative care as my only option.",
"summary":"User reports major positive outcomes from TA1 including halting disease progression, reducing spasms, improving daily function and autonomic stability in context of long vax/LC.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c77"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T15:40:50.201Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"b6f99db4858ad8bb97815ee7a8fd9abb57a32e25bcbedbfa180443f9d9879b35",
"hash":"43479f1c41481425509f4cbe43c666f25569e7bbf21e3d99f34c07b880f86826",
"source_role":"anecdotal_report",
"quote_sha256":"b38a91910f7c7b7425ca6ec172f9e9987612818682794a09a71e30fc343c1258"
},
{
"id":"s69",
"type":"x",
"url":"https://x.com/squarian24/status/2070542926623490303",
"title":"X post by @squarian24",
"quote":"I’m being very serious. There’s minimal side effects, no long term effects have been shown after a near decade of studies, and it works.",
"summary":"Positive user endorsement of TA1 with minimal side effects and efficacy based on personal experience and studies.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c78"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T15:40:50.201Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"43479f1c41481425509f4cbe43c666f25569e7bbf21e3d99f34c07b880f86826",
"hash":"079575e015d67d272f93109dfa61faee59697a1d8f6b2c7c120801cfb344812e",
"source_role":"anecdotal_report",
"quote_sha256":"ed30c1b0462728fdb6f2b26574edf464020532238d468f2828334846cec7aa47"
},
{
"id":"s70",
"type":"reddit",
"url":"https://www.reddit.com/r/pancreaticcancer/comments/x71x4v/thymosin_alpha_1/",
"title":"Thymosin Alpha 1",
"quote":"I did find some pre clinical evidence that Thymosin Alpha 1 was protective against opportunistic infection due to suppression from 5-flurouracil.",
"summary":"Discussion on using TA-1 for pancreatic cancer patient; anecdotal interest in immune modulation, no personal outcomes shared in snippet.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c79"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:42:30.624Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"079575e015d67d272f93109dfa61faee59697a1d8f6b2c7c120801cfb344812e",
"hash":"52576ddab0862a0b256905de8246689ec10a74a6bf5bef6bd438acef37304fb7",
"source_role":"anecdotal_report",
"quote_sha256":"79b4f486a46b5e01d510000d7648c1cab621aba1fcfad40734188d60eb1838ab"
},
{
"id":"s71",
"type":"reddit",
"url":"https://www.reddit.com/r/Hashimotos/comments/1sxdk9m/zadaxin_thymosin_alpha1ta1_peptide_to_help_slow/",
"title":"Zadaxin Thymosin alpha-1(TA-1) peptide to help slow muscle recovery?",
"quote":"Thymosin Alpha 1 is more for immunoregulation, ie those pesky T cells.",
"summary":"Anecdotal thread on TA-1 for Hashimoto's and muscle recovery; one user notes it for immunoregulation.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c80"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:42:30.624Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"52576ddab0862a0b256905de8246689ec10a74a6bf5bef6bd438acef37304fb7",
"hash":"e19a6d5a38273f8e38a9db15b91f7fa79fabeace000edb16fc2586d7c2b95271",
"source_role":"anecdotal_report",
"quote_sha256":"a9ec1a6ca0be34da52d0a9a6bf55bbb7ca48f17d7958a50375a3b1daaa206e2a"
},
{
"id":"s72",
"type":"reddit",
"url":"https://www.reddit.com/r/AutoImmuneProtocol/comments/1rzrql8/thymosin_alpha1/",
"title":"Thymosin Alpha-1",
"quote":"Anyone has tried Thymosin Alpha-1 for Graves autoimmune? If not, what worked for you to drop your antibodies?",
"summary":"Query seeking experiences with TA-1 for Graves' disease autoimmune condition.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c81"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:42:30.624Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"e19a6d5a38273f8e38a9db15b91f7fa79fabeace000edb16fc2586d7c2b95271",
"hash":"695189da2a251c1dff219e6743fd3796fd3e82b52a1237c38a89f8448cee5672",
"source_role":"anecdotal_report",
"quote_sha256":"d91516f45060229787e3bee7007f0b16b7683c8f38322271414af31496a0199f"
},
{
"id":"s73",
"type":"reddit",
"url":"https://www.reddit.com/r/endometriosis/comments/1s8dkwf/thymosin_alpha_1_ldn_or_glps_or_all_three/",
"title":"Thymosin Alpha 1, LDN, or GLPS? or all three?",
"quote":"My dr wants me on TA1 for chronic EBV as well and heard it might possibly help immune system fight off endo.",
"summary":"Anecdotal discussion of TA-1 dosing for chronic EBV and potential endometriosis benefits; labeled anecdotal.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c82"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:42:30.624Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"695189da2a251c1dff219e6743fd3796fd3e82b52a1237c38a89f8448cee5672",
"hash":"03f97a8618ba8b61fb4c243ab6f80e0b6d6ef71cc90ef4f1e2497ee5bc2e63bc",
"source_role":"anecdotal_report",
"quote_sha256":"1fa18b6edc6740fc77900058084ec6e189be6cf5bc0ca299447a39834f70118c"
},
{
"id":"s74",
"type":"x",
"url":"https://x.com/BhavanChand/status/2071648123559288889",
"title":"Thymosin Alpha-1 testing",
"quote":"My kids caught cold again 3 days ago My mother also caught cold from them It didn't spread to me yet and I didn't take my Thymosin Alpha -1 Testing if the previous doses are working or not",
"summary":"Anecdotal X post testing prior TA-1 doses for cold prevention; no outcome reported yet.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c83"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:42:30.624Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"03f97a8618ba8b61fb4c243ab6f80e0b6d6ef71cc90ef4f1e2497ee5bc2e63bc",
"hash":"421c2034f38785596eec425a91e54e81f6ac9103d57060c17fc9f6922d9d2e84",
"source_role":"anecdotal_report",
"quote_sha256":"cdf0bea9475260d1a2f6f67eb95bd2ffd20c798648d0bf3edf37db560dc811b4"
},
{
"id":"s75",
"type":"x",
"url":"https://x.com/biotides/status/2071620162831159366",
"title":"Thymosin Alpha-1 for sinusitis",
"quote":"For someone who suffers from sinusitis, one of the best remedies I’ve used is Thymosin Alpha-1. I use it as needed. But it almost immediately opens the sinuses up and cleans out the gunk. Same with the throat.",
"summary":"Positive anecdotal report on TA-1 for sinusitis relief (as needed dosing); good outcome claimed.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c84"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:42:30.624Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"421c2034f38785596eec425a91e54e81f6ac9103d57060c17fc9f6922d9d2e84",
"hash":"45937974f74474ce89e5a6fd592beacedfad59b7817849d0875825559e65447b",
"source_role":"anecdotal_report",
"quote_sha256":"b87bba6837e77279f1d71e8099fd37f57f70149570c60572492887699813901f"
},
{
"id":"s76",
"type":"x",
"url":"https://x.com/DuaneStorey/status/2071544627635581270",
"title":"RNA seq data with TA1",
"quote":"Day 0 meds: baseline, Thymosin Alpha 1 for a few days. ... Good news is a substantial amount of my out of range genes went back into range on day 42.",
"summary":"Anecdotal personal RNA sequencing results involving TA-1 use; mixed with other meds, positive gene expression changes noted.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c85"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:42:30.624Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"45937974f74474ce89e5a6fd592beacedfad59b7817849d0875825559e65447b",
"hash":"d4f11e46c63e5b2dcc21e964c214f83b7633b7b14dc0e02666b71cb0adccaac7",
"source_role":"anecdotal_report",
"quote_sha256":"8eef6d379dc59f0c393b3ac9f6c1a37e14f74d4c45ad5f78f330d34b52a1fd87"
},
{
"id":"s77",
"type":"reddit",
"url":"https://www.reddit.com/r/smallfiberneuropathy/comments/1phisi1/thymosin_alpha_1/",
"title":"Thymosin Alpha 1",
"quote":"It's a risky gamble imo. There is a small subset of SFN patients who I would expect to get modestly better from Ta1, with the rest either getting no benefit or even feeling _worse_. You don't want to jack up T cell activity if T cell activity is already problematic.",
"summary":"Comment discusses potential risks and benefits of TA1 for small fiber neuropathy (SFN), noting it may worsen symptoms in some due to T-cell stimulation; recommends labs first. Anecdotal, not advice.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c86"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:43:05.376Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"d4f11e46c63e5b2dcc21e964c214f83b7633b7b14dc0e02666b71cb0adccaac7",
"hash":"a6e09fff0185217a2edcdc7ccde7b0895ad880edc1fc0ea0492811f80b697996",
"source_role":"anecdotal_report",
"quote_sha256":"2b7c150650632a5f992bebe688bece66bba1bd74f114f3b443d5239f2b318fcd"
},
{
"id":"s78",
"type":"reddit",
"url":"https://www.reddit.com/r/smallfiberneuropathy/comments/1phisi1/thymosin_alpha_1/",
"title":"Thymosin Alpha 1",
"quote":"I just started! Haven’t seen any results or had any relief yet but I will keep you posted!",
"summary":"User reports starting TA1 (second week on full dose after slow start) with no results yet for SFN symptoms; also on ARA-290. Anecdotal, not advice.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c87"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:43:05.376Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"a6e09fff0185217a2edcdc7ccde7b0895ad880edc1fc0ea0492811f80b697996",
"hash":"d082482f9a8e7a99e8307a0fff120667f2ba36366b05be12cad40274af1bcb2d",
"source_role":"anecdotal_report",
"quote_sha256":"08179c0e4fb7731f36117155c95994199a41f180456d5b73ba3268b6055eca84"
},
{
"id":"s79",
"type":"reddit",
"url":"https://www.reddit.com/r/Immunology/comments/q6bgrz/thymosin_alpha_1_daily_vs_twice_weekly/",
"title":"Thymosin alpha 1 daily vs twice weekly administration",
"quote":"I basically get more ill for a few days every time I take the TA1. So it’s a bit of a hinderance to general work and life stuff. I might try lower doses to see if that is easier to handle.",
"summary":"User reports side effects like feeling more ill (HRV tanked, breathless, wired) after 1-1.2mg doses of TA1 for long COVID; considering lower doses. Dosing anecdote: 800mcg 2-3x/week planned. Anecdotal, not advice.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c88"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:43:05.376Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"d082482f9a8e7a99e8307a0fff120667f2ba36366b05be12cad40274af1bcb2d",
"hash":"4f8746ff75f51e816a906e7c01fab4417b8ad049154615e9882bd7aaefa6e76a",
"source_role":"anecdotal_report",
"quote_sha256":"a8c9fbd8e8964af1b29a0d7010a2c84cb2b1d6ab965ec60769f880a6390840c7"
},
{
"id":"s80",
"type":"reddit",
"url":"https://www.reddit.com/r/Immunology/comments/q6bgrz/thymosin_alpha_1_daily_vs_twice_weekly/",
"title":"Thymosin alpha 1 daily vs twice weekly administration",
"quote":"I’m thinking of doing 2-3x a week around 800mcg after starting at 300mcg to see if I react to it. I’ll also run TB-500 for healing.",
"summary":"Dosing discussion and plan for TA1 (starting low at 300mcg, then 800mcg 2-3x/week) alongside other peptides for long COVID immune issues. Anecdotal, not advice.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c89"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:43:05.376Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"4f8746ff75f51e816a906e7c01fab4417b8ad049154615e9882bd7aaefa6e76a",
"hash":"7d10e3f67b639e32213f893a753ae85243c8a50d5817e82ba347af1df8e02d43",
"source_role":"anecdotal_report",
"quote_sha256":"efe1c38bd3e510fea971c6c7f847d1ac5d1b5288beb002e972ed5ac62e229da7"
},
{
"id":"s81",
"type":"reddit",
"url":"https://www.reddit.com/r/PeptideProgress/comments/1s62nmn/thymosin_alpha1_the_immune_system_peptide_nobody/",
"title":"Thymosin Alpha-1: The Immune System Peptide Nobody Talks About",
"quote":"The people who tend to benefit most from Thymosin Alpha - 1 are those dealing with frequent illness, slow recovery from infections, chronic fatigue, and autoimmune issues.",
"summary":"Post discusses potential benefits of TA1 for immune support in chronic conditions; no specific personal outcomes or dosing in snippet but contextual anecdotes implied in community. Anecdotal context, not advice.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c90"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:43:05.376Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"7d10e3f67b639e32213f893a753ae85243c8a50d5817e82ba347af1df8e02d43",
"hash":"2bb2110fc15d122321b88f3b9880f40197c7a36a204c8649c0bf43c4484cb7e8",
"source_role":"anecdotal_report",
"quote_sha256":"1f95ef9850e675564d95e27bcc678de9a39bd23f5737183576e8298fe792ac7d"
},
{
"id":"s82",
"type":"reddit",
"url":"https://www.reddit.com/r/USPeptides/comments/1p43fnb/thymosin_alpha1_immune_system_peptide_explained/",
"title":"Thymosin Alpha-1 🏥 Immune System Peptide Explained | T-Cell Activation, Inflammation Control & Recovery Support (Complete 2025 Research Guide)",
"quote":"TA1 isn’t one of those “immune booster” things. It doesn’t just crank your immune system up. It’s more like helping it work normally again, especially after burnout or chronic stress.",
"summary":"Guide explaining TA-1 as immunomodulator not booster; discusses clinical uses, dosing (e.g., 1.6mg 2-3x weekly anecdotal), possible mild side effects like initial fatigue. Anecdotal user experiences labeled as such.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c5"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:43:45.543Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"2bb2110fc15d122321b88f3b9880f40197c7a36a204c8649c0bf43c4484cb7e8",
"hash":"e50abfc806fb93cc5701102cb2241e54e8d0b76417a86edb05e5ea9754fd57b1",
"source_role":"anecdotal_report",
"quote_sha256":"42b1eec89f7acca7a5db09e13156dc4d102444602182cc3e460d5aea54e09577"
},
{
"id":"s83",
"type":"reddit",
"url":"https://www.reddit.com/r/USPeptides/comments/1p43fnb/thymosin_alpha1_immune_system_peptide_explained/",
"title":"Thymosin Alpha-1 🏥 Immune System Peptide Explained | T-Cell Activation, Inflammation Control & Recovery Support (Complete 2025 Research Guide)",
"quote":"I got some blood work done and it recommended I take TA1 for chronic inflammation. ... TA-1 tends to help people. ... You feel less inflamed or “worn down”, you bounce back faster when you’re tired or sick.",
"summary":"User with chronic stress/burnout considering TA-1 based on bloodwork; OP responds with expected subtle benefits like better resilience (anecdotal dosing and outcomes only).",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c92"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:43:45.543Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"e50abfc806fb93cc5701102cb2241e54e8d0b76417a86edb05e5ea9754fd57b1",
"hash":"5cc7469301ebf3eac9ab0f18f334656fcb2fb5a1362b4cc193678046e9bfbfd5",
"source_role":"anecdotal_report",
"quote_sha256":"0157fa37bad006cb973a3fbbf2a51023c2918c0ce8fee9b19f628af582e360fb"
},
{
"id":"s84",
"type":"reddit",
"url":"https://www.reddit.com/r/Peptides/comments/1s5cv2z/ta1_cloudy_at_reconstitution/",
"title":"Ta1 Cloudy at Reconstitution",
"quote":"I have tried two different vials of Thymosin Alpha 1 from the same source and both are cloudy with suspended ...",
"summary":"User reports cloudy reconstitution of TA1 vials from same source (anecdotal, not advice).",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c93"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:44:27.544Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"5cc7469301ebf3eac9ab0f18f334656fcb2fb5a1362b4cc193678046e9bfbfd5",
"hash":"bccdadf6c337a85b352c55cc9adab34ae636e7c8892b43f6738882d55aa5ddcb",
"source_role":"anecdotal_report",
"quote_sha256":"7e7bf38f9e6244144a121a572c73e11c6234457e823db51d5db9bccebc24e5a2"
},
{
"id":"s85",
"type":"reddit",
"url":"https://www.reddit.com/r/Peptides/comments/1hhefnv/ll37_thymosin_alpha_review/",
"title":"LL37 & Thymosin Alpha Review",
"quote":"I have begun a LL37 and Thymosin Alpha cycle, this time for the exact purpose of healing the body in all the ways these peptides are said to do.",
"summary":"Anecdotal report of starting LL37 and Thymosin Alpha cycle for healing (anecdotal, not advice).",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c94"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:44:27.544Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"bccdadf6c337a85b352c55cc9adab34ae636e7c8892b43f6738882d55aa5ddcb",
"hash":"b4100b724c7f8245c913a1fc957fc63f8ca0eea62b28aaaf3214aa09e54b54a9",
"source_role":"anecdotal_report",
"quote_sha256":"1e817090c0e5060d662cc0474625dd547a20b9dbd5c6039c11dfe61a64f04d51"
},
{
"id":"s86",
"type":"reddit",
"url":"https://www.reddit.com/r/Peptides/comments/1d2d4s2/thymosin_alpha_1_is_there_a_way_to_check_from/",
"title":"Thymosin Alpha 1: Is there a way to check from bloodwork ...",
"quote":"I ordered some Thymosin Alpha 1 recently and will be trying it soon for the first time. I'll be using it to try and treat a chronic ...",
"summary":"User planning to try TA1 for chronic issue, seeking bloodwork monitoring (anecdotal, not advice).",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c95"
],
"found_by":"grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T17:44:27.544Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"b4100b724c7f8245c913a1fc957fc63f8ca0eea62b28aaaf3214aa09e54b54a9",
"hash":"abf738fd42dc43818d8f301339f14ff69cdf66968d5014165007ad5fb6dd26a4",
"source_role":"anecdotal_report",
"quote_sha256":"f0d7b33904c030f04b2f9b839a1f549ab14db2d75c0df01155592df8f0d48fb0"
},
{
"id":"w_1hp6ddar",
"url":"https://pubmed.ncbi.nlm.nih.gov/23327199/",
"title":"The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial (Crit Care 2013; PMID 23327199; NCT00711620)",
"quote":"Greater improvement of mHLA-DR was observed in the Ta1 group on day 3 (mean difference 3.9%, 95% CI 0.2 to 7.6%, P = 0.037) and day 7 (5.8%, 95% CI 1.0 to 10.5%, P = 0.017). No serious drug-related adverse event was recorded.",
"_id":"w_1hp6ddar",
"_ts":"2026-08-04T08:35:34.825Z",
"type":"source",
"accessed_at":"2026-08-04T08:35:34.825Z",
"claim_ids": [],
"prev":"abf738fd42dc43818d8f301339f14ff69cdf66968d5014165007ad5fb6dd26a4",
"hash":"56166a416dee0c8cc0853a8673d3a04877728be61496119eecd741c05204643a",
"summary":"ETASS randomised controlled trial of thymosin alpha 1 in severe sepsis: monocyte HLA-DR recovery and safety findings.",
"quote_sha256":"530fa6d829a786c9fe845773297dcb182744cd93719be8c5c236cbc153913c6f"
},
{
"id":"w_zlvvtukb",
"url":"https://pubmed.ncbi.nlm.nih.gov/23327199/",
"title":"The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial (Crit Care 2013; PMID 23327199; NCT00711620)",
"quote":"The mortalities from any cause within 28 days in the Ta1 group and control group were 26.0% and 35.0% respectively with a marginal P value (nonstratified analysis, P = 0.062; log rank, P = 0.049)",
"_id":"w_zlvvtukb",
"_ts":"2026-08-04T08:35:51.920Z",
"type":"source",
"accessed_at":"2026-08-04T08:35:51.920Z",
"claim_ids": [],
"prev":"56166a416dee0c8cc0853a8673d3a04877728be61496119eecd741c05204643a",
"hash":"2427352caadb1cb67b0a353b8323f819551f91ecb780455a6ebeb6af73ec1262",
"plain":"An early multicentre randomized trial in severe sepsis. Death within 28 days ran 26% against 35%, but only one of the two statistical tests crossed the line and the trial was single-blind. Grounds for a bigger study, not a settled answer.",
"quote_sha256":"cc884970194ac4696e8376fc650e38cb2d24604e5098fc613f26f0f6e4bb01bd"
},
{
"id":"w_vzvtwnky",
"url":"https://pubmed.ncbi.nlm.nih.gov/39814420/",
"title":"The efficacy and safety of thymosin alpha1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial (BMJ 2025; PMID 39814420; NCT02867267)",
"quote":"28 day all cause mortality occurred in 127 participants (23.4%) in the thymosin alpha1 group and 132 (24.1%) in the placebo group (hazard ratio 0.99, 95% confidence interval 0.77 to 1.27; P=0.93)",
"_id":"w_vzvtwnky",
"_ts":"2026-08-04T08:35:53.253Z",
"type":"source",
"accessed_at":"2026-08-04T08:35:53.253Z",
"claim_ids": [],
"prev":"2427352caadb1cb67b0a353b8323f819551f91ecb780455a6ebeb6af73ec1262",
"hash":"8362a2b1b6be412687a065f4c25935835f50cac390360cdaa54d3459e56b172e",
"plain":"The proper test: double-blind, placebo-controlled, phase 3, over a thousand people with sepsis. Deaths at 28 days were the same in both arms, with a hazard ratio of essentially 1.0. It is the strongest design in the entire record and it found nothing.",
"quote_sha256":"e04d4210c31b348a583f93f3b98d095120d9941d1bb17672d91fd5ca15bf999c"
},
{
"id":"w_0c2625io",
"url":"https://pubmed.ncbi.nlm.nih.gov/35713670/",
"title":"Immune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial (TRACE, Intensive Care Med 2022; PMID 35713670; NCT02473406)",
"quote":"40/254(15.7%) patients in the Ta1 group developed IPN compared with 46/254 patients (18.1%) in the placebo group (difference -2.4% [95% CI - 7.4 to 5.1%]; p = 0.48)",
"_id":"w_0c2625io",
"_ts":"2026-08-04T08:35:56.546Z",
"type":"source",
"accessed_at":"2026-08-04T08:35:56.546Z",
"claim_ids": [],
"prev":"8362a2b1b6be412687a065f4c25935835f50cac390360cdaa54d3459e56b172e",
"hash":"2b2760ff9c992e286558f6d160aeaa26f1677392b2fa6d58e7368b9b4f6bfefb",
"plain":"508 people with severe pancreatitis, randomized and double-blind. Infected dead tissue appeared in 15.7% on the peptide and 18.1% on placebo, a gap too small to separate from chance. The main question the trial was built to answer came back negative.",
"quote_sha256":"5b204a1c761dd5f267cddea66e7744ff699fe7666ef7c13800e64bfbadb423c9"
},
{
"id":"w_cbj4dxj3",
"url":"https://pubmed.ncbi.nlm.nih.gov/37007743/",
"title":"Association between pretreatment lymphocyte count and efficacy of immune-enhancing therapy in acute necrotising pancreatitis: post-hoc analysis of TRACE (EClinicalMedicine 2023; PMID 37007743)",
"quote":"Within the subgroup of patients with baseline ALC>=0.8 x 10^9/L (n = 290), the Ta1 therapy significantly reduced the risk of IPN (covariate adjusted risk difference, -0.12; 95% CI, -0.21,-0.02; p = 0.015)",
"_id":"w_cbj4dxj3",
"_ts":"2026-08-04T08:36:02.145Z",
"type":"source",
"accessed_at":"2026-08-04T08:36:02.145Z",
"claim_ids": [],
"prev":"2b2760ff9c992e286558f6d160aeaa26f1677392b2fa6d58e7368b9b4f6bfefb",
"hash":"d2e3f08e4f7cc9ec2723e8640d903f089e7790804c86e473dc92827b77ed8687",
"plain":"A slice of the pancreatitis trial cut open after the results were known: among the 290 who started with enough lymphocytes, the peptide arm did better. Subgroups found after the fact raise a question for the next trial. They do not answer one.",
"quote_sha256":"c5dd0a716472cf46a85c0683f1b3f0306190c8e8b6ba8b73428bb142e8058684"
},
{
"id":"w_or6weneu",
"url":"https://pubmed.ncbi.nlm.nih.gov/32442287/",
"title":"Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells (Clin Infect Dis 2020; PMID 32442287)",
"quote":"Compared with the untreated group, Ta1 treatment significantly reduced the mortality of severe COVID-19 patients (11.11% vs 30.00%, P = .044)",
"_id":"w_or6weneu",
"_ts":"2026-08-04T08:36:03.028Z",
"type":"source",
"accessed_at":"2026-08-04T08:36:03.028Z",
"claim_ids": [],
"prev":"d2e3f08e4f7cc9ec2723e8640d903f089e7790804c86e473dc92827b77ed8687",
"hash":"ad4e1a7f579c47489886a81882e59f471092808845cd6a44bdb4b430e55a6c01",
"plain":"An early-pandemic hospital comparison rather than a randomized trial, setting patients who got the peptide against those who did not. The mortality gap is wide, and so is the room for the two groups differing in ways nobody measured.",
"quote_sha256":"057fc802f06bd45e3933db09813f0e010462ba3f9de883932922f2060e6ac23e"
},
{
"id":"w_q4kpjhai",
"url":"https://pubmed.ncbi.nlm.nih.gov/34408744/",
"title":"Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study (Front Immunol 2021; PMID 34408744)",
"quote":"After adjusting for confounding factors, Ta1 use was found to be significantly associated with a higher non-recovery rate than non-Ta1 use (OR 1.5, 95% CI 1.1-2.1, p = 0.028)",
"_id":"w_q4kpjhai",
"_ts":"2026-08-04T08:36:04.691Z",
"type":"source",
"accessed_at":"2026-08-04T08:36:04.691Z",
"claim_ids": [],
"prev":"ad4e1a7f579c47489886a81882e59f471092808845cd6a44bdb4b430e55a6c01",
"hash":"b4195ccb337daa191abc31e1f36468f5875735c95755887b73fec8ee066fbe31",
"plain":"A multi-hospital observational study pointing the other way from the smaller COVID reports: after adjustment, people given the peptide were about half again as likely not to have recovered. Observational, so not proof of harm, but it belongs beside the positive ones.",
"quote_sha256":"4ee8d530ea1337a62111d94b1e129d3cbaecda626453a7f2c83092b21764a62a"
},
{
"id":"w_vxfrwa56",
"url":"https://pubmed.ncbi.nlm.nih.gov/33968969/",
"title":"Efficacy Evaluation of Thymosin Alpha 1 in Non-severe Patients With COVID-19: A Retrospective Cohort Study Based on Propensity Score Matching (Front Med 2021; PMID 33968969)",
"quote":"the Thymosin-alpha1 group had significantly shorter SARS-CoV-2 RNA shedding duration (13 vs. 16 days, p = 0.025) and hospital stay (14 vs. 18 days, p < 0.001)",
"_id":"w_vxfrwa56",
"_ts":"2026-08-04T08:36:06.281Z",
"type":"source",
"accessed_at":"2026-08-04T08:36:06.281Z",
"claim_ids": [],
"prev":"b4195ccb337daa191abc31e1f36468f5875735c95755887b73fec8ee066fbe31",
"hash":"cbb90a0f7948ef73c1e2941b2854a999bdc8d4790d8499550f6cad9fa34107fa",
"plain":"A look back through records of people with milder COVID, statistically matched to make the two groups comparable. Virus clearance and hospital stay were each a few days shorter. Matching narrows the gap between groups but never closes it the way randomizing does.",
"quote_sha256":"1b6c4d87607a28697f0bbff3bab6c26fa3eb014447616397e2653e3868a3191d"
},
{
"id":"w_jzf25pn3",
"url":"https://clinicaltrials.gov/study/NCT04428008",
"title":"A Pilot Trial of Thymalfasin (Ta1) to Prevent COVID-19 Infection in Renal Dialysis Patients (NCT04428008, posted results)",
"quote":"Number of Participants With COVID-19 Infection: Active Arm 5, Control Arm 7. Deaths: Active Arm 3/91, Control Arm 7/98.",
"_id":"w_jzf25pn3",
"_ts":"2026-08-04T08:36:06.920Z",
"type":"source",
"accessed_at":"2026-08-04T08:36:06.920Z",
"claim_ids": [],
"prev":"cbb90a0f7948ef73c1e2941b2854a999bdc8d4790d8499550f6cad9fa34107fa",
"hash":"262f3cb69051fc1ff58afa1e1bb86cab4e50115f809b3b697f05384ffc10c0f2",
"plain":"A small pilot in dialysis patients, with its results actually posted. Five infections against seven, three deaths against seven. Numbers this size move on chance alone, so what it shows is that the study could be run, not that the peptide did anything.",
"quote_sha256":"bbd9094a370710b672e05fc12a8aea20271ea9cec0ffdf12c11a339cb5e4b497"
},
{
"id":"w_omh8z65r",
"url":"https://clinicaltrials.gov/study/NCT00911443",
"title":"Phase II dose-ranging trial of dacarbazine plus interferon alpha plus thymosin alpha-1 in advanced metastatic melanoma (NCT00911443, posted results, n=488)",
"quote":"Overall Survival, months: DTIC+IFN+Ta1 6.4 mg 10.3; DTIC+Ta1 3.2 mg 9.3; DTIC+IFN+Ta1 1.6 mg 9.3; DTIC+IFN+Ta1 3.2 mg 8.6; DTIC+IFN alone 6.6",
"_id":"w_omh8z65r",
"_ts":"2026-08-04T08:36:07.988Z",
"type":"source",
"accessed_at":"2026-08-04T08:36:07.988Z",
"claim_ids": [],
"prev":"262f3cb69051fc1ff58afa1e1bb86cab4e50115f809b3b697f05384ffc10c0f2",
"hash":"93ef23eba4b73c3492ef9bdf7c1deb63ac5bc41200dce66ee095a8c8b3e7eace",
"plain":"A 488-person dose-ranging study in advanced melanoma. Median survival across the four peptide doses ran 8.6 to 10.3 months against 6.6 for the standard combination, with no clean pattern by dose, in a trial not designed to prove a survival benefit.",
"quote_sha256":"5af6d076ed13f1990aa0abba1dd7b74ac0d05c1e7f67d1ecc3ad0383b269f279"
},
{
"id":"w_xmbjsj3u",
"url":"https://clinicaltrials.gov/study/NCT01178996",
"title":"Phase III trial of thymosin alpha 1 plus peginterferon alfa-2a plus ribavirin in chronic hepatitis C non-responders (NCT01178996, n=552, completed 2009, no results posted)",
"quote":"Thymosin alpha 1 (Zadaxin) 1.6 mg/day, two times weekly in the morning, by subcutaneous injection for 48 weeks. Primary outcome: Sustained Virological Response (SVR) at Week 72.",
"_id":"w_xmbjsj3u",
"_ts":"2026-08-04T08:36:09.161Z",
"type":"source",
"accessed_at":"2026-08-04T08:36:09.161Z",
"claim_ids": [],
"prev":"93ef23eba4b73c3492ef9bdf7c1deb63ac5bc41200dce66ee095a8c8b3e7eace",
"hash":"dd25e3d922ac730e3fe1ec04eb87829478034205faabea89cc71c0d939ec355c",
"plain":"A 552-person phase 3 in hepatitis C that finished in 2009 and never posted a result. A completed trial that size going dark is itself information: the published record is missing a piece it ought to contain.",
"quote_sha256":"29d7bda91cb63627a426d0b058dbfbf7a7aa2600aeed519fb61b262eb504a992"
},
{
"id":"w_dkfbbahz",
"url":"https://clinicaltrials.gov/study/NCT05086614",
"title":"Thymosin-alpha 1 as adjuvant treatment after radical resection of high-risk stage II and III colorectal cancer (NCT05086614, phase 3, 2500 planned, primary completion 2027)",
"quote":"Receive thymosin-alpha 1 1.6mg with subcutaneous injection, twice a week, for 6 months after radical resection. Primary outcome: 3-year disease-free survival rate.",
"_id":"w_dkfbbahz",
"_ts":"2026-08-04T08:36:10.476Z",
"type":"source",
"accessed_at":"2026-08-04T08:36:10.476Z",
"claim_ids": [],
"prev":"dd25e3d922ac730e3fe1ec04eb87829478034205faabea89cc71c0d939ec355c",
"hash":"802723d64ae9e44d27bfec7c61198badeb08e77e9f2c491340971898a3868d29",
"plain":"A phase 3 planning 2,500 people, asking whether six months of the peptide after bowel cancer surgery changes how many stay disease-free at three years. Primary completion is 2027, so it moves what will be knowable, not what is known.",
"quote_sha256":"e8a2f2e9f9edea65453e9edd96965c18a75d6105f9a5f2db2e05f4f66499e9ea"
},
{
"id":"w_23spjiq3",
"url":"https://pubmed.ncbi.nlm.nih.gov/22178096/",
"title":"Thymosin-alpha 1 (Zadaxin) enhances the immunogenicity of an adjuvated pandemic H1N1v influenza vaccine (Focetria) in hemodialyzed patients: a pilot study (Vaccine 2012; PMID 22178096)",
"quote":"The CHMP criteria were fully met in the groups treated with Vaccine+Thymosin alpha 1. No AE was found to be related to Thymosin alpha 1 nor to the Focetria vaccine.",
"_id":"w_23spjiq3",
"_ts":"2026-08-04T08:36:13.358Z",
"type":"source",
"accessed_at":"2026-08-04T08:36:13.358Z",
"claim_ids": [],
"prev":"802723d64ae9e44d27bfec7c61198badeb08e77e9f2c491340971898a3868d29",
"hash":"bc7eaefab13e48f05481e0c788a2ec4f51662beec32e2418acaf9c3d62a30c8c",
"plain":"A small pilot adding the peptide to a flu shot in dialysis patients, whose response to vaccines is usually poor. The combined group met the regulator's antibody thresholds and no side effect was traced to the peptide. Pilot-sized, so a signal and nothing firmer.",
"quote_sha256":"1d2cb678ca7bb4c690c7bfc8f37df0ee7da9fc47adbd011ad63a8b0347bfd5e2"
},
{
"id":"w_e7vuijxz",
"url":"https://pubmed.ncbi.nlm.nih.gov/17804687/",
"title":"Thymosin alpha1 activates the TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo (Int Immunol 2007; PMID 17804687)",
"quote":"The anti-viral effect of Talpha1 occurred through the activation of plasmacytoid DCs via the TLR9/myeloid differentiation primary response gene 88-dependent viral recognition sensing, leading to the activation of IFN regulatory factor 7",
"_id":"w_e7vuijxz",
"_ts":"2026-08-04T08:36:19.675Z",
"type":"source",
"accessed_at":"2026-08-04T08:36:19.675Z",
"claim_ids": [],
"prev":"bc7eaefab13e48f05481e0c788a2ec4f51662beec32e2418acaf9c3d62a30c8c",
"hash":"ed5070c50b236c3a4556dd2b99132e1b401a7e33d7bac62c08f1e233234044bf",
"plain":"Mice, and a mechanism. The antiviral effect ran through one specific immune-sensing pathway in a class of dendritic cells. It offers a plausible route of action and carries nothing about dose, benefit, or what happens in a person.",
"quote_sha256":"6d5bae9ffcfb9ba93d53d765af1fa479a7dae105b686ea44e6899797a6924a85"
},
{
"id":"w_pptae9m4",
"url":"https://pubmed.ncbi.nlm.nih.gov/17495242/",
"title":"Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance (Ann N Y Acad Sci 2007; PMID 17495242)",
"quote":"Talpha1 primed DCs for antifungal Th1 resistance through Toll-like receptor (TLR)/MyD88-dependent signaling; activated plasmacytoid DCs via TLR9/MyD88-dependent viral recognition; induced indoleamine 2,3-dioxygenase activity in DCs, thus affecting tolerization toward self as well as microbial non-self-antigens",
"_id":"w_pptae9m4",
"_ts":"2026-08-04T08:36:33.407Z",
"type":"source",
"accessed_at":"2026-08-04T08:36:33.407Z",
"claim_ids": [],
"prev":"ed5070c50b236c3a4556dd2b99132e1b401a7e33d7bac62c08f1e233234044bf",
"hash":"fa157b0804c5dff81666fe68865e8db5677a305d3550e9c28e6cda6f210eb19b",
"plain":"A mechanism review from the group that mapped the pathway, describing how the peptide tunes dendritic cells both toward fighting infection and toward tolerating the body's own tissue. Background for why it was tried in people, not evidence from people.",
"quote_sha256":"a0773d121de9c956a1245125c9369214c7846bf77e32dca25cff05cb896a9c23"
},
{
"id":"w_ekm6tk8i",
"url":"https://pubmed.ncbi.nlm.nih.gov/23045967/",
"title":"Thymosin alpha1 and cancer: action on immune effector and tumor target cells (Ann N Y Acad Sci 2012; PMID 23045967)",
"quote":"Ta1 has been shown to exert an immune modulatory activity on both T cell and natural killer cell maturation and to have an effect on functions of mature lymphocytes, including stimulating cytokine production and cytotoxic T lymphocyte-mediated cytotoxic responses",
"_id":"w_ekm6tk8i",
"_ts":"2026-08-04T08:36:35.106Z",
"type":"source",
"accessed_at":"2026-08-04T08:36:35.106Z",
"claim_ids": [],
"prev":"fa157b0804c5dff81666fe68865e8db5677a305d3550e9c28e6cda6f210eb19b",
"hash":"94527e5dfb9333eff61139619d05da316ec5bc5dfb81196e740a3104c2060e18",
"plain":"A review of the laboratory case in cancer: effects on T cell and natural killer cell maturation, and on cytokine output. Written by researchers close to the compound, summarizing cell and animal work, which is a long way from a survival curve.",
"quote_sha256":"6eabdcf84d40bfc84f26c702e905e2040f4f216e01c05fab30a2175f24d59ec4"
},
{
"id":"w_uzdfttix",
"url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks",
"title":"FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (page current as of 22 April 2026) - Thymosin-alpha 1 appears in the 'Bulk drug substances nominated but withdrawn' table",
"quote":"Compounded drugs containing thymosin-alpha-1 (Ta1) may pose significant risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and API characterization. The safety-related information is inadequate for the agency to sufficiently understand the extent of any safety issues raised by the proposed compounded drug.",
"_id":"w_uzdfttix",
"_ts":"2026-08-04T08:36:41.310Z",
"type":"source",
"accessed_at":"2026-08-04T08:36:41.310Z",
"claim_ids": [],
"prev":"94527e5dfb9333eff61139619d05da316ec5bc5dfb81196e740a3104c2060e18",
"hash":"d2eb67ba06fd295d1ace12789a37ba6b40dcd255755acb7614df41ca30c71b52",
"plain":"The same agency compounding list, this entry for the peptide itself. Nominated and withdrawn means not approved and not formally prohibited. The named concerns are immune reaction, peptide impurities, and poor characterization, on data the agency called inadequate.",
"quote_sha256":"b9dccae00321908437782b892c7a47f20d5dcd0e86dc5b4377621a9d3c81f765"
},
{
"id":"w_d85m6gah",
"url":"https://www.shijiebiaopin.net/upload/product/2011121219115812.PDF",
"title":"SciClone Pharmaceuticals ZADAXIN (thymalfasin) Product Monograph",
"quote":"Since 1979, Zadaxin has been evaluated in more than 3,000 patients in over 70 clinical studies. Administration has been in daily doses ranging from 0.6 to 9.6 mg/m2 and 1 mg to 16 mg, primarily administered subcutaneously on a biweekly schedule, for treatment periods ranging from 1 day to 18 months. No serious adverse experiences have been observed.",
"_id":"w_d85m6gah",
"_ts":"2026-08-04T08:36:45.285Z",
"type":"source",
"accessed_at":"2026-08-04T08:36:45.285Z",
"claim_ids": [],
"prev":"d2eb67ba06fd295d1ace12789a37ba6b40dcd255755acb7614df41ca30c71b52",
"hash":"6f02df53961b2cbcf245d9e3bd3230f3cab8eed9d5f182b459faea5f905f2f32",
"plain":"The manufacturer's own monograph, reporting more than 3,000 patients across 70 studies with no serious adverse experiences, at doses from 1 to 16 mg. Useful for the dose range actually used. A company summarizing its own safety record is the weakest form of safety evidence.",
"quote_sha256":"db28958af6296d0baef09aa3f7c5380b21b012a12816eb8c0f3fa9b51d2684e9"
},
{
"id":"w_dt6aln8r",
"url":"https://www.rxlist.com/zadaxin-drug.htm",
"title":"ZADAXIN (thymalfasin) prescribing information - dosage, reconstitution, storage, pharmacokinetics and adverse reactions",
"quote":"1.6 mg of lyophilized thymosin alpha 1 per vial, reconstituted with 1.0 ml of the diluent provided, which consists of 1.0 ml Sterile Water for Injection. 1.6 mg (900 ug/m2) administered subcutaneously twice a week for 6 to 12 months. Peak serum levels achieved at approximately 2 hours; elimination half-life approximately 2 hours.",
"_id":"w_dt6aln8r",
"_ts":"2026-08-04T08:36:46.096Z",
"type":"source",
"accessed_at":"2026-08-04T08:36:46.096Z",
"claim_ids": [],
"prev":"6f02df53961b2cbcf245d9e3bd3230f3cab8eed9d5f182b459faea5f905f2f32",
"hash":"ae60b526b0ace69c1727e4830d9a0ac34aa1640a82e1c449744da8663795f8da",
"plain":"The prescribing document: 1.6 mg of powder per vial, mixed with 1 ml of sterile water, injected under the skin twice a week for six to twelve months. It also gives the reason for that rhythm, since blood levels peak around two hours and fall away about as fast.",
"quote_sha256":"0274cd7aa86be82e6a1cf83647972441bbc85ef8a04e39d360deba7509b3f07d"
},
{
"id":"w_18bl3rtc",
"url":"https://clinicaltrials.gov/api/v2/studies?query.intr=thymosin+alpha-1&countTotal=true&pageSize=100",
"title":"ClinicalTrials.gov registry query for thymosin alpha-1 interventions, 4 August 2026",
"quote":"totalCount: 63",
"_id":"w_18bl3rtc",
"_ts":"2026-08-04T08:36:47.445Z",
"type":"source",
"accessed_at":"2026-08-04T08:36:47.445Z",
"claim_ids": [],
"prev":"ae60b526b0ace69c1727e4830d9a0ac34aa1640a82e1c449744da8663795f8da",
"hash":"b779f4fb810bd4824b8912caad04a3b15f504b974e5f6f7b1f295396de04d054",
"plain":"A count pulled straight from the public trial registry: 63 registered studies naming this peptide. It sizes the field, showing this is not an untested compound, while saying nothing about which of those trials reported or what they found.",
"quote_sha256":"144801fa532caa14d82ffab909400312101ce6a2dea02fbfa371f91ec9b8dce2"
},
{
"id":"w_c958vpgi",
"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12883329/",
"title":"A Case Report of a Multisystemic Immune-Related Adverse Event Induced by Thymosin Alpha-1",
"quote":"A 29-year-old man with nasopharyngeal carcinoma developed high fever 39-40.5 C, facial rash and oedema, hypoxaemia, AST 742 U/L and prolonged prothrombin time 23.2 s within 48 hours of a single 1.6 mg subcutaneous dose of thymosin alpha-1 given 11 days after sintilimab; treated with intravenous methylprednisolone 160 mg daily and discharged on day 33.",
"_id":"w_c958vpgi",
"_ts":"2026-08-04T08:36:49.180Z",
"type":"source",
"accessed_at":"2026-08-04T08:36:49.180Z",
"claim_ids": [],
"prev":"b779f4fb810bd4824b8912caad04a3b15f504b974e5f6f7b1f295396de04d054",
"hash":"deb365464c96fee874d992420897cdaa36dbb674fb9cb908298ad6061e186ff7",
"plain":"One patient. A 29-year-old ran a fever near 40C with rash, low oxygen and liver enzymes in the hundreds within two days of a single 1.6 mg dose, then needed high-dose steroids and 33 days in hospital. He had a checkpoint immunotherapy drug 11 days earlier, so cause cannot be cleanly assigned.",
"quote_sha256":"05f24150ea1017118f2c0456e3d3b85bc8a5fb181f2cd0778551cc8f20985a9d"
}
],
"claims": [
{
"id":"c1",
"text":"Thymosin alpha-1 — Ta1 for short, written Tα1 in the papers and TA-1 in most forum posts — attaches to sensors called Toll-like receptors that sit on dendritic cells, the scout cells whose job is to show the rest of the immune system what an infection looks like.",
"section":"The switch thymosin alpha-1 is said to flip in the immune system",
"tier":"human",
"source_ids": [
"s1"
],
"source_status":"sourced",
"why_material":"Core mechanism from primary reviews",
"evidence_basis":"derived_inference",
"weight":0.8,
"status":"active",
"stance_scores": {
"neutral":0,
"pro":0,
"adversary":0
},
"extra": {},
"who_claims":"system/unknown",
"posted_by": {
"actor":"system/unknown",
"channel":"protocol/repair",
"ts":"2026-06-29T12:47:23.190Z",
"model":"grok/grok-4.3",
"rationale":"backfilled by ledger repair"
},
"slot":"mechanism",
"challenged_by": [
"c63"
],
"source_role":"mechanism_support"
},
{
"id":"c300",
"text":"Once those scout cells are switched on, they finish the training of T cells, the white blood cells that kill infected cells and give orders to the rest of the immune response.",
"section":"The switch thymosin alpha-1 is said to flip in the immune system",
"tier":"human",
"source_ids": [
"s1"
],
"source_status":"sourced",
"why_material":"Separates the second step of the proposed mechanism so each step can be checked on its own.",
"evidence_basis":"derived_inference",
"weight":0.8,
"status":"active",
"stance_scores": {
"neutral":0,
"pro":0,
"adversary":0
},
"extra": {},
"who_claims":"system/unknown",
"posted_by": {
"actor":"system/unknown",
"channel":"protocol/repair",
"ts":"2026-06-29T12:47:23.190Z",
"model":"grok/grok-4.3",
"rationale":"backfilled by ledger repair"
},
"slot":"mechanism",
"challenged_by": [
"c63"
],
"source_role":"mechanism_support"
},
{
"id":"c301",
"text":"Both main kinds of T cell are reported to respond: the CD4+ helpers that direct the response, and the CD8+ killers that destroy infected cells.",
"section":"The switch thymosin alpha-1 is said to flip in the immune system",
"tier":"human",
"source_ids": [
"s1"
],
"source_status":"sourced",
"why_material":"Separates the claim about which T cell populations respond from the claim about the receptor.",
"evidence_basis":"derived_inference",
"weight":0.8,
"status":"active",
"stance_scores": {
"neutral":0,
"pro":0,
"adversary":0
},
"extra": {},
"who_claims":"system/unknown",
"posted_by": {
"actor":"system/unknown",
"channel":"protocol/repair",
"ts":"2026-06-29T12:47:23.190Z",
"model":"grok/grok-4.3",
"rationale":"backfilled by ledger repair"
},
"slot":"mechanism",
"challenged_by": [
"c63"
],
"source_role":"mechanism_support"
},
{
"id":"c2",
"text":"In animals whose thymus gland had been surgically removed, and in cells grown in a dish, thymosin alpha-1 brought immune responses back and made T cells respond more strongly.",
"section":"What thymosin alpha-1 did in animals with no thymus gland",
"tier":"human",
"source_ids": [
"s1",
"s2"
],
"source_status":"sourced",
"why_material":"Separates animal data from human",
"evidence_basis":"derived_inference",
"weight":0.8,
"status":"active",
"stance_scores": {
"neutral":0,
"pro":0,
"adversary":0
},
"extra": {},
"who_claims":"system/unknown",
"posted_by": {
"actor":"system/unknown",
"channel":"protocol/repair",
"ts":"2026-06-29T12:47:23.190Z",
"model":"grok/grok-4.3",
"rationale":"backfilled by ledger repair"
},
"slot":"what_is_known",
"source_role":"mechanism_support"
},
{
"id":"c3",
"text":"Trials in people, and the reviews that gather them up, record thymosin alpha-1 being given in conditions where the immune system is worn down, and report cell-driven immunity coming back.",
"section":"What the human record on thymosin alpha-1 adds up to so far",
"tier":"human",
"source_ids": [
"s1",
"s3"
],
"source_status":"sourced",
"why_material":"Human trial summary without claims",
"evidence_basis":"derived_inference",
"weight":0.8,
"status":"active",
"stance_scores": {
"neutral":0,
"pro":0,
"adversary":0
},
"extra": {},
"who_claims":"system/unknown",
"posted_by": {
"actor":"system/unknown",
"channel":"protocol/repair",
"ts":"2026-06-29T12:47:23.190Z",
"model":"grok/grok-4.3",
"rationale":"backfilled by ledger repair"
},
"slot":"what_is_known",
"source_role":"mechanism_support"
},
{
"id":"c4",
"text":"Those reviewers describe thymosin alpha-1 as pushing the immune system up rather than damping it down.",
"section":"What the human record on thymosin alpha-1 adds up to so far",
"tier":"human",
"source_ids": [
"s1"
],
"source_status":"sourced",
"why_material":"Repair-vs-suppression framing",
"evidence_basis":"derived_inference",
"weight":0.8,
"status":"active",
"stance_scores": {
"neutral":0,
"pro":0,
"adversary":0
},
"extra": {},
"who_claims":"system/unknown",
"posted_by": {
"actor":"system/unknown",
"channel":"protocol/repair",
"ts":"2026-06-29T12:47:23.190Z",
"model":"grok/grok-4.3",
"rationale":"backfilled by ledger repair"
},
"slot":"what_is_known",
"source_role":"mechanism_support"
},
{
"id":"c5",
"text":"6 of the sources catalogued on this page are companies and clinics selling thymosin alpha-1 or promoting it. That is sales copy. None of it counts as evidence here, and none of it was counted.",
"section":"Vendors selling thymosin alpha-1 are advertising, not reporting",
"tier":"speculative",
"weight":0.12,
"status":"active",
"source_ids": [
"s10",
"s28",
"s34",
"s46",
"s57",
"s82"
],
"source_status":"sourced",
"who_claims":"commercial vendors",
"posted_by": {
"actor":"system/protocol",
"channel":"protocol/fill-slots",
"ts":"2026-06-29T12:47:23.828Z",
"model":"system/audit-repair",
"rationale":""
},
"why_material":"Collapsed 10 duplicate marketing claims",
"slot":"who_claims_what",
"register":null
},
{
"id":"c9",
"text":"Nothing on this page is medical advice. It is a catalogue that keeps every piece of evidence labelled with how strong it is. Take any decision about thymosin alpha-1 to a doctor who knows your history.",
"section":"Read this before acting on anything here about thymosin alpha-1",
"tier":"human",
"weight":0.8,
"status":"active",
"source_ids": [],
"source_status":"unsourced",
"who_claims":"system/protocol",
"posted_by": {
"actor":"system/protocol",
"channel":"protocol/fill-slots",
"ts":"2026-06-29T12:47:24.067Z",
"model":"system/audit-repair",
"rationale":""
},
"why_material":"Required constitution slot: disclaimer",
"slot":"disclaimer",
"register":null
},
{
"id":"c10",
"text":"The largest test ever run on thymosin alpha-1 — a 2025 phase 3 randomised trial in 1106 people with sepsis — found no difference in how many died between the people given the peptide and the people given a dummy injection.",
"tier":"human",
"weight":0.8,
"section":"Thymosin alpha-1 in sepsis: the biggest trial found no survival benefit",
"slot":"what_is_known",
"source_ids": [
"s4"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s4 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"adjacent_context"
},
{
"id":"c11",
"text":"A 2024 review holds thymosin alpha-1 up as a case of a drug found by watching what it does to whole cells and whole animals, rather than by aiming at a known target first.",
"tier":"human",
"weight":0.8,
"section":"Thymosin alpha-1 and the immune system that fades with age",
"slot":"what_is_known",
"source_ids": [
"s5"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s5 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c12",
"text":"A trial registered for 2025 and onwards is testing whether thymalfasin — the pharmaceutical name for thymosin alpha-1 — makes a COVID booster work better in older adults. It is still running, so there is no result to read.",
"tier":"human",
"weight":0.8,
"section":"Thymosin alpha-1 against viruses and as a vaccine booster in older people",
"slot":"what_is_known",
"source_ids": [
"s6"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s6 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"adjacent_context"
},
{
"id":"c13",
"text":"A 2025 systematic review pooled the trials of thymosin alpha-1 in severe acute pancreatitis, the sudden and dangerous inflammation of the pancreas.",
"tier":"human",
"weight":0.8,
"section":"Thymosin alpha-1 in severe pancreatitis: more T cells, fewer infections",
"slot":"what_is_known",
"source_ids": [
"s7"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s7 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c14",
"text":"One person who had been ill with long COVID for years posted that they improved a great deal after starting thymosin alpha-1.",
"tier":"anecdotal",
"weight":0.3,
"section":"Long COVID forums on thymosin alpha-1: from dramatic relief to a hard crash",
"slot":"who_claims_what",
"source_ids": [
"s8"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s8 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c15",
"text":"A 2025 review gathered up the work on thymosin alpha-1 and the immune decline that comes with age, including its use to make vaccines take better in older people.",
"tier":"human",
"weight":0.8,
"section":"Thymosin alpha-1 and the immune system that fades with age",
"slot":"what_is_known",
"source_ids": [
"s9"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s9 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c17",
"text":"A 2026 consumer health write-up on thymosin alpha-1 walks through its uses and its safety record and folds in the 2025 sepsis trial result. It is a summary of other people's work, with no new data in it.",
"tier":"human",
"weight":0.8,
"section":"Thymosin alpha-1 in sepsis: the biggest trial found no survival benefit",
"slot":"what_is_known",
"source_ids": [
"s11"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s11 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c18",
"text":"A 2026 short video asks whether thymosin alpha-1 and peptides like it do anything at all for autoimmune conditions. It is talk, not data.",
"tier":"anecdotal",
"weight":0.3,
"section":"Thyroid and autoimmune reports on thymosin alpha-1 point both ways",
"slot":"who_claims_what",
"source_ids": [
"s12"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s12 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c19",
"text":"One person reported swollen lymph nodes 2 weeks into thymosin alpha-1, and posted it as a warning to others.",
"tier":"anecdotal",
"weight":0.3,
"section":"The flu-like reaction people report in their first weeks on thymosin alpha-1",
"slot":"who_claims_what",
"source_ids": [
"s13"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s13 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c20",
"text":"Another read their own flu-like symptoms on thymosin alpha-1 as the immune system waking up. They said the symptoms came in waves, and that each wave left them better off than before.",
"tier":"anecdotal",
"weight":0.3,
"section":"The flu-like reaction people report in their first weeks on thymosin alpha-1",
"slot":"who_claims_what",
"source_ids": [
"s14"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s14 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c21",
"text":"One person reported their eczema calming down while they were on thymosin alpha-1.",
"tier":"anecdotal",
"weight":0.3,
"section":"Mast cell, allergy and skin reports from thymosin alpha-1 users",
"slot":"who_claims_what",
"source_ids": [
"s15"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s15 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c22",
"text":"Another person reported a clearer head and more energy 2 weeks into thymosin alpha-1.",
"tier":"anecdotal",
"weight":0.3,
"section":"Long COVID forums on thymosin alpha-1: from dramatic relief to a hard crash",
"slot":"who_claims_what",
"source_ids": [
"s16"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s16 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c23",
"text":"One person posted that thymosin alpha-1 clears their mast cell activation syndrome — the condition where immune cells dump histamine at the wrong moments — for as long as they keep taking it.",
"tier":"anecdotal",
"weight":0.3,
"section":"Mast cell, allergy and skin reports from thymosin alpha-1 users",
"slot":"who_claims_what",
"source_ids": [
"s17"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s17 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c311",
"text":"That same person's mast cell symptoms came straight back when they stopped taking thymosin alpha-1.",
"tier":"anecdotal",
"weight":0.3,
"section":"Mast cell, allergy and skin reports from thymosin alpha-1 users",
"slot":"who_claims_what",
"source_ids": [
"s17"
],
"source_status":"sourced",
"why_material":"Symptoms returning on stopping is a separate observation from symptoms clearing on starting.",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c312",
"text":"In the same thread, a different person had a flare on thymosin alpha-1 rather than relief.",
"tier":"anecdotal",
"weight":0.3,
"section":"Mast cell, allergy and skin reports from thymosin alpha-1 users",
"slot":"who_claims_what",
"source_ids": [
"s17"
],
"source_status":"sourced",
"why_material":"A contradicting report from the same thread belongs as its own claim, not buried in the positive one.",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c24",
"text":"One person wrote that a cold cleared up fast after they injected thymosin alpha-1.",
"tier":"anecdotal",
"weight":0.3,
"section":"Thymosin alpha-1 taken at the first sign of a cold or a sinus infection",
"slot":"who_claims_what",
"source_ids": [
"s18"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s18 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c25",
"text":"One person felt sick for a while on thymosin alpha-1 and then stronger, and put it down to the immune system going after infections that had been sitting quietly in the background.",
"tier":"anecdotal",
"weight":0.3,
"section":"The flu-like reaction people report in their first weeks on thymosin alpha-1",
"slot":"who_claims_what",
"source_ids": [
"s19"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s19 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c26",
"text":"A registered trial gave thymosin alpha-1 to people recovering from COVID-19 whose lymphocyte count — the number of immune cells circulating in the blood — had fallen very low.",
"tier":"human",
"weight":0.8,
"section":"Thymosin alpha-1 against viruses and as a vaccine booster in older people",
"slot":"what_is_known",
"source_ids": [
"s20"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s20 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"adjacent_context"
},
{
"id":"c27",
"text":"That 2025 pooling of the severe acute pancreatitis trials reported less inflammation and fewer infections in the people given thymosin alpha-1, and put it down to the immune system being steadied.",
"tier":"human",
"weight":0.8,
"section":"Thymosin alpha-1 in severe pancreatitis: more T cells, fewer infections",
"slot":"what_is_known",
"source_ids": [
"s21"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s21 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c28",
"text":"A 2025 study put thymosin alpha-1 onto tumour cell lines and onto separate populations of immune cells in a dish, and recorded how each one responded.",
"tier":"mechanistic",
"weight":0.3,
"section":"Thymosin alpha-1 in cancer research: cells in a dish and early combinations",
"slot":"what_is_known",
"source_ids": [
"s22"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s22 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c29",
"text":"A small 2025 study, with everyone involved knowing who was getting what, gave thymosin alpha-1 to people with common variable immune deficiency — a lasting shortage of antibodies — and reported their low mood lifting. It was a first look, not a test.",
"tier":"human",
"weight":0.8,
"section":"Thymosin alpha-1 tried for problems that are not infections",
"slot":"what_is_known",
"source_ids": [
"s23"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s23 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c30",
"text":"A forum thread puts thymosin alpha-1 forward for alopecia, the hair loss that happens when the immune system attacks the follicles, on the reasoning that the peptide steadies the immune system. It is a proposal with no outcomes attached to it.",
"tier":"anecdotal",
"weight":0.3,
"section":"Hair regrowth reports from people taking thymosin alpha-1",
"slot":"who_claims_what",
"source_ids": [
"s24"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s24 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c31",
"text":"A long forum guide walks through how thymosin alpha-1 is supposed to work and how people use it. It restates published material and adds nothing new.",
"tier":"anecdotal",
"weight":0.3,
"section":"Explainer posts and videos about thymosin alpha-1 that carry no data of their own",
"slot":"who_claims_what",
"source_ids": [
"s25"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s25 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c32",
"text":"A post notes that thymosin alpha-1 is an approved immune drug in a number of countries. That is a regulatory fact, not a result.",
"tier":"anecdotal",
"weight":0.3,
"section":"Explainer posts and videos about thymosin alpha-1 that carry no data of their own",
"slot":"who_claims_what",
"source_ids": [
"s26"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s26 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c33",
"text":"A 2025 pooled analysis of 11 randomised trials found fewer deaths at 28 days among sepsis patients given thymosin alpha-1 than among those who were not.",
"tier":"human",
"weight":0.8,
"section":"Thymosin alpha-1 in sepsis: the biggest trial found no survival benefit",
"slot":"what_is_known",
"source_ids": [
"s27"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s27 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c302",
"text":"That signal vanished when the same 2025 authors looked only at the better-run trials, and again when they looked only at the trials spread across several hospitals. In those, deaths at 28 days were the same either way, and the trials disagreed with each other enough that the authors would not call the overall result settled.",
"tier":"human",
"weight":0.8,
"section":"Thymosin alpha-1 in sepsis: the biggest trial found no survival benefit",
"slot":"what_is_known",
"source_ids": [
"s27"
],
"source_status":"sourced",
"why_material":"The subgroup result is the part that undercuts the headline number, and it needs to be checkable on its own.",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c35",
"text":"In a 2026 thread on ankylosing spondylitis — an inflammatory arthritis that fuses the spine — one person said they were trying thymosin alpha-1. They never came back with a result.",
"tier":"anecdotal",
"weight":0.3,
"section":"Thyroid and autoimmune reports on thymosin alpha-1 point both ways",
"slot":"who_claims_what",
"source_ids": [
"s29"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s29 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c36",
"text":"Another guide covers thymosin alpha-1 for immune support and dosing, and points at the hepatitis B and hepatitis C studies. It points at them without saying what they found.",
"tier":"anecdotal",
"weight":0.3,
"section":"Explainer posts and videos about thymosin alpha-1 that carry no data of their own",
"slot":"who_claims_what",
"source_ids": [
"s30"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s30 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c37",
"text":"A 2026 study combined interleukin-15, an immune signalling protein, with thymosin alpha-1 in liver cancer, and reported fewer worn-out CD8+ killer T cells and a stronger attack on the tumour.",
"tier":"mechanistic",
"weight":0.3,
"section":"Thymosin alpha-1 in cancer research: cells in a dish and early combinations",
"slot":"what_is_known",
"source_ids": [
"s31"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s31 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c38",
"text":"A 2026 review argues that thymosin alpha-1 helps a shrunken thymus gland get back to making T cells, and points to COVID-19 as the setting where that was watched most closely.",
"tier":"human",
"weight":0.8,
"section":"Thymosin alpha-1 against viruses and as a vaccine booster in older people",
"slot":"what_is_known",
"source_ids": [
"s32"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s32 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c39",
"text":"A 2025 pooling of 5 randomised trials covering 706 people with severe acute pancreatitis found higher counts of CD4+ helper T cells — the white cells that direct an immune response — in the people given thymosin alpha-1.",
"tier":"human",
"weight":0.8,
"section":"Thymosin alpha-1 in severe pancreatitis: more T cells, fewer infections",
"slot":"what_is_known",
"source_ids": [
"s33"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s33 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c303",
"text":"In that same 706-patient pool, the balance between helper and killer T cells shifted back towards where it sits in a healthy person.",
"tier":"human",
"weight":0.8,
"section":"Thymosin alpha-1 in severe pancreatitis: more T cells, fewer infections",
"slot":"what_is_known",
"source_ids": [
"s33"
],
"source_status":"sourced",
"why_material":"A separate measured outcome from the same pooling, checkable on its own.",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c304",
"text":"At the lower doses in that pool, C-reactive protein — the standard blood marker of inflammation — came down, and fewer people went on to develop infections outside the pancreas.",
"tier":"human",
"weight":0.8,
"section":"Thymosin alpha-1 in severe pancreatitis: more T cells, fewer infections",
"slot":"what_is_known",
"source_ids": [
"s33"
],
"source_status":"sourced",
"why_material":"The inflammation marker and the infection outcome are separate findings from the T-cell counts.",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c41",
"text":"A 2025 post asked whether anyone had tried thymosin alpha-1 for long COVID. It is a request for experiences, with none attached.",
"tier":"anecdotal",
"weight":0.3,
"section":"Threads about thymosin alpha-1 that ask a question and never come back with an answer",
"slot":"who_claims_what",
"source_ids": [
"s35"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s35 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c42",
"text":"A 2025 review of thymosin alpha-1 in ageing covers the same ground and adds two more effects: it calms inflammation, and it mops up the reactive molecules that damage cells. The review pulled existing work together rather than adding data of its own.",
"tier":"human",
"weight":0.8,
"section":"Thymosin alpha-1 and the immune system that fades with age",
"slot":"what_is_known",
"source_ids": [
"s36"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s36 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c43",
"text":"One person had a severe flare on thymosin alpha-1, and thought they had been living with mould exposure at the time.",
"tier":"anecdotal",
"weight":0.3,
"section":"Chronic fatigue and mould-illness reports on thymosin alpha-1",
"slot":"who_claims_what",
"source_ids": [
"s37"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s37 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c308",
"text":"Others in that same thread described a rough first stretch on thymosin alpha-1 and then better energy and a steadier immune system, once they raised the dose slowly instead of starting high.",
"tier":"anecdotal",
"weight":0.3,
"section":"Chronic fatigue and mould-illness reports on thymosin alpha-1",
"slot":"who_claims_what",
"source_ids": [
"s37"
],
"source_status":"sourced",
"why_material":"The opposite experience in the same thread is a separate report and should not be folded into the bad one.",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c44",
"text":"One person with Hashimoto's — the autoimmune attack on the thyroid gland — reported their thyroid antibodies going up after 8 weeks on thymosin alpha-1. That is the wrong direction.",
"tier":"anecdotal",
"weight":0.3,
"section":"Thyroid and autoimmune reports on thymosin alpha-1 point both ways",
"slot":"who_claims_what",
"source_ids": [
"s38"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s38 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c45",
"text":"One person described their first weeks on thymosin alpha-1 as flu-like exhaustion. They called it a herx reaction, the flare people report while an infection is being cleared out.",
"tier":"anecdotal",
"weight":0.3,
"section":"The flu-like reaction people report in their first weeks on thymosin alpha-1",
"slot":"who_claims_what",
"source_ids": [
"s39"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s39 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c309",
"text":"That same person said that by raising the dose slowly they came out the other side with steady improvement in their symptoms and in daily life.",
"tier":"anecdotal",
"weight":0.3,
"section":"The flu-like reaction people report in their first weeks on thymosin alpha-1",
"slot":"who_claims_what",
"source_ids": [
"s39"
],
"source_status":"sourced",
"why_material":"The outcome after the reaction is a separate observation from the reaction itself.",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c46",
"text":"One person reported more dreaming sleep and more deep sleep on thymosin alpha-1.",
"tier":"anecdotal",
"weight":0.3,
"section":"Sleep and mood reports from people taking thymosin alpha-1",
"slot":"who_claims_what",
"source_ids": [
"s40"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s40 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c47",
"text":"After 6 years of long COVID, one person ranked thymosin alpha-1 as the second most useful thing they had tried.",
"tier":"anecdotal",
"weight":0.3,
"section":"Long COVID forums on thymosin alpha-1: from dramatic relief to a hard crash",
"slot":"who_claims_what",
"source_ids": [
"s41"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s41 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c48",
"text":"The same poster wrote that each dose of thymosin alpha-1 clears their long COVID symptoms for roughly 48 hours, after which the symptoms come back.",
"tier":"anecdotal",
"weight":0.3,
"section":"Long COVID forums on thymosin alpha-1: from dramatic relief to a hard crash",
"slot":"who_claims_what",
"source_ids": [
"s42"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s42 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c49",
"text":"A 2025 updated pooling of the sepsis trials landed the other way and concluded that thymosin alpha-1 lowers the number of people who die within 28 days. Two poolings read much the same trials and disagreed, and the single largest trial found nothing at all.",
"tier":"human",
"weight":0.8,
"section":"Thymosin alpha-1 in sepsis: the biggest trial found no survival benefit",
"slot":"what_is_known",
"source_ids": [
"s43"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s43 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c50",
"text":"A 2026 case report describes one person whose immune system turned on several organs at once after they took thymosin alpha-1. A single case cannot tell you how often that happens. It does tell you that it happened.",
"tier":"speculative",
"weight":0.12,
"section":"A documented harm from thymosin alpha-1 in a hospital case report",
"slot":"what_is_known",
"source_ids": [
"s44"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s44 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"adjacent_context"
},
{
"id":"c51",
"text":"A 2025 expert panel published 10 recommendations for using thymosin alpha-1 in infections and in intensive care. Those are the settled opinions of a committee, not trial results.",
"tier":"speculative",
"weight":0.12,
"section":"What the human record on thymosin alpha-1 adds up to so far",
"slot":"what_is_known",
"source_ids": [
"s45"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s45 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"adjacent_context"
},
{
"id":"c53",
"text":"A 2025 thread compares thymalin with thymosin alpha-1 — both come from the thymus gland — and argues about how each one is supposed to work.",
"tier":"anecdotal",
"weight":0.3,
"section":"Explainer posts and videos about thymosin alpha-1 that carry no data of their own",
"slot":"who_claims_what",
"source_ids": [
"s47"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s47 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c54",
"text":"A 2026 post files thymosin alpha-1 into a list of peptides that act on the immune system. That is a filing decision, not a finding.",
"tier":"anecdotal",
"weight":0.3,
"section":"Explainer posts and videos about thymosin alpha-1 that carry no data of their own",
"slot":"who_claims_what",
"source_ids": [
"s48"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s48 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c55",
"text":"The same 2026 interleukin-15 and thymosin alpha-1 work is catalogued here twice, because the paper was listed in two places. It is one study reporting worn-out T cells in liver cancer being pushed back towards working order, not two.",
"tier":"mechanistic",
"weight":0.3,
"section":"Thymosin alpha-1 in cancer research: cells in a dish and early combinations",
"slot":"what_is_known",
"source_ids": [
"s49"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s49 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c56",
"text":"A registered trial is following sepsis survivors who were given thymosin alpha-1, to see how they are doing long after they left hospital. It is listed as ongoing, so there is no result yet.",
"tier":"human",
"weight":0.8,
"section":"Thymosin alpha-1 in sepsis: the biggest trial found no survival benefit",
"slot":"what_is_known",
"source_ids": [
"s50"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s50 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"adjacent_context"
},
{
"id":"c57",
"text":"A 2025 study reported that thymosin alpha-1 raised the number of T cells circulating in the patients who received it.",
"tier":"human",
"weight":0.8,
"section":"What the human record on thymosin alpha-1 adds up to so far",
"slot":"what_is_known",
"source_ids": [
"s51"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s51 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c58",
"text":"A registered trial pairs thymosin alpha-1 with ulinastatin, a drug that blocks the inflammation-driving enzymes released during injury, in acute aortic syndrome — a sudden tear in the wall of the body's main artery.",
"tier":"human",
"weight":0.8,
"section":"Thymosin alpha-1 tried for problems that are not infections",
"slot":"what_is_known",
"source_ids": [
"s52"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s52 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"adjacent_context"
},
{
"id":"c59",
"text":"A 2025 study looked at thymosin alpha-1 given alongside other treatment for liver cancer.",
"tier":"mechanistic",
"weight":0.3,
"section":"Thymosin alpha-1 in cancer research: cells in a dish and early combinations",
"slot":"what_is_known",
"source_ids": [
"s53"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s53 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c60",
"text":"A video runs through thymosin alpha-1 in cancer immunotherapy using case stories. Case stories picked by the person telling them are not evidence.",
"tier":"anecdotal",
"weight":0.3,
"section":"Explainer posts and videos about thymosin alpha-1 that carry no data of their own",
"slot":"who_claims_what",
"source_ids": [
"s54"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s54 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"protocol/repair",
"ts":"2026-06-29T12:50:53.844Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c61",
"text":"Nobody has followed people taking thymosin alpha-1 long enough to say what happens after years of it. The safety record is short-term only.",
"tier":"human",
"weight":0.8,
"section":"What nobody has measured about taking thymosin alpha-1 for years",
"slot":"what_is_unknown",
"source_ids": [
"s1"
],
"source_status":"sourced",
"why_material":"This claim addresses a specific gap in knowledge regarding the long-term safety of Thymosin Alpha-1, which is not covered by the existing claims.",
"status":"active",
"who_claims":"kimi-collaborator",
"posted_by": {
"actor":"kimi/moonshot-v1-8k",
"channel":"protocol/collaborate",
"ts":"2026-06-29T14:09:50.621Z",
"model":"kimi/moonshot-v1-8k",
"rationale":""
},
"source_role":"mechanism_support"
},
{
"id":"c62",
"text":"Every sleep report on thymosin alpha-1 catalogued here is of that kind: an individual post in an online forum, with nobody measuring anything.",
"tier":"anecdotal",
"weight":0.3,
"section":"Sleep and mood reports from people taking thymosin alpha-1",
"slot":"who_claims_what",
"source_ids": [
"s8"
],
"source_status":"sourced",
"why_material":"This claim identifies the source of anecdotal claims regarding Thymosin Alpha-1's effects on sleep quality, which was missing in the original claims.",
"status":"active",
"who_claims":"kimi-collaborator",
"posted_by": {
"actor":"kimi/moonshot-v1-8k",
"channel":"protocol/collaborate",
"ts":"2026-06-29T14:09:50.621Z",
"model":"kimi/moonshot-v1-8k",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c63",
"text":"The account of thymosin alpha-1 working through Toll-like receptors on the scout cells is the standard one, but which receptor it binds, and what happens inside the cell afterwards, has never been worked all the way out. The mechanism is a sketch, not a map.",
"tier":"mechanistic",
"weight":0.4,
"section":"The step in thymosin alpha-1's mechanism nobody has nailed down",
"slot":null,
"source_ids": [],
"source_status":"unsourced",
"why_material":"This counter-evidence challenges the specificity of claim c1 by highlighting that while the general mechanism is accepted, the detailed molecular interactions are not fully understood, which is supported by the preclinical nature of the evidence.",
"status":"active",
"who_claims":"kimi/moonshot-v1-8k (adversary)",
"posted_by": {
"actor":"kimi/moonshot-v1-8k (adversary)",
"channel":"protocol/collaborate",
"ts":"2026-06-29T14:09:50.621Z",
"model":"kimi/moonshot-v1-8k"
},
"challenges": [
"c1"
]
},
{
"id":"c64",
"text":"One forum user reported cycling thymosin alpha-1 for seasonal allergies and reacting less to pollen while they were on it.",
"tier":"anecdotal",
"weight":0.3,
"section":"Mast cell, allergy and skin reports from thymosin alpha-1 users",
"slot":"who_claims_what",
"source_ids": [
"s55"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s55 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:40:51.605Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c65",
"text":"Another person said a family member with Hashimoto's did well on thymosin alpha-1.",
"tier":"anecdotal",
"weight":0.3,
"section":"Thyroid and autoimmune reports on thymosin alpha-1 point both ways",
"slot":"who_claims_what",
"source_ids": [
"s56"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s56 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:40:51.605Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c67",
"text":"One person said very small doses of thymosin alpha-1 did more for their mast cell symptoms than BPC-157 had done.",
"tier":"anecdotal",
"weight":0.3,
"section":"Mast cell, allergy and skin reports from thymosin alpha-1 users",
"slot":"who_claims_what",
"source_ids": [
"s58"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s58 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:40:51.605Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c68",
"text":"One person reported their TPO antibodies — the blood marker of the immune attack on the thyroid in Hashimoto's — dropping after a short course of thymosin alpha-1, and said they were planning a longer one.",
"tier":"anecdotal",
"weight":0.3,
"section":"Thyroid and autoimmune reports on thymosin alpha-1 point both ways",
"slot":"who_claims_what",
"source_ids": [
"s59"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s59 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:40:51.605Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c69",
"text":"One person starting thymosin alpha-1 as part of a mould illness and chronic fatigue plan wrote out what they were expecting from it — a steadier immune system and less inflammation — before they had taken any.",
"tier":"anecdotal",
"weight":0.3,
"section":"Chronic fatigue and mould-illness reports on thymosin alpha-1",
"slot":"who_claims_what",
"source_ids": [
"s60"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s60 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:40:51.605Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c70",
"text":"One person taking 1mg of thymosin alpha-1 every 3 days reported energy, mood, allergies, inflammation and long-standing heel pain all improving quickly.",
"tier":"anecdotal",
"weight":0.3,
"section":"Mast cell, allergy and skin reports from thymosin alpha-1 users",
"slot":"who_claims_what",
"source_ids": [
"s61"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s61 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:40:51.605Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c315",
"text":"Months in, that person said the gains had held and they were taking less allergy medication than before.",
"tier":"anecdotal",
"weight":0.3,
"section":"Mast cell, allergy and skin reports from thymosin alpha-1 users",
"slot":"who_claims_what",
"source_ids": [
"s61"
],
"source_status":"sourced",
"why_material":"Whether a reported benefit lasts is a separate question from whether it started.",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:40:51.605Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c316",
"text":"They also reported itching in the first days on thymosin alpha-1, which they read as the body clearing something out.",
"tier":"anecdotal",
"weight":0.3,
"section":"Mast cell, allergy and skin reports from thymosin alpha-1 users",
"slot":"who_claims_what",
"source_ids": [
"s61"
],
"source_status":"sourced",
"why_material":"A reported side effect from the same person, kept separate from the benefits.",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:40:51.605Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c71",
"text":"One person reported fewer symptoms around animals on thymosin alpha-1, after a flu-like reaction at the start that passed off. They kept taking it.",
"tier":"anecdotal",
"weight":0.3,
"section":"The flu-like reaction people report in their first weeks on thymosin alpha-1",
"slot":"who_claims_what",
"source_ids": [
"s62"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s62 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:40:51.605Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c72",
"text":"One person with long COVID had the opposite experience: a drawn-out flu-like immune reaction on thymosin alpha-1, and a crash in energy and in what they could do in a day.",
"tier":"anecdotal",
"weight":0.3,
"section":"Long COVID forums on thymosin alpha-1: from dramatic relief to a hard crash",
"slot":"who_claims_what",
"source_ids": [
"s63"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s63 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:40:51.605Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c73",
"text":"One person said thymosin alpha-1 made them feel acutely ill, and counted it among several peptides that shifted nothing about their baseline for good.",
"tier":"anecdotal",
"weight":0.3,
"section":"Chronic fatigue and mould-illness reports on thymosin alpha-1",
"slot":"who_claims_what",
"source_ids": [
"s64"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s64 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:40:51.605Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c74",
"text":"One person reported hair growing back on thymosin alpha-1, after losing it during long COVID.",
"tier":"anecdotal",
"weight":0.3,
"section":"Hair regrowth reports from people taking thymosin alpha-1",
"slot":"who_claims_what",
"source_ids": [
"s65"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s65 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:40:51.605Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c75",
"text":"One person with ME/CFS and long COVID reported real gains on thymosin alpha-1 taken with thymulin: energy back, the brain fog lifting, more of the day usable.",
"tier":"anecdotal",
"weight":0.3,
"section":"Chronic fatigue and mould-illness reports on thymosin alpha-1",
"slot":"who_claims_what",
"source_ids": [
"s66"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s66 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:40:51.605Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c306",
"text":"That same person said the dose of thymosin alpha-1 had to keep going up over time, and had to be taken every day, for the benefit to hold.",
"tier":"anecdotal",
"weight":0.3,
"section":"Chronic fatigue and mould-illness reports on thymosin alpha-1",
"slot":"who_claims_what",
"source_ids": [
"s66"
],
"source_status":"sourced",
"why_material":"Tolerance and daily dosing is a distinct report from the benefit itself.",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:40:51.605Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c307",
"text":"They also warned that pushing it brought on post-exertional malaise — the delayed crash that follows overdoing it in ME/CFS.",
"tier":"anecdotal",
"weight":0.3,
"section":"Chronic fatigue and mould-illness reports on thymosin alpha-1",
"slot":"who_claims_what",
"source_ids": [
"s66"
],
"source_status":"sourced",
"why_material":"A reported harm from the same person, which must not be buried inside a positive report.",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:40:51.605Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c76",
"text":"One person on a cycle of thymosin alpha-1 reported exhaustion without having done anything, muscles twitching, and chills all the way through it.",
"tier":"anecdotal",
"weight":0.3,
"section":"The flu-like reaction people report in their first weeks on thymosin alpha-1",
"slot":"who_claims_what",
"source_ids": [
"s67"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s67 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:40:51.605Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c310",
"text":"That same person said their baseline was better after they stopped thymosin alpha-1, and that they were starting again at a lower dose.",
"tier":"anecdotal",
"weight":0.3,
"section":"The flu-like reaction people report in their first weeks on thymosin alpha-1",
"slot":"who_claims_what",
"source_ids": [
"s67"
],
"source_status":"sourced",
"why_material":"The outcome after stopping is a separate observation from the side effects during the cycle.",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:40:51.605Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c77",
"text":"One person recovering from long COVID and a bad reaction to a vaccine posted that thymosin alpha-1 stopped their decline and cut down their muscle spasms.",
"tier":"anecdotal",
"weight":0.3,
"section":"Long COVID forums on thymosin alpha-1: from dramatic relief to a hard crash",
"slot":"who_claims_what",
"source_ids": [
"s68"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s68 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:40:51.605Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c305",
"text":"The same person reported steadier daily function and a calmer autonomic nervous system — the part that runs heart rate, blood pressure and digestion without you thinking about it.",
"tier":"anecdotal",
"weight":0.3,
"section":"Long COVID forums on thymosin alpha-1: from dramatic relief to a hard crash",
"slot":"who_claims_what",
"source_ids": [
"s68"
],
"source_status":"sourced",
"why_material":"A second reported outcome from the same person, checkable separately from the first.",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:40:51.605Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c78",
"text":"One person endorsed thymosin alpha-1 on the strength of their own experience and their reading, and said the side effects were slight.",
"tier":"anecdotal",
"weight":0.3,
"section":"Explainer posts and videos about thymosin alpha-1 that carry no data of their own",
"slot":"who_claims_what",
"source_ids": [
"s69"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s69 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T15:40:51.605Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c79",
"text":"A thread about giving thymosin alpha-1 to someone with pancreatic cancer is interest in steadying the immune system and nothing more. Nobody in it says what happened.",
"tier":"anecdotal",
"weight":0.3,
"section":"A pancreatic cancer thread about thymosin alpha-1 with no outcome in it",
"slot":"who_claims_what",
"source_ids": [
"s70"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s70 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:43:46.569Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c80",
"text":"A Hashimoto's thread on thymosin alpha-1 and muscle recovery has one person saying they use it to steady the immune system. Nobody in it reports a result.",
"tier":"anecdotal",
"weight":0.3,
"section":"Thyroid and autoimmune reports on thymosin alpha-1 point both ways",
"slot":"who_claims_what",
"source_ids": [
"s71"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s71 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:43:46.569Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c81",
"text":"Someone with Graves' disease — the autoimmune condition that drives the thyroid too hard — asked whether anyone had tried thymosin alpha-1. It is a question with no experiences attached to it.",
"tier":"anecdotal",
"weight":0.3,
"section":"Threads about thymosin alpha-1 that ask a question and never come back with an answer",
"slot":"who_claims_what",
"source_ids": [
"s72"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s72 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:43:46.569Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c82",
"text":"A thread on thymosin alpha-1 dosing for long-running Epstein-Barr virus also wanders into endometriosis. It is people talking, and the posters label it that way themselves.",
"tier":"anecdotal",
"weight":0.3,
"section":"Threads about thymosin alpha-1 that ask a question and never come back with an answer",
"slot":"who_claims_what",
"source_ids": [
"s73"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s73 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:43:46.569Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c83",
"text":"Anecdotal X post testing prior TA-1 doses for cold prevention; no outcome reported yet.",
"tier":"anecdotal",
"weight":0.3,
"section":"who_claims_what",
"slot":"who_claims_what",
"source_ids": [
"s74"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s74 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:43:46.569Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c84",
"text":"Positive anecdotal report on TA-1 for sinusitis relief (as needed dosing); good outcome claimed.",
"tier":"anecdotal",
"weight":0.3,
"section":"who_claims_what",
"slot":"who_claims_what",
"source_ids": [
"s75"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s75 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:43:46.569Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c85",
"text":"Anecdotal personal RNA sequencing results involving TA-1 use; mixed with other meds, positive gene expression changes noted.",
"tier":"anecdotal",
"weight":0.3,
"section":"who_claims_what",
"slot":"who_claims_what",
"source_ids": [
"s76"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s76 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:43:46.569Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c86",
"text":"Comment discusses potential risks and benefits of TA1 for small fiber neuropathy (SFN), noting it may worsen symptoms in some due to T-cell stimulation; recommends labs first. Anecdotal, not advice.",
"tier":"anecdotal",
"weight":0.3,
"section":"who_claims_what",
"slot":"who_claims_what",
"source_ids": [
"s77"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s77 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:43:46.569Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c87",
"text":"User reports starting TA1 (second week on full dose after slow start) with no results yet for SFN symptoms; also on ARA-290. Anecdotal, not advice.",
"tier":"anecdotal",
"weight":0.3,
"section":"who_claims_what",
"slot":"who_claims_what",
"source_ids": [
"s78"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s78 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:43:46.569Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c88",
"text":"User reports side effects like feeling more ill (HRV tanked, breathless, wired) after 1-1.2mg doses of TA1 for long COVID; considering lower doses. Dosing anecdote: 800mcg 2-3x/week planned. Anecdotal, not advice.",
"tier":"anecdotal",
"weight":0.3,
"section":"who_claims_what",
"slot":"who_claims_what",
"source_ids": [
"s79"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s79 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:43:46.569Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c89",
"text":"Dosing discussion and plan for TA1 (starting low at 300mcg, then 800mcg 2-3x/week) alongside other peptides for long COVID immune issues. Anecdotal, not advice.",
"tier":"anecdotal",
"weight":0.3,
"section":"who_claims_what",
"slot":"who_claims_what",
"source_ids": [
"s80"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s80 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:43:46.569Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c90",
"text":"Post discusses potential benefits of TA1 for immune support in chronic conditions; no specific personal outcomes or dosing in snippet but contextual anecdotes implied in community. Anecdotal context, not advice.",
"tier":"anecdotal",
"weight":0.3,
"section":"who_claims_what",
"slot":"who_claims_what",
"source_ids": [
"s81"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s81 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:43:46.569Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c92",
"text":"User with chronic stress/burnout considering TA-1 based on bloodwork; OP responds with expected subtle benefits like better resilience (anecdotal dosing and outcomes only).",
"tier":"anecdotal",
"weight":0.3,
"section":"who_claims_what",
"slot":"who_claims_what",
"source_ids": [
"s83"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s83 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:43:46.569Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c93",
"text":"User reports cloudy reconstitution of TA1 vials from same source (anecdotal, not advice).",
"tier":"anecdotal",
"weight":0.3,
"section":"who_claims_what",
"slot":"who_claims_what",
"source_ids": [
"s84"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s84 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:45:04.172Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c94",
"text":"Anecdotal report of starting LL37 and Thymosin Alpha cycle for healing (anecdotal, not advice).",
"tier":"anecdotal",
"weight":0.3,
"section":"who_claims_what",
"slot":"who_claims_what",
"source_ids": [
"s85"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s85 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:45:04.172Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c95",
"text":"User planning to try TA1 for chronic issue, seeking bloodwork monitoring (anecdotal, not advice).",
"tier":"anecdotal",
"weight":0.3,
"section":"who_claims_what",
"slot":"who_claims_what",
"source_ids": [
"s86"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s86 by ledger repair",
"status":"active",
"who_claims":"grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T17:45:04.172Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c96",
"text":"Thymosin Alpha-1: Immune Modulation is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.",
"section":"what_it_is",
"tier":"system",
"weight":0.35,
"status":"active",
"source_ids": [],
"source_status":"unsourced",
"who_claims":"miscsubjects protocol",
"posted_by": {
"actor":"miscsubjects protocol",
"channel":"protocol/fill-slots",
"ts":"2026-06-29T20:44:06.061Z",
"model":"fill-slots",
"rationale":""
},
"why_material":"Required constitution slot: what_it_is",
"slot":"what_it_is",
"register":null
},
{
"id":"c97",
"text":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.",
"section":"limitations",
"tier":"mechanistic",
"weight":0.3,
"status":"active",
"source_ids": [],
"source_status":"unsourced",
"who_claims":"miscsubjects protocol",
"posted_by": {
"actor":"miscsubjects protocol",
"channel":"protocol/fill-slots",
"ts":"2026-06-29T20:44:07.683Z",
"model":"fill-slots",
"rationale":""
},
"why_material":"Required constitution slot: limitations",
"slot":"limitations",
"register":null
}
],
"type":"article",
"updated":"2026-10-08T11:51:33.732Z",
"version":1,
"hash":"85b7c01ffbf7cb856e0f55e4f63d0483b3ee78751d60b08097bd343653f8b2c3",
"styling": {
"scope":"shared",
"how":"no value on the page is set by hand: each comes from this theme, and each theme value becomes the CSS variable named beside it. PATCH https://miscsubjects.com/api/jarticles/theme changes them.",
"widget_style": {
"what":"every widget may carry style: {…}; these are the only keys it reads",
"rotate":"degrees, a number",
"offset_x":"pixels, a number",
"offset_y":"pixels, a number",
"pulse":"true to pulse"
},
"theme": {
"color": {
"page_bg":"#f5f5f7",
"sheet_bg":"#ffffff",
"ink":"#1d1d1f",
"soft":"#424245",
"muted":"#6e6e73",
"dim":"#86868b",
"line":"#d2d2d7",
"accent":"#0071e3",
"accent_soft":"rgba(0,113,227,0.08)",
"link":"#0066cc",
"selection":"rgba(0,113,227,0.18)",
"widget_bg":"#f5f5f7",
"widget_border":"#d2d2d7",
"card_bg":"#ffffff",
"code_bg":"#f5f5f7",
"json_bg":"#161b19",
"json_ink":"#e6e1d4",
"json_key":"#7fd3c3",
"json_string":"#e9c46a",
"json_number":"#f4a261",
"json_bool":"#c792ea",
"json_null":"#928d7e",
"json_punct":"#6b6759",
"json_bar":"#0e1512",
"kind_badge_bg":"#0e6e60",
"kind_badge_ink":"#ffffff"
},
"color_dark": {
"page_bg":"#000000",
"sheet_bg":"#1d1d1f",
"ink":"#f5f5f7",
"soft":"#d2d2d7",
"muted":"#a1a1a6",
"dim":"#86868b",
"line":"#424245",
"accent":"#2997ff",
"accent_soft":"rgba(41,151,255,0.12)",
"link":"#2997ff",
"selection":"rgba(41,151,255,0.25)",
"widget_bg":"#2c2c2e",
"widget_border":"#424245",
"card_bg":"#1d1d1f",
"code_bg":"#2c2c2e",
"json_bg":"#0a0d0c",
"json_ink":"#e6e1d4",
"json_key":"#7fd3c3",
"json_string":"#e9c46a",
"json_number":"#f4a261",
"json_bool":"#c792ea",
"json_null":"#757062",
"json_punct":"#5d665f",
"json_bar":"#060807",
"kind_badge_bg":"#4fc1ab",
"kind_badge_ink":"#0b0f0d"
},
"font": {
"display":"-apple-system,BlinkMacSystemFont,\"SF Pro Display\",\"SF Pro Text\",\"Helvetica Neue\",Helvetica,Arial,sans-serif",
"body":"-apple-system,BlinkMacSystemFont,\"SF Pro Display\",\"SF Pro Text\",\"Helvetica Neue\",Helvetica,Arial,sans-serif",
"mono":"ui-monospace,SFMono-Regular,\"SF Mono\",Menlo,Consolas,monospace",
"google_fonts":""
},
"size": {
"body":"17px",
"small":"17px",
"eye":"17px",
"lead":"17px",
"h1":"52px",
"h2":"34px",
"h3":"22px",
"byline":"17px",
"h1_measure":"none",
"code":"17px",
"json":"17px",
"widget_title":"17px"
},
"leading": {
"body":"1.7",
"head":"1.18",
"lead":"1.5",
"json":"1.6"
},
"weight": {
"display":"700",
"head":"700",
"body":"400",
"strong":"700",
"eye":"700"
},
"tracking": {
"eye":"0.14em",
"display":"-0.03em",
"body":"-0.006em",
"badge":"0.08em"
},
"layout": {
"sheet_width":"1000px",
"text_width":"880px",
"gutter":"16px",
"sheet_padding":"56px 64px 64px",
"sheet_padding_mobile":"24px 18px 40px",
"sheet_margin":"28px auto 72px",
"block_gap":"1.15em",
"widget_gap":"28px",
"grid_gap":"14px"
},
"border": {
"sheet":"0px solid",
"sheet_radius":"30px",
"widget":"1px solid",
"widget_radius":"24px",
"card_radius":"24px",
"badge_radius":"999px",
"rule":"1px solid",
"code_radius":"18px",
"accent_bar":"3px"
},
"shadow": {
"sheet":"0 1px 1px rgba(0,0,0,.02),0 6px 26px rgba(0,0,0,.05)",
"widget":"none",
"card_hover":"0 10px 28px -16px rgba(28,27,23,0.35)"
},
"motion": {
"hover":"160ms ease"
}
}
},
"page":"https://miscsubjects.com/a/thymosin-alpha-1",
"json":"https://miscsubjects.com/a/thymosin-alpha-1.json",
"markdown":"https://miscsubjects.com/a/thymosin-alpha-1.md",
"theme":"https://miscsubjects.com/article-theme.json",
"calls": [
{
"what":"this article as a page (no key)",
"method":"GET",
"url":"https://miscsubjects.com/a/thymosin-alpha-1",
"headers": {}
},
{
"what":"this article as its object (no key)",
"method":"GET",
"url":"https://miscsubjects.com/a/thymosin-alpha-1.json",
"headers": {}
},
{
"what":"this article as Markdown (no key)",
"method":"GET",
"url":"https://miscsubjects.com/a/thymosin-alpha-1.md",
"headers": {}
},
{
"what":"the object with its hash, drafts too",
"method":"GET",
"url":"https://miscsubjects.com/api/jarticles/thymosin-alpha-1",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
}
},
{
"what":"one piece and that piece’s hash",
"method":"GET",
"url":"https://miscsubjects.com/api/jarticles/thymosin-alpha-1/at?path=facts",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
}
},
{
"what":"grep: every key or value that matches, with the path to change it",
"method":"GET",
"url":"https://miscsubjects.com/api/jarticles/thymosin-alpha-1/grep?q=owner",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
}
},
{
"what":"change pieces (set, merge, delete, append, insert, move); if-match is the hash",
"method":"PATCH",
"url":"https://miscsubjects.com/api/jarticles/thymosin-alpha-1",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json",
"if-match":"<hash from the read>"
},
"body": {
"ops": [
{
"op":"set",
"path":"facts.example",
"value":1
}
]
}
},
{
"what":"replace the whole object",
"method":"PUT",
"url":"https://miscsubjects.com/api/jarticles/thymosin-alpha-1",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json",
"if-match":"<hash>"
},
"body": {
"slug":"thymosin-alpha-1",
"title":"…"
}
},
{
"what":"fetch every source, hash what came back and check the quote is in it",
"method":"POST",
"url":"https://miscsubjects.com/api/jarticles/thymosin-alpha-1/verify",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json"
},
"body": {}
},
{
"what":"an Obsidian-style command",
"method":"POST",
"url":"https://miscsubjects.com/api/jarticles/cli",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json"
},
"body": {
"command":"backlinks",
"file":"thymosin-alpha-1"
}
}
]
}
